0000310158-22-000034.txt : 20221103 0000310158-22-000034.hdr.sgml : 20221103 20221103162844 ACCESSION NUMBER: 0000310158-22-000034 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 87 CONFORMED PERIOD OF REPORT: 20220930 FILED AS OF DATE: 20221103 DATE AS OF CHANGE: 20221103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 221358479 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20220930.htm 10-Q mrk-20220930
FALSE2022Q3000031015812/310.10000http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpenseP1D00003101582022-01-012022-09-300000310158us-gaap:CommonStockMember2022-01-012022-09-300000310158mrk:A0.500Notesdue2024Member2022-01-012022-09-300000310158mrk:A1.875Notesdue2026Member2022-01-012022-09-300000310158mrk:A2.500Notesdue2034Member2022-01-012022-09-300000310158mrk:A1.375Notesdue2036Member2022-01-012022-09-3000003101582022-10-31xbrli:shares00003101582022-07-012022-09-30iso4217:USD00003101582021-07-012021-09-3000003101582021-01-012021-09-30iso4217:USDxbrli:shares00003101582022-09-3000003101582021-12-3100003101582020-12-3100003101582021-09-300000310158mrk:OrganonCoMember2021-06-0200003101582021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MaximumMember2021-06-022021-06-020000310158srt:MinimumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158srt:MaximumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158mrk:OrganonCoMember2022-07-012022-09-300000310158mrk:OrganonCoMember2022-01-012022-09-300000310158mrk:OrganonCoMember2022-09-300000310158mrk:OrganonCoMember2021-12-310000310158mrk:OrganonCoMember2021-06-022021-06-02xbrli:pure0000310158mrk:OrganonCoMember2021-07-012021-09-300000310158mrk:OrganonCoMember2021-01-012021-09-300000310158us-gaap:SubsequentEventMember2022-10-012022-10-310000310158us-gaap:LicensingAgreementsMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:SubsequentEventMembermrk:OrnaTherapeuticsMember2022-10-012022-12-310000310158mrk:OrionCorporationMemberus-gaap:LicensingAgreementsMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:FirstCommercialSaleMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:PandionTherapeuticsMember2021-04-012021-04-300000310158mrk:PandionTherapeuticsMember2021-04-300000310158mrk:PandionTherapeuticsMember2021-01-012021-09-300000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-31mrk:research_programmrk:collaboration_target0000310158mrk:ArtivaBiotherapeuticsIncMembermrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMembersrt:MinimumMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembersrt:MaximumMember2021-01-012021-01-310000310158mrk:COVID19Member2021-01-012021-09-300000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-01-012022-03-310000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-03-310000310158mrk:LynparzaMember2022-01-012022-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-09-300000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-09-300000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-09-300000310158us-gaap:OtherNoncurrentAssetsMembermrk:LynparzaMember2022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:EisaiMember2021-03-012021-03-310000310158mrk:LenvimaMembermrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-09-300000310158mrk:LenvimaMemberus-gaap:OtherNoncurrentAssetsMember2022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-01-310000310158us-gaap:OtherIntangibleAssetsMembermrk:AdempasMember2022-09-300000310158mrk:VerquvoMemberus-gaap:OtherIntangibleAssetsMember2022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-31mrk:marketmrk:course0000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158srt:MinimumMemberus-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembersrt:MaximumMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembermrk:RegulatoryMilestonesMember2022-01-012022-09-300000310158srt:ScenarioForecastMember2022-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-12-310000310158mrk:AcceleratedDepreciationMember2021-12-310000310158us-gaap:OtherRestructuringMember2021-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-09-300000310158mrk:AcceleratedDepreciationMember2022-09-300000310158us-gaap:OtherRestructuringMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2022-01-012022-09-300000310158srt:MaximumMemberus-gaap:NondesignatedMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMember2022-07-012022-09-300000310158mrk:EurodominatedNotesMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMember2022-01-012022-09-300000310158mrk:EurodominatedNotesMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300000310158us-gaap:InterestRateSwapMember2022-02-28mrk:interest_rate_swap0000310158mrk:A2.35NotesDue2022Memberus-gaap:InterestRateSwapMember2022-02-280000310158mrk:A2.35NotesDue2022Member2022-02-280000310158us-gaap:InterestRateSwapMember2022-09-300000310158mrk:A2.40NotesDue2022Memberus-gaap:InterestRateSwapMember2022-09-300000310158mrk:A2.40NotesDue2022Member2022-09-300000310158mrk:A2.40NotesDue2022Member2022-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2022-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:ForeignExchangeContractMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:NondesignatedMember2022-09-300000310158us-gaap:NondesignatedMember2021-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300000310158us-gaap:InterestRateSwapMember2022-07-012022-09-300000310158us-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:InterestRateSwapMember2022-01-012022-09-300000310158us-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-07-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-01-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-01-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2022-07-012022-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-07-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2022-01-012022-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-01-012021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000310158us-gaap:CommercialPaperMember2022-09-300000310158us-gaap:CommercialPaperMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMember2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:EquityFundsMember2022-07-012022-09-300000310158us-gaap:EquityFundsMember2021-07-012021-09-300000310158us-gaap:EquityFundsMember2022-01-012022-09-300000310158us-gaap:EquityFundsMember2021-01-012021-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel2Member2022-09-300000310158us-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:SanofiPasteurMember2022-09-3000003101582021-01-012021-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2022-09-300000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2021-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2022-09-300000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2021-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-09-300000310158mrk:FosamaxMember2022-09-30mrk:case0000310158mrk:FosamaxMembermrk:FederalMembermrk:FemurFractureLitigationMember2014-03-012014-03-310000310158mrk:JanuviaMembermrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember2022-09-30mrk:claim0000310158country:USmrk:GardasilGardasil9Member2022-09-300000310158mrk:GardasilGardasil9Memberus-gaap:NonUsMember2022-09-300000310158mrk:GardasilGardasil9Membercountry:CO2022-09-300000310158mrk:ZetiaantitrustlitigationMember2020-08-310000310158us-gaap:PendingLitigationMembermrk:ZetiaantitrustlitigationMember2022-06-302022-06-300000310158us-gaap:PatentsMembermrk:BridionMemberus-gaap:PendingLitigationMembersrt:ScenarioForecastMember2022-12-192022-12-190000310158us-gaap:PatentsMembermrk:BridionMember2022-01-012022-09-300000310158us-gaap:PatentsMembermrk:BridionMemberus-gaap:PendingLitigationMember2022-09-300000310158us-gaap:PatentsMembermrk:JanuviaAndJanumetMember2022-01-012022-09-300000310158us-gaap:PendingLitigationMembersrt:ScenarioForecastMembermrk:PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember2023-01-092023-01-090000310158mrk:LegalDefenseCostsMember2022-09-300000310158mrk:LegalDefenseCostsMember2021-12-310000310158us-gaap:CommonStockMember2021-06-300000310158us-gaap:AdditionalPaidInCapitalMember2021-06-300000310158us-gaap:RetainedEarningsMember2021-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000310158us-gaap:TreasuryStockCommonMember2021-06-300000310158us-gaap:NoncontrollingInterestMember2021-06-3000003101582021-06-300000310158us-gaap:RetainedEarningsMember2021-07-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000310158us-gaap:TreasuryStockCommonMember2021-07-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000310158us-gaap:CommonStockMember2021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-09-300000310158us-gaap:RetainedEarningsMember2021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000310158us-gaap:TreasuryStockCommonMember2021-09-300000310158us-gaap:NoncontrollingInterestMember2021-09-300000310158us-gaap:CommonStockMember2022-06-300000310158us-gaap:AdditionalPaidInCapitalMember2022-06-300000310158us-gaap:RetainedEarningsMember2022-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000310158us-gaap:TreasuryStockCommonMember2022-06-300000310158us-gaap:NoncontrollingInterestMember2022-06-3000003101582022-06-300000310158us-gaap:RetainedEarningsMember2022-07-012022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000310158us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000310158us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000310158us-gaap:CommonStockMember2022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-09-300000310158us-gaap:RetainedEarningsMember2022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000310158us-gaap:TreasuryStockCommonMember2022-09-300000310158us-gaap:NoncontrollingInterestMember2022-09-300000310158us-gaap:CommonStockMember2020-12-310000310158us-gaap:AdditionalPaidInCapitalMember2020-12-310000310158us-gaap:RetainedEarningsMember2020-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000310158us-gaap:TreasuryStockCommonMember2020-12-310000310158us-gaap:NoncontrollingInterestMember2020-12-310000310158us-gaap:RetainedEarningsMember2021-01-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000310158us-gaap:TreasuryStockCommonMember2021-01-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-01-012021-09-300000310158us-gaap:CommonStockMember2021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-12-310000310158us-gaap:RetainedEarningsMember2021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000310158us-gaap:TreasuryStockCommonMember2021-12-310000310158us-gaap:NoncontrollingInterestMember2021-12-310000310158us-gaap:RetainedEarningsMember2022-01-012022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000310158us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000310158us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-07-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:SegmentDiscontinuedOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:SegmentDiscontinuedOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-30mrk:segment0000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158us-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158us-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158country:USus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158country:USus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158country:USus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158country:US2022-07-012022-09-300000310158mrk:InternationalMember2022-07-012022-09-300000310158country:US2021-07-012021-09-300000310158mrk:InternationalMember2021-07-012021-09-300000310158country:US2022-01-012022-09-300000310158mrk:InternationalMember2022-01-012022-09-300000310158country:US2021-01-012021-09-300000310158mrk:InternationalMember2021-01-012021-09-300000310158us-gaap:EMEAMember2022-07-012022-09-300000310158us-gaap:EMEAMember2021-07-012021-09-300000310158us-gaap:EMEAMember2022-01-012022-09-300000310158us-gaap:EMEAMember2021-01-012021-09-300000310158country:CN2022-07-012022-09-300000310158country:CN2021-07-012021-09-300000310158country:CN2022-01-012022-09-300000310158country:CN2021-01-012021-09-300000310158country:JP2022-07-012022-09-300000310158country:JP2021-07-012021-09-300000310158country:JP2022-01-012022-09-300000310158country:JP2021-01-012021-09-300000310158srt:AsiaPacificMember2022-07-012022-09-300000310158srt:AsiaPacificMember2021-07-012021-09-300000310158srt:AsiaPacificMember2022-01-012022-09-300000310158srt:AsiaPacificMember2021-01-012021-09-300000310158srt:LatinAmericaMember2022-07-012022-09-300000310158srt:LatinAmericaMember2021-07-012021-09-300000310158srt:LatinAmericaMember2022-01-012022-09-300000310158srt:LatinAmericaMember2021-01-012021-09-300000310158mrk:OtherCountriesMember2022-07-012022-09-300000310158mrk:OtherCountriesMember2021-07-012021-09-300000310158mrk:OtherCountriesMember2022-01-012022-09-300000310158mrk:OtherCountriesMember2021-01-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
126 East Lincoln Avenue
RahwayNew Jersey07065
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
The number of shares of common stock outstanding as of the close of business on October 31, 2022: 2,535,395,974




Table of Contents




Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Sales$14,959 $13,154 $45,453 $35,183 
Costs, Expenses and Other
Cost of sales3,934 3,450 13,530 9,752 
Selling, general and administrative2,520 2,336 7,355 6,804 
Research and development4,399 2,445 9,773 9,177 
Restructuring costs94 107 288 487 
Other (income) expense, net429 (450)1,576 (1,007)
 11,376 7,888 32,522 25,213 
Income from Continuing Operations Before Taxes3,583 5,266 12,931 9,970 
Taxes on Income from Continuing Operations330 695 1,423 1,436 
Net Income from Continuing Operations3,253 4,571 11,508 8,534 
Less: Net Income Attributable to Noncontrolling Interests5 4 6 9 
Net Income from Continuing Operations Attributable to Merck & Co., Inc.3,248 4,567 11,502 8,525 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests— — — 766 
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.81 $4.55 $3.37 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.81 $4.55 $3.67 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.80 $4.53 $3.36 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.80 $4.53 $3.66 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2022202120222021
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized gain on derivatives, net of reclassifications338 84 584 324 
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization(186)38 92 1,522 
Cumulative translation adjustment
(568)(84)(990)(251)
 (416)38 (314)1,595 
Comprehensive Income Attributable to Merck & Co., Inc.$2,832 $4,605 $11,188 $10,886 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
September 30, 2022December 31, 2021
Assets
Current Assets
Cash and cash equivalents
$11,145 $8,096 
Short-term investments103 — 
Accounts receivable (net of allowance for doubtful accounts of $77 in 2022
 and $62 in 2021)
9,482 9,230 
Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021
classified in Other assets - see Note 7)
5,614 5,953 
Other current assets
7,217 6,987 
Total current assets33,561 30,266 
Investments984 370 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921
in 2022 and $18,192 in 2021
20,424 19,279 
Goodwill21,160 21,264 
Other Intangibles, Net21,368 22,933 
Other Assets9,584 11,582 
 $107,081 $105,694 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt
$1,936 $2,412 
Trade accounts payable
3,371 4,609 
Accrued and other current liabilities
14,222 13,859 
Income taxes payable
1,698 1,224 
Dividends payable
1,771 1,768 
Total current liabilities22,998 23,872 
Long-Term Debt28,482 30,690 
Deferred Income Taxes2,417 3,441 
Other Noncurrent Liabilities8,660 9,434 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2022 and 2021
1,788 1,788 
Other paid-in capital
44,243 44,238 
Retained earnings
59,928 53,696 
Accumulated other comprehensive loss
(4,743)(4,429)
101,216 95,293 
Less treasury stock, at cost:
1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021
56,758 57,109 
Total Merck & Co., Inc. stockholders’ equity44,458 38,184 
Noncontrolling Interests66 73 
Total equity44,524 38,257 
 $107,081 $105,694 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Nine Months Ended
September 30,
 20222021
Cash Flows from Operating Activities of Continuing Operations
Net income from continuing operations$11,508 $8,534 
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:
Amortization1,623 1,231 
Depreciation1,394 1,148 
Intangible asset impairment charges910 — 
Loss (income) from investments in equity securities, net1,361 (1,535)
Charge for the acquisition of Pandion Therapeutics, Inc.— 1,556 
Deferred income taxes
(1,261)28 
Share-based compensation
396 360 
Other
1,169 499 
Net changes in assets and liabilities
(2,435)(3,794)
Net Cash Provided by Operating Activities of Continuing Operations14,665 8,027 
Cash Flows from Investing Activities of Continuing Operations
Capital expenditures(3,239)(3,240)
Purchases of securities and other investments(710)(1)
Proceeds from sales of securities and other investments709 497 
Acquisition of Pandion Therapeutics, Inc., net of cash acquired— (1,554)
Other acquisitions, net of cash acquired(121)(89)
Other149 15 
Net Cash Used in Investing Activities of Continuing Operations(3,212)(4,372)
Cash Flows from Financing Activities of Continuing Operations
Net change in short-term borrowings— (3,983)
Payments on debt(2,250)(1,153)
Distribution from Organon & Co.— 9,000 
Purchases of treasury stock— (822)
Dividends paid to stockholders(5,262)(4,967)
Proceeds from exercise of stock options119 68 
Other(172)(253)
Net Cash Used in Financing Activities of Continuing Operations(7,565)(2,110)
Cash Flows from Discontinued Operations
Net cash provided by operating activities— 1,051 
Net cash used in investing activities— (134)
Net cash used in financing activities— (504)
Net Cash Flows Provided by Discontinued Operations— 413 
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(776)(65)
Net Increase in Cash, Cash Equivalents and Restricted Cash3,112 1,893 
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of
$71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)
8,167 8,153 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134
and $30 at September 30, 2022 and 2021, respectively, included in Other current assets)
$11,279 $10,046 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -
Notes to Condensed Consolidated Financial Statements (unaudited)

1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).
Recently Adopted Accounting Standards
In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
- 6 -
Notes to Condensed Consolidated Financial Statements (unaudited)
2. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100 million and $293 million and related cost of sales of $104 million and $312 million for the three and nine months ended September 30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September 30, 2022 and September 30, 2021.
The amounts due from Organon under all of the above agreements were $567 million and $964 million at September 30, 2022 and December 31, 2021, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $333 million and $400 million at September 30, 2022 and December 31, 2021, respectively, and are included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s condensed consolidated statement of income as Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million for the nine months ended September 30, 2021 related to the spin-off of Organon, which are also included in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees.

- 7 -
Notes to Condensed Consolidated Financial Statements (unaudited)
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
 Nine Months Ended September 30,
($ in millions)
2021 (1)
Sales$2,512 
Costs, Expenses and Other
Cost of sales789 
Selling, general and administrative877 
Research and development103 
Restructuring costs1 
Other (income) expense, net(15)
1,755 
Income from discontinued operations before taxes757 
Income tax benefit(12)
Income from discontinued operations, net of taxes769 
Less: Income of discontinued operations attributable to noncontrolling interests3 
$766 
(1)    Reflects amounts through the June 2, 2021 spin-off date.
3.    Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge in Research and development expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties
- 8 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in the fourth quarter of 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved.
Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in the first nine months of 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $101 million to fund Kelun-Biotech’s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
2021 Transactions
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and Research and development expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in Research and development expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.
- 9 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
As part of Merck’s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in the first nine months of 2021, which are reflected in Cost of sales and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.
4.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. As of September 30, 2022, sales-based milestone payments accrued but not yet paid totaled $600 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.

- 10 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lynparza$284 $246 $825 $721 
Alliance revenue - Koselugo10 6 43 20 
Total alliance revenue$294 $252 $868 $741 
Cost of sales (1)
64 42 425 125 
Selling, general and administrative45 44 135 127 
Research and development28 27 79 87 
($ in millions)September 30, 2022December 31, 2021
Receivables from AstraZeneca included in Other current assets
$290 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
12 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1) Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2) Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

- 11 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lenvima$202 $188 $660 $498 
Cost of sales (1)
53 49 159 143 
Selling, general and administrative42 34 115 88 
Research and development24 43 128 165 
($ in millions)September 30, 2022December 31, 2021
Receivables from Eisai included in Other current assets
$202 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
1 625 
(1) Represents amortization of capitalized milestone payments.
(2) Amount as of December 31, 2021 includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September 30, 2022 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Adempas/Verquvo$88 $100 $258 $248 
Net sales of Adempas recorded by Merck57 59 181 188 
Net sales of Verquvo recorded by Merck6 2 15 3 
Total sales$151 $161 $454 $439 
Cost of sales (1)
55 53 158 328 
Selling, general and administrative42 31 107 84 
Research and development18 16 52 36 
($ in millions)September 30, 2022December 31, 2021
Receivables from Bayer included in Other current assets
$144 $114 
Payables to Bayer included in Accrued and other current liabilities (2)
75 472 
(1) Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
(2) Amount as of December 31, 2021 includes accrued milestone payment.

- 12 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Lagevrio has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for Lagevrio in more than 40 markets. As of September 30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Lagevrio sales
$436 $— $4,859 $— 
Cost of sales (1)
234 4 2,580 56 
Selling, general and administrative41 6 105 13 
Research and development 8 58 29 167 
($ in millions)September 30, 2022December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2)
$193 $283 
(1) Includes royalty expense and amortization of capitalized milestone payments.
(2) Includes accrued royalty and milestone payments.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $39 million (consisting of royalties) within Sales in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104 million, as well as the receipt of a regulatory approval milestone payment of $20 million.
5.    Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to
- 13 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
restructuring program activities. Since inception of the Restructuring Program through September 30, 2022, Merck has recorded total pretax accumulated costs of approximately $3.2 billion. For the full year of 2022, the Company expects to record charges of approximately $600 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $16 $38 $54 $— $51 $116 $167 
Selling, general and administrative— 5 21 26 — 17 57 74 
Research and development— — 1 1 — 29 1 30 
Restructuring costs65 — 29 94 197 — 91 288 
$65 $21 $89 $175 $197 $97 $265 $559 
 Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $11 $37 $48 $— $32 $81 $113 
Selling, general and administrative— 4 1 5 — 8 1 9 
Research and development— 7 1 8 — 20 1 21 
Restructuring costs17 — 90 107 310 — 177 487 
$17 $22 $129 $168 $310 $60 $260 $630 
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 11) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2022:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2022
$596 $— $41 $637 
Expense197 97 265 559 
(Payments) receipts, net(303)— (458)(761)
Non-cash activity— (97)183 86 
Restructuring reserves September 30, 2022 (1)
$490 $— $31 $521 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
6.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
- 14 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
- 15 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20222021202220212022202120222021
Net Investment Hedging Relationships
Foreign exchange contracts
$(1)$1 $(47)$(27)$— $(4)$(2)$(12)
Euro-denominated notes(250)(77)(431)(199)— — — — 
(1) No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
In February 2022, five interest rate swap contracts with a total notional amount of $1.25 billion matured. These swaps effectively converted the Company’s $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt. In September 2022, four interest rate swap contracts with a total notional amount of $1.0 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.40% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2022December 31, 2021September 30, 2022December 31, 2021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$— $2,263 $— $13 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2022December 31, 2021
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Balance Sheet Caption
Interest rate swap contractsOther current assets$— $— $— $14 $— $2,250 
Foreign exchange contractsOther current assets826 — 7,250 271 — 6,778 
Foreign exchange contractsOther Assets85 — 1,408 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities— 1 37 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities— 1 93 — 1 43 
  $911 $2 $8,788 $328 $25 $12,245 
Derivatives Not Designated as Hedging Instruments
Balance Sheet Caption      
Foreign exchange contractsOther current assets$597 $— $9,523 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities— 240 7,715 — 96 10,640 
  $597 $240 $17,238 $221 $96 $20,713 
  $1,508 $242 $26,026 $549 $121 $32,958 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master
- 16 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2022December 31, 2021
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$1,508 $242 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(217)(217)(110)(110)
Cash collateral received(794)— (164)— 
Net amounts$497 $25 $275 $11 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)202220212022202120222021202220212022202120222021
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,959 $13,154 $429 $(450)$(416)$38 $45,453 $35,183 $1,576 $(1,007)$(314)$1,595 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — 1 (9)— — — — (13)(29)— — 
Derivatives designated as hedging instruments
— — — (1)— — — — 4 (1)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
— — — — 682 72 — — — — 1,233 193 
Increase (decrease) in Sales as a result of AOCL reclassifications
253 (36)— — (253)36 491 (219)— — (491)219 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)— — — — — (2)(2)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)— — — — — (2)(2)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2022202120222021
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(41)$18 $(77)$234 
Foreign exchange contracts (2)
Sales(4)(4)(42)6 
(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
At September 30, 2022, the Company estimates $864 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.

- 17 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2022December 31, 2021
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$67 $— $— $67 $80 $— $— $80 
Commercial paper4 — — 4 — — — — 
Corporate notes and bonds3 — — 3 4 — — 4 
Foreign government bonds2 — — 2 2 — — 2 
Total debt securities$76 $— $— $76 $86 $— $— $86 
Publicly traded equity securities (1)
1,334 1,647 
Total debt and publicly traded equity securities
$1,410 $1,733 
(1) Unrealized net losses of $221 million and $415 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022. Unrealized net (gains) losses of $(90) million and $109 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2021, respectively, on equity securities still held at September 30, 2021.
At September 30, 2022 and September 30, 2021, the Company also had $705 million and $578 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first nine months of 2022, the Company recorded unrealized gains of $21 million and unrealized net losses of $12 million related to certain of these equity investments still held at September 30, 2022. During the first nine months of 2021, the Company recorded unrealized gains of $104 million and unrealized losses of $1 million related to certain of these investments still held at September 30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September 30, 2022 were $255 million and $19 million, respectively.
At September 30, 2022 and September 30, 2021, the Company also had $655 million and $1.2 billion, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $141 million and $(391) million for the third quarter of 2022 and 2021, respectively, and were $952 million and $(893) million for the first nine months of 2022 and 2021, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

- 18 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2022December 31, 2021
Assets
Investments
Commercial paper$— $4 $— $4 $— $— $— $— 
Foreign government bonds— 2 — 2 — 2 — 2 
Publicly traded equity securities1,081 — — 1,081 368 — — 368 
 1,081 6 — 1,087 368 2 — 370 
Other assets (1)
U.S. government and agency securities67 — — 67 80 — — 80 
Corporate notes and bonds3 — — 3 4 — — 4 
Publicly traded equity securities253 — — 253 1,279 — — 1,279 
323 — — 323 1,363 — — 1,363 
Derivative assets (2)
Forward exchange contracts— 945 — 945 — 351 — 351 
Purchased currency options— 563 — 563 — 184 — 184 
Interest rate swaps— — — — — 14 — 14 
 — 1,508 — 1,508 — 549 — 549 
Total assets$1,404 $1,514 $— $2,918 $1,731 $551 $— $2,282 
Liabilities
Other liabilities
Contingent consideration$— $— $499 $499 $— $— $777 $777 
Derivative liabilities (2)
Forward exchange contracts— 242 — 242 — 120 — 120 
Written currency options— — — — — 1 — 1 
— 242 — 242 — 121 — 121 
Total liabilities$— $242 $499 $741 $— $121 $777 $898 
(1) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of September 30, 2022 and December 31, 2021, Cash and cash equivalents included $10.0 billion and $6.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(156)73 
Payments(119)— 
Other(3)(12)
Fair value September 30 (2)
$499 $902 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) At September 30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.

- 19 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2022, was $25.9 billion compared with a carrying value of $30.4 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable as of September 30, 2022 and December 31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September 30, 2022 and December 31, 2021, the Company had collected $55 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $794 million and $164 million at September 30, 2022 and December 31, 2021, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
7.    Inventories
Inventories consisted of:
($ in millions)September 30, 2022December 31, 2021
Finished goods$1,683 $1,747 
Raw materials and work in process6,532 6,220 
Supplies227 196 
Total (approximates current cost)8,442 8,163 
Decrease to LIFO cost(187)(16)
 $8,255 $8,147 
Recognized as:
Inventories$5,614 $5,953 
Other assets2,641 2,194 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At September 30, 2022 and December 31, 2021, these amounts included $2.2 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $417 million and $256 million at September 30, 2022 and December 31, 2021, respectively, of inventories produced in preparation for product launches.
- 20 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
8. Other Intangibles
In the third quarter of 2022, the Company recorded $887 million of impairment charges within Research and development expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $807 million represents an in-process research and development (IPR&D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&D impairment charge noted above. The remaining IPR&D intangible asset related to nemtabrutinib is $1.2 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.
9.    Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September 30, 2022, approximately 3,450 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck’s motion and ruled that plaintiffs’ failure to warn claims are preempted as a matter of law to the extent they
- 21 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court’s preemption ruling to the Third Circuit.
Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Januvia (sitagliptin) and/or Janumet (sitagliptin and metformin HCl).
Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants’ summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants’ motions to exclude plaintiffs’ expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court’s judgment is now final and no longer appealable with respect to remaining claims.
Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants’ summary judgment motions and also granting defendants’ motions to exclude plaintiffs’ expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.
Gardasil/Gardasil 9
Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September 30, 2022, approximately 65 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
- 22 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.
340B Program Litigation
Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if
- 23 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA has granted pediatric exclusivity with respect to Januvia, Janumet, and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.
In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a three-day bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.
Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for Janumet in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the Janumet SPCs in Europe. In June 2021, a German court decided that the SPC for Janumet is invalid, which decision the Company has appealed. The validity of the Janumet SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided
- 24 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
that the SPC for Janumet was invalid in a first instance decision. In August 2022, the validity of the SPC for Janumet was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: ex-parte preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be prima facie valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for ex parte preliminary injunctions were refused in Portugal.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2022 and December 31, 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
10.    Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20213,577 $1,788 $44,039 $48,777 $(4,628)1,044 $(56,682)$94 $33,388 
Net income attributable to Merck & Co., Inc.— — — 4,567 — — — — 4,567 
Other comprehensive income, net of taxes— — — — 38 — — — 38 
Cash dividends declared on common stock ($0.65 per share)
— — — (1,653)— — — — (1,653)
Treasury stock shares purchased— — — — — 8 (583)— (583)
Share-based compensation plans and other— — 110 — — — 21 — 131 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at July 1, 20223,577 $1,788 $44,115 $58,437 $(4,327)1,044 $(56,770)$75 $43,318 
Net income attributable to Merck & Co., Inc.— — — 3,248 — — — — 3,248 
Other comprehensive loss, net of taxes— — — — (416)— — — (416)
Cash dividends declared on common stock ($0.69 per share)
— — — (1,757)— — — — (1,757)
Share-based compensation plans and other— — 128 — — — 12 — 140 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Distributions attributable to noncontrolling interests— — — — — — — (14)(14)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
- 25 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20213,577 $1,788 $39,588 $47,362 $(6,634)1,047 $(56,787)$87 $25,404 
Net income attributable to Merck & Co., Inc.— — — 9,291 — — — — 9,291 
Other comprehensive income, net of taxes— — — — 1,595 — — — 1,595 
Cash dividends declared on common stock ($1.95 per share)
— — — (4,962)— — — — (4,962)
Treasury stock shares purchased— — — — — 11 (822)— (822)
Spin-off of Organon & Co.— — 4,643 — 449 — — (1)5,091 
Share-based compensation plans and other— — (82)— — (6)365 — 283 
Net income attributable to noncontrolling interests— — — — — — — 12 12 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 11,502 — — — — 11,502 
Other comprehensive loss, net of taxes— — — — (314)— — — (314)
Cash dividends declared on common stock ($2.07 per share)
— — — (5,270)— — — — (5,270)
Share-based compensation plans and other— — 5 — — (5)351 — 356 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests— — — — — — — (13)(13)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
11.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$91 $66 $104 $75 $289 $213 $302 $254 
Interest cost123 35 102 33 330 110 305 92 
Expected return on plan assets(182)(93)(188)(105)(576)(292)(568)(313)
Amortization of unrecognized prior service credit
(8)(3)(9)(3)(24)(10)(29)(12)
Net loss amortization10 24 75 32 122 73 218 110 
Termination benefits1 — 2 — 2 1 54 3 
Curtailments3 — (1)— 11 — 15 (27)
Settlements79 — 139 — 180 — 139 2 
 $117 $29 $224 $32 $334 $95 $436 $109 

- 26 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Service cost$11 $11 $36 $37 
Interest cost11 12 34 34 
Expected return on plan assets(21)(20)(64)(59)
Amortization of unrecognized prior service credit(14)(16)(42)(48)
Net gain amortization(11)(12)(32)(30)
Termination benefits— — — 37 
Curtailments— (1)(1)(29)
 $(24)$(26)$(69)$(58)
Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.
In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company’s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $296 million to net pension liabilities and also resulted in a related adjustment to AOCL. Remeasurements during the first nine months of 2022 have resulted in a net increase of $131 million to net pension liabilities with related adjustments to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests if related to the spin-off of Organon (each as noted above).
12.    Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Interest income$(40)$(7)$(62)$(27)
Interest expense244 196 727 597 
Exchange losses96 46 220 202 
Loss (income) from investments in equity securities, net (1)
371 (683)1,361 (1,535)
Net periodic defined benefit plan (credit) cost other than service cost(60)40 (208)(159)
Other, net(182)(42)(462)(85)
 $429 $(450)$1,576 $(1,007)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Interest paid for the nine months ended September 30, 2022 and 2021 was $660 million and $570 million, respectively.

- 27 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
13.    Taxes on Income
The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related to the settlement of certain federal income tax matters as discussed below.
In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.
14.    Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2022202120222021
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $8,525 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests— — — 766 
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Average common shares outstanding2,533 2,530 2,531 2,531 
Common shares issuable (1)
9 6 9 8 
Average common shares outstanding assuming dilution 2,542 2,536 2,540 2,539 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.81 $4.55 $3.37 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.81 $4.55 $3.67 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.80 $4.53 $3.36 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.80 $4.53 $3.66 
(1)Issuable primarily under share-based compensation plans.
For the third quarter of 2022 and 2021, 2 million and 8 million, respectively, and for the first nine months of 2022 and 2021, 5 million and 10 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.

- 28 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
15.    Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance July 1, 2021, net of taxes$(26)$(3,028)$(1,574)$(4,628)
Other comprehensive income (loss) before reclassification adjustments, pretax72 (24)(96)(48)
Tax(16)16 12 12 
Other comprehensive income (loss) before reclassification adjustments, net of taxes56 (8)(84)(36)
Reclassification adjustments, pretax36 
(1)
68 
(2)
— 104 
Tax(8)(22)— (30)
Reclassification adjustments, net of taxes28 

46 

— 74 
Other comprehensive income (loss), net of taxes84 38 (84)38 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance July 1, 2022, net of taxes$390 $(2,465)$(2,252)$(4,327)
Other comprehensive income (loss) before reclassification adjustments, pretax682 (294)(618)(230)
Tax(143)62 50 (31)
Other comprehensive income (loss) before reclassification adjustments, net of taxes539 (232)(568)(261)
Reclassification adjustments, pretax(254)
(1)
77 
(2)
— (177)
Tax53 (31)— 22 
Reclassification adjustments, net of taxes(201)

46 

— (155)
Other comprehensive income (loss), net of taxes338 (186)(568)(416)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
Nine Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2021, net of taxes$(266)$(4,540)$(1,828)$(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax193 1,739 (167)1,765 
Tax(41)(385)(84)(510)
Other comprehensive income (loss) before reclassification adjustments, net of taxes152 1,354 (251)1,255 
Reclassification adjustments, pretax218 
(1)
210 
(2)
— 428 
Tax(46)(42)— (88)
Reclassification adjustments, net of taxes172 168 — 340 
Other comprehensive income (loss), net of taxes324 1,522 (251)1,595 
Spin-off of Organon (see Note 2)
— 28 421 449 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax1,233 (125)(1,001)107 
Tax(259)25 11 (223)
Other comprehensive income (loss) before reclassification adjustments, net of taxes974 (100)(990)(116)
Reclassification adjustments, pretax(493)
(1)
266 
(2)
— (227)
Tax103 (74)— 29 
Reclassification adjustments, net of taxes(390)192 — (198)
Other comprehensive income (loss), net of taxes584 92 (990)(314)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
(1) Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).


- 29 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
16.    Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.

- 30 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,331 $2,095 $5,426 $2,580 $1,954 $4,534 $9,307 $6,180 $15,487 $7,108 $5,501 $12,609 
Alliance revenue-Lynparza (1)
144 140 284 129 117 246 427 397 825 371 350 721 
Alliance revenue-Lenvima (1)
142 60 202 114 74 188 426 235 660 287 211 498 
Alliance revenue-Reblozyl (2)
32 7 39 — — — 87 37 124 — — — 
Vaccines
Gardasil/Gardasil 9
957 1,337 2,294 839 1,154 1,993 1,803 3,624 5,428 1,605 2,539 4,144 
ProQuad/M-M-R II/Varivax
532 136 668 537 125 661 1,337 379 1,716 1,255 371 1,626 
RotaTeq154 102 256 135 92 227 427 218 644 364 229 593 
Pneumovax 23
68 63 131 181 97 277 280 177 457 354 247 600 
Vaqta27 36 64 32 16 48 72 62 134 80 58 138 
Hospital Acute Care
Bridion233 190 423 181 188 369 665 579 1,244 545 551 1,096 
Prevymis49 64 114 39 57 96 136 174 310 111 159 270 
Dificid72 6 77 52 2 54 184 12 196 108 7 115 
Primaxin— 63 63 — 69 70 1 185 185 — 194 194 
Noxafil13 49 62 19 45 64 39 141 180 48 149 197 
Invanz2 48 50 (2)55 53 4 144 148 (2)159 157 
Cancidas1 42 43 1 56 56 5 133 138 4 164 168 
Zerbaxa24 19 43 (1)(1)(2)64 55 120 (5)(6)(11)
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
85 3 88 73 27 100 244 14 258 222 26 248 
Adempas— 57 57 — 59 59 — 181 181 — 188 188 
Virology
Lagevrio— 436 436 — — — 1,523 3,336 4,859 — — — 
Isentress/Isentress HD
68 93 161 77 112 189 196 270 466 222 368 590 
Neuroscience
Belsomra20 42 62 23 58 81 60 139 199 56 183 238 
Immunology
Simponi— 173 173 — 203 203 — 540 540 — 619 619 
Remicade— 49 49 — 73 73 — 163 163 — 233 233 
Diabetes
Januvia332 385 717 365 487 852 958 1,294 2,252 997 1,448 2,445 
Janumet90 327 417 86 401 487 258 1,089 1,347 244 1,205 1,449 
Other pharmaceutical (4)
244 321 564 210 306 518 616 949 1,565 637 950 1,589 
Total Pharmaceutical segment sales6,620 6,343 12,963 5,670 5,826 11,496 19,119 20,707 39,826 14,611 16,103 30,714 
Animal Health:
Livestock186 643 829 190 675 864 521 1,965 2,486 508 1,996 2,503 
Companion Animals289 253 542 277 276 553 904 929 1,834 855 948 1,804 
Total Animal Health segment sales475 896 1,371 467 951 1,417 1,425 2,894 4,320 1,363 2,944 4,307 
Total segment sales7,095 7,239 14,334 6,137 6,777 12,913 20,544 23,601 44,146 15,974 19,047 35,021 
Other (5)
227 398 625 139 101 241 383 925 1,307 192 (30)162 
 $7,322 $7,637 $14,959 $6,276 $6,878 $13,154 $20,927 $24,526 $45,453 $16,166 $19,017 $35,183 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2022 and 2021 also includes $156 million and $191 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.

- 31 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.3 billion and $3.1 billion for the three months ended September 30, 2022 and 2021, respectively, and $9.1 billion for both the nine months ended September 30, 2022 and 2021.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
United States$7,322 $6,276 $20,927 $16,166 
Europe, Middle East and Africa3,286 3,342 11,228 9,912 
China1,442 1,307 3,957 3,004 
Japan673 638 2,776 1,929 
Asia Pacific (other than China and Japan)854 613 2,792 1,782 
Latin America684 599 1,933 1,631 
Other698 379 1,840 759 
 $14,959 $13,154 $45,453 $35,183 
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Segment profits:
Pharmaceutical segment$9,590 $8,606 $28,263 $22,450 
Animal Health segment515 505 1,672 1,629 
Total segment profits10,105 9,111 29,935 24,079 
Other profits377 141 831 29 
Unallocated:
Interest income40 7 62 27 
Interest expense(244)(196)(727)(597)
Amortization(460)(360)(1,623)(1,231)
Depreciation(448)(358)(1,257)(1,031)
Research and development(4,277)(2,312)(9,374)(8,775)
Restructuring costs(94)(107)(288)(487)
Other unallocated, net(1,416)(660)(4,628)(2,044)
 $3,583 $5,266 $12,931 $9,970 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.

- 32 -

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management
In October 2022, Merck announced that its board of directors unanimously elected Robert M. Davis, currently Chief Executive Officer and President, to serve as chairman of the board, effective December 1, 2022. He will succeed Kenneth C. Frazier, who will retire on November 30, 2022.
Business Developments
Below is a summary of significant business development activity thus far in 2022. See Note 3 to the condensed consolidated financial statements for additional information.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge in Research and development expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments, as well as regulatory and sales-based milestone payments contingent upon the progress of the multiple vaccine and therapeutic programs, as well as royalties on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in the fourth quarter of 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022.
Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent developmental, regulatory and sales-based milestone payments, as well as tiered royalties on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer (NSCLC) and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in the first nine months of 2022, and agreed to make additional payments upon completion of specified project activities, technology transfer, as well as payments to fund Kelun-Biotech’s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent developmental and sales-based milestone payments and royalties on future net sales.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed
- 33 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2 to the condensed consolidated financial statements).
Other Developments
War in Ukraine
In February 2022, Russia invaded Ukraine. The Company’s primary concerns are the safety and well-being of its employees and ensuring patients and customers have continued access to medicines and vaccines needed for patient and public health. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials. For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. The financial impacts of the war were immaterial to the Company’s consolidated financial statements for the third quarter and first nine months of 2022. Combined sales to Russia and Ukraine were approximately 1% of total Merck consolidated sales for the full year of 2021.
The combination of Russia’s invasion of Ukraine, as well as the resultant economic sanctions imposed by the U.S., the European Union (EU) and other governments are having pervasive effects in markets worldwide. The Company is unable to determine at this time the future impacts of this war either directly or indirectly on the Company’s business.
COVID-19
Although COVID-19-related disruptions had some negative effects on sales for the third quarter and first nine months of 2022, Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic. Merck’s sales of Lagevrio (molnupiravir), an investigational oral antiviral COVID-19 medicine, were $436 million and $4.9 billion in the third quarter and first nine months of 2022, respectively. In the third quarter and first nine months of 2021, COVID-19-related disruptions resulted in an estimated negative impact to Pharmaceutical segment sales of approximately $350 million and $1.3 billion, respectively, because a substantial portion of Merck’s Pharmaceutical segment revenue is comprised of physician-administered products, which were unfavorably affected by social distancing measures and fewer well visits.
In April 2021, Merck announced it was discontinuing the development of MK-7110 for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck’s acquisition of OncoImmune (see Note 3 to the condensed consolidated financial statements). This decision resulted in charges of $207 million to Cost of sales in the first nine months of 2021.
In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided Merck with $102 million of funding in the first quarter of 2022 to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. The funding was recognized as a reduction to Cost of sales over the production period through September 30, 2022, offsetting the depreciation expense related to the amounts that were capitalized in connection with the modification of the manufacturing facilities. Merck and Johnson & Johnson have commenced an arbitration regarding a dispute concerning two agreements pursuant to which Merck was supporting the manufacturing and supply of Johnson & Johnson’s SARS-CoV-2/COVID 19 vaccine and vaccine drug product. The amounts included in the condensed consolidated financial statements for these agreements were immaterial for the third quarter and first nine months of 2022. Merck does not believe the outcome of the arbitration will have a material impact on the Company’s financial results.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first nine months of 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., Congress recently passed the Inflation Reduction Act, which makes significant changes to how drugs are covered and paid for under the Medicare
- 34 -

program, including the creation of financial penalties for drugs whose prices rise faster than the rate of inflation, redesign of the Medicare Part D program to require manufacturers to bear more of the liability for certain drug benefits, and government price-setting for certain Medicare Part D drugs, starting in 2026, and Medicare Part B drugs starting in 2028. The Company anticipates all of these actions and additional actions in the future will negatively affect sales and profits.
Supply Chain
As a result of global macroeconomic conditions, the Company is experiencing some disruption and volatility in its global supply chain network, and the Company may in the future experience disruptions in availability and delays in shipments of raw materials and packaging, as well as related cost inflation.
Operating Results
Sales
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
United States$7,322 $6,276 17 %17 %$20,927 $16,166 29 %29 %
International7,637 6,878 11 %19 %24,526 19,017 29 %35 %
Total$14,959 $13,154 14 %18 %$45,453 $35,183 29 %32 %
U.S. plus international may not equal total due to rounding.
Worldwide sales grew 14% to $15.0 billion in the third quarter of 2022 primarily due to higher sales in the oncology franchise, largely driven by strong growth of Keytruda (pembrolizumab) and increased alliance revenue from Reblozyl (luspatercept-aamt) and Lynparza (olaparib), as well as higher sales in the virology franchise driven by Lagevrio (molnupiravir). Also contributing to revenue growth in the third quarter of 2022 were higher sales in the vaccines franchise, primarily attributable to growth of Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), as well as higher sales of hospital acute care products, including Bridion (sugammadex) Injection and Zerbaxa (ceftolozane and tazobactam). Higher revenue related to third-party manufacturing arrangements also contributed to revenue growth in the third quarter of 2022.
Worldwide sales rose 29% to $45.5 billion in the first nine months of 2022. Revenue growth was attributable in part to higher sales in the virology franchise driven by Lagevrio. Also contributing to revenue growth in the first nine months of 2022 were higher sales in the oncology franchise largely driven by strong growth of Keytruda and increased alliance revenue from Lenvima (lenvatinib), Reblozyl and Lynparza, as well as higher sales in the vaccines franchise, primarily attributable to growth of Gardasil and Gardasil 9. Higher sales of hospital acute care products, including Bridion and Zerbaxa, as well as higher revenue related to third-party manufacturing arrangements also drove revenue growth in the first nine months of 2022.
As discussed above, COVID-19-related disruptions had some negative effects on sales in the third quarter and first nine months of 2022, but to a lesser extent than in the same periods of 2021 which benefited year-over-year sales growth in both periods.
Revenue growth in the third quarter and first nine months of 2022 was partially offset by lower combined sales of diabetes products Januvia (sitagliptin) and Janumet (sitagliptin and metformin HCl), lower sales of Pneumovax 23 (pneumococcal vaccine polyvalent) and lower sales of virology products Isentress/Isentress HD (raltegravir). Lower revenue from the receipt of upfront and milestone payments for out-licensing arrangements also partially offset sales growth in the third quarter and first nine months of 2022.
See Note 16 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.

- 35 -

Pharmaceutical Segment
Oncology
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Keytruda$5,426 $4,534 20 %26 %$15,487 $12,609 23 %28 %
Alliance Revenue - Lynparza (1)
284 246 16 %23 %825 721 14 %20 %
Alliance Revenue - Lenvima (1)
202 188 7 %11 %660 498 33 %36 %
Alliance Revenue - Reblozyl
39 — ——124 — ——
(1) Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, endometrial carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), NSCLC, melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma, tumor mutational burden-high (TMB-H) cancer (solid tumors), and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, Keytruda is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) or stage IIB, IIC or III melanoma. Keytruda is also approved for certain patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, Keytruda is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER-2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for metastatic TNBC, in combination with axitinib for advanced RCC, and in combination with Lenvima for both endometrial carcinoma and RCC. The Keytruda clinical development program includes studies across a broad range of cancer types. See “Research and Development Update” below.
Global sales of Keytruda grew 20% and 23% in the third quarter and first nine months of 2022, respectively. Sales growth was primarily driven by higher demand as the Company continues to launch Keytruda with multiple new indications globally. Sales in the U.S. continue to build across the multiple approved metastatic indications, in particular for the treatment of certain types of RCC, HNSCC, and MSI-H cancers. Keytruda sales growth in the U.S. also benefited from increased uptake across recent launches in earlier-stage indications including in high-risk, early stage TNBC, as well as certain types of RCC and melanoma. Keytruda sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe.
Keytruda received the following regulatory approvals thus far in 2022.
Date
Approval
January 2022
European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.
February 2022
Japan Ministry of Health, Labour and Welfare (MHLW) approval of the combination of Keytruda plus Lenvima for radically unresectable or metastatic RCC, based on the CLEAR (Study 307)/KEYNOTE-581 trial.
February 2022
Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.
March 2022
U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation, based on the KEYNOTE-158 trial (Cohorts D & K).
April 2022
EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1, based on the KEYNOTE-826 trial.
April 2022
EC approval as monotherapy for the treatment of certain adult patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer, based on the KEYNOTE-164 and KEYNOTE-158 trials.
- 36 -

May 2022
EC approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced or early-stage TNBC at high risk of recurrence, based on the KEYNOTE-522 trial.
June 2022
EC approval as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma and who have undergone complete resection, based on the KEYNOTE-716 trial. Additionally, EC approval expanding the indications in advanced (unresectable or metastatic) melanoma and stage III melanoma with lymph node involvement (as adjuvant treatment following complete resection) to include adolescent patients aged 12 years and older.
September 2022Japan MHLW approval in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and HER2-negative breast cancer at high risk of recurrence, based on the KEYNOTE-522 trial.
September 2022Japan MHLW approval as monotherapy for the adjuvant treatment of certain patients with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions, based on the KEYNOTE-564 trial.
September 2022Japan MHLW approval in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with advanced or recurrent cervical cancer with no prior chemotherapy who are not amenable to curative treatment, based on the KEYNOTE-826 trial.
September 2022Japan MHLW approval as monotherapy for the adjuvant treatment of patients with stage IIB or IIC melanoma after complete resection, based on the KEYNOTE-716 trial.
Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 4 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza increased 16% and 14% in the third quarter and first nine months of 2022, respectively, largely driven by higher demand globally across the multiple approved indications, particularly in the U.S. largely attributable to uptake in the earlier-stage breast cancer indication following recent approval by the FDA. In March 2022, Lynparza was approved by the FDA for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, followed by approvals in the EU and Japan in August 2022, based on the OlympiA trial. In September 2022, Lynparza was approved in China as first-line maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency-positive status. This approval was based on the PAOLA-1 trial.
Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 4 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with RCC, and in combination with Keytruda for both endometrial carcinoma and RCC. Alliance revenue related to Lenvima grew 7% and 33% in the third quarter and first nine months of 2022, respectively, reflecting uptake in the advanced RCC and advanced endometrial carcinoma indications, particularly in the U.S. Growth in the third quarter was partially offset by the timing of shipments in China.
Reblozyl is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (see Note 4 to the condensed consolidated financial statements). Reblozyl is approved for the treatment of certain types of anemia. Merck recorded alliance revenue of $39 million (consisting of royalties) in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104 million, as well as the receipt of a regulatory approval milestone payment of $20 million.
Vaccines
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Gardasil/Gardasil 9
$2,294 $1,993 15 %20 %$5,428 $4,144 31 %35 %
ProQuad264 244 8 %10 %640 598 7 %9 %
M-M-R II
124 127 (2)%(1)%330 295 12 %14 %
Varivax280 290 (3)%(2)%746 733 2 %3 %
RotaTeq256 227 12 %16 %644 593 9 %11 %
Pneumovax 23131 277 (53)%(50)%457 600 (24)%(21)%
- 37 -

Combined worldwide sales of Gardasil and Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 15% and 31% in the third quarter and first nine months of 2022, respectively, driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Sales of Gardasil 9 in the U.S. increased in the third quarter and first nine months of 2022 due to public sector buying patterns.
China’s National Medical Products Administration expanded the use of Gardasil 9 for use in girls and women ages 9 to 45. The vaccine was previously approved for use in girls and women ages 16 to 26.
Global sales of ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, increased 8% and 7% in the third quarter and first nine months of 2022, respectively, primarily reflecting higher demand in Europe and higher pricing in the U.S.
Worldwide sales of M‑M‑R II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, grew 12% in the first nine months of 2022 primarily due to higher pricing and demand in the U.S., as well as higher tenders in Latin America.
Global sales of Varivax (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), grew 2% in the first nine months of 2022 primarily attributable to higher pricing in the U.S., partially offset by lower tenders in Latin America.
Global sales of RotaTeq (Rotavirus Vaccine, Live Oral, Pentavalent), a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 12% and 9% in the third quarter and first nine months of 2022, respectively, primarily due to public sector buying patterns and higher pricing in the U.S. Higher volumes in China also contributed to RotaTeq sales growth in the third quarter of 2022.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, declined 53% and 24% in the third quarter and first nine months of 2022, respectively, primarily reflecting lower demand in the U.S. as the market continues to shift toward newer adult pneumococcal conjugate vaccines following changes in the recommendations of the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) in 2021. The Company expects the decline in U.S. sales of Pneumovax 23 will continue. Lower demand in Europe also contributed to the Pneumovax 23 sales declines in the third quarter and first nine months of 2022.
In June 2022, the FDA approved an expanded indication for Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) to include use in infants and children. Vaxneuvance is now indicated for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. The FDA’s approval was based on data from seven randomized, double-blind clinical studies assessing safety, tolerability and immunogenicity of Vaxneuvance in infants and children. Vaxneuvance was previously approved by the FDA in 2021 for use in adults 18 years of age and older. Also in June 2022, the CDC’s ACIP unanimously voted to include Vaxneuvance as a recommended option for vaccination in infants and children, including routine use in children under 2 years of age. These recommendations subsequently were adopted by the director of the CDC and the U.S. Department of Health and Human Services, and published in the CDC’s Morbidity and Mortality Weekly Report (MMWR). The ACIP also unanimously voted to include Vaxneuvance in the Vaccines for Children program. In October 2022, the EC approved an expanded indication for Vaxneuvance to include active immunization for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae (S. pneumoniae) in infants, children and adolescents from 6 weeks to less than 18 years of age. Vaxneuvance was previously approved for use in the EU for individuals 18 years of age and older. In September 2022, Vaxneuvance was approved in Japan for use in adult patients. Vaxneuvance remains under review in Japan for use in pediatric patients.
Hospital Acute Care
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Bridion$423 $369 15 %22 %$1,244 $1,096 13 %19 %
Zerbaxa43 (2)**120 (11)**
*Calculation not meaningful.
Worldwide sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 15% and 13% in the third quarter and first nine months of 2022, respectively, due to higher demand globally, particularly in the U.S., largely attributable to Bridion’s growing share among neuromuscular blockade reversal agents and an increase in surgical procedures.
- 38 -

In December 2020, the Company temporarily suspended sales of Zerbaxa, a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. The phased resupply for Zerbaxa that was initiated in the fourth quarter of 2021 has been completed during 2022.
Cardiovascular
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Alliance Revenue - Adempas/Verquvo (1)
$88 $100 (12)%12 %$258 $248 4 %4 %
Adempas57 59 (5)%12 %181 188 (4)%8 %
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4 to the condensed consolidated financial statements).
Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 4 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension. Verquvo was approved in the U.S. in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. Alliance revenue from the collaboration declined 12% and grew 4% in the third quarter and first nine months of 2022, respectively. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories.
Virology
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Lagevrio$436 $— ——$4,859 $— ——
Isentress/Isentress HD161 189 (15)%(11)%466 590 (21)%(17)%
Lagevrio is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note 4 to the condensed consolidated financial statements). Lagevrio has received multiple authorizations or approvals worldwide. Sales of Lagevrio were $436 million in the third quarter of 2022 primarily consisting of sales in Australia, South Korea, Japan and the United Kingdom (UK). Merck’s initial supply commitment of Lagevrio to the U.S. was fulfilled in the first quarter of 2022; therefore, there were no sales of Lagevrio in the U.S. in the second or third quarters of 2022. Sales of Lagevrio were $4.9 billion in the first nine months of 2022 primarily consisting of sales in the U.S., the UK, Japan and Australia. Merck has entered into advance purchase and supply agreements for Lagevrio in more than 40 markets. The Company expects full-year 2022 Lagevrio sales to be between $5.2 billion and $5.4 billion.
Global combined sales of Isentress/Isentress HD, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 15% and 21% in the third quarter and first nine months of 2022, respectively, primarily due to lower global demand, reflecting in part competitive pressure in Europe and the U.S. The Company expects competitive pressure for Isentress/Isentress HD to continue.
Diabetes
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Januvia/Janumet$1,133 $1,339 (15)%(9)%$3,599 $3,895 (8)%(2)%
Worldwide combined sales of Januvia and Janumet, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 15% and 8% in the third quarter and first nine months of 2022, respectively, primarily reflecting the loss of exclusivity in several markets in Europe and the Asia Pacific region, as well as lower demand in the U.S. The sales decline in the first nine months of 2022 was partially offset by higher demand in China, increased demand in Latin America reflecting in part higher government tenders, as well as the impact of a prior year unfavorable adjustment to rebate reserves in the U.S. The Company anticipates U.S. pricing pressure will unfavorably affect sales of Januvia and Janumet in future periods. Januvia and Janumet lost patent exclusivity with respect to the sitagliptin compound patent in China in July 2022, although not with respect to the patent claiming the specific sitagliptin salt form, which expires in June 2024. In addition, the Company lost market
- 39 -

exclusivity with respect to Januvia in the EU in September 2022, and additional exclusivity afforded Janumet that expires in April 2023 is being challenged. The Company anticipates sales of Januvia and Janumet in these markets will decline substantially in future periods following the loss of exclusivity.
The Company will lose sitagliptin compound patent protection for Januvia and Janumet in the U.S. in January 2023. However, in September 2022, the U.S. Court of Appeals for the Federal Circuit ruled in favor of Merck in a patent challenge related to the specific sitagliptin salt form that is the active ingredient in Januvia and Janumet, affirming the May 2021 decision in Merck’s favor by the U.S. Patent Office in an inter partes review. Also in September 2022, the U.S. District Court for the Northern District of West Virginia ruled in favor of the Company in an infringement suit related to the same sitagliptin salt patent, as well as a Janumet formulation patent, finding both Merck patents valid and infringed. The rulings from the U.S. Court of Appeals and the U.S District Court in West Virginia provide Januvia and Janumet patent protection through May 2027; although Merck has settled with multiple generic companies, providing that these generic companies can bring their products to the market in May 2026 or earlier under certain circumstances. The decision from the U.S. District Court in West Virginia is under appeal to the U.S. Court of Appeals for the Federal Circuit. (See Note 9 to the condensed consolidated financial statements.)
Combined sales of Januvia and Janumet in China, Europe and the U.S. represented 10%, 21% and 34%, respectively, of total combined Januvia and Janumet sales for the first nine months of 2022.
In response to a request from a regulatory authority, Merck evaluated its sitagliptin-containing products for the presence of nitrosamines. Nitrosamines are organic compounds found at trace levels in water and food. Nitrosamines can also result from chemical reactions and can form in drugs either due to the drug’s manufacturing process, chemical structure, or the conditions in which the drugs are stored or packaged. The Company detected a nitrosamine identified as Nitroso-STG-19 (NTTP) in some batches of its sitagliptin-containing medicines. The Company has engaged with major health authorities around the world and has implemented additional quality controls to ensure its portfolio of sitagliptin-containing products meet health authorities’ interim acceptable NTTP limits for continuing distribution of product to the market. The Company does not anticipate any significant impact on supply of these medicines.
Animal Health Segment
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20222021% Change20222021% Change
Livestock$829 $864 (4)%4 %$2,486 $2,503 (1)%6 %
Companion Animal542 553 (2)%4 %1,834 1,804 2 %6 %
Sales of livestock products declined 4% and 1% in the third quarter and first nine months of 2022, respectively. Excluding the unfavorable effect of foreign exchange in both periods, livestock sales performance primarily reflects higher pricing, as well as increased demand for poultry and ruminant products. Sales of companion animal products declined 2% in the third quarter of 2022 and grew 2% in first nine months of 2022. Excluding the unfavorable effect of foreign exchange in both periods, sales performance primarily reflects higher pricing and demand in the companion animal portfolio, led by the Bravecto (fluralaner) line of products, partially offset by lower sales of vaccines due to supply constraints. Sales of the Bravecto line of products represented approximately 20% of animal health sales in the first nine months of 2022.
Costs, Expenses and Other
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)20222021% Change20222021% Change
Cost of sales$3,934 $3,450 14 %$13,530 $9,752 39 %
Selling, general and administrative2,520 2,336 8 %7,355 6,804 8 %
Research and development4,399 2,445 80 %9,773 9,177 6 %
Restructuring costs94 107 (12)%288 487 (41)%
Other (income) expense, net429 (450)*1,576 (1,007)*
$11,376 $7,888 44 %$32,522 $25,213 29 %
*Calculation not meaningful.
Cost of Sales
Cost of sales increased 14% and 39% in the third quarter and first nine months of 2022, respectively. Cost of sales includes $234 million and $2.6 billion in the third quarter and first nine months of 2022, respectively, related to the collaboration with Ridgeback for Lagevrio (see Note 4 to the condensed consolidated financial statements). Cost of sales also
- 40 -

includes the amortization of intangible assets recorded in connection with acquisitions, collaborations and licensing arrangements, which totaled $445 million and $346 million in the third quarter of 2022 and 2021, respectively, and $1.6 billion and $1.2 billion in the first nine months of 2022 and 2021, respectively. Amortization expense in the first nine months of 2022 and 2021 includes $250 million and $153 million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with AstraZeneca and Bayer, respectively, (see Note 4 to the condensed consolidated financial statements). Additionally, costs in the first nine months of 2021 include charges of $225 million related to the discontinuation of COVID-19 development programs. Also included in cost of sales are expenses associated with restructuring activities which amounted to $54 million and $48 million in the third quarter of 2022 and 2021, respectively, and $167 million and $113 million in the first nine months of 2022 and 2021, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
Gross margin was 73.7% in the third quarter of 2022 compared with 73.8% in the third quarter of 2021. Gross margin was 70.2% in the first nine months of 2022 compared with 72.3% in the first nine months of 2021. The gross margin declines primarily reflect the impacts of higher revenue from third-party manufacturing arrangements and sales of Lagevrio, both of which have lower gross margins, as well as higher amortization of intangible assets (noted above). The gross margin declines were partially offset by the favorable effects of product mix and foreign exchange. The gross margin decline in the first nine months of 2022 was also partially offset by charges in 2021 related to the discontinuation of COVID-19 development programs.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses increased 8% in both the third quarter and first nine months of 2022 primarily due to higher administrative costs, including compensation and benefits, as well as higher promotional spending and restructuring costs, partially offset by the favorable effect of foreign exchange.
Research and Development
Research and development (R&D) expenses increased to $4.4 billion and $9.8 billion in the third quarter and first nine months of 2022, respectively, from $2.4 billion and $9.2 billion in the third quarter and first nine months of 2021, respectively. The increase in both periods was primarily due to $887 million of intangible asset impairment charges related to ArQule, Inc. (see Note 8 to the condensed consolidated financial statements), higher charges related to collaborations and licensing arrangements, increased clinical development spending, increased investments in technology in support of the digital enablement of Merck’s research operations, as well as higher compensation and benefit costs, partially offset by the favorable effect of foreign exchange. In addition, the increase in R&D expenses in the first nine months of 2022 was partially offset by a $1.7 billion charge in the prior year period related to the acquisition of Pandion Therapeutics, Inc. (Pandion).
R&D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $2.0 billion and $1.8 billion for the third quarter of 2022 and 2021, respectively, and were $5.6 billion and $5.3 billion for the first nine months of 2022 and 2021, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $1.5 billion and $710 million for the third quarter of 2022 and 2021, respectively, and $3.2 billion and $2.1 billion for the first nine months of 2022 and 2021, respectively. The increase in these expenses in the third quarter and first nine months of 2022 compared with the same periods of 2021 largely reflects $690 million of upfront and option payments in the aggregate for collaborations and licensing agreements with Orion, Moderna and Orna. Additionally, R&D expenses in the first nine months of 2022 include $887 million of intangible assets impairment charges and in the first nine months of 2021 include a $1.7 billion charge for the acquisition of Pandion as noted above. See Note 3 for additional information related to business development activity in the current and prior year.
Restructuring Costs
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. Merck expects to record charges of approximately $600 million for the full year of 2022 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in annual net cost savings of approximately $900 million by the end of 2023.
- 41 -

Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $94 million and $107 million for the third quarter of 2022 and 2021, respectively, and $288 million and $487 million for the first nine months of 2022 and 2021, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to restructuring program activities (see Note 5 to the condensed consolidated financial statements).
Other (Income) Expense, Net
Other (income) expense, net, was $429 million of expense in the third quarter of 2022 compared with $450 million of income in the third quarter of 2021. Other (income) expense, net, was $1.6 billion of expense for the first nine months of 2022 compared with $1.0 billion of income for the first nine months of 2021. The change in both periods is primarily due to net unrealized losses from investments in equity securities recorded in the third quarter and first nine months of 2022 compared with net realized and unrealized gains from investments in equity securities recorded in the third quarter and first nine months of 2021. The unfavorability in both periods was partially offset by lower pension costs.
For details on the components of Other (income) expense, net, see Note 12 to the condensed consolidated financial statements.
Segment Profits
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Pharmaceutical segment profits$9,590 $8,606 $28,263 $22,450 
Animal Health segment profits515 505 1,672 1,629 
Other(6,522)(3,845)(17,004)(14,109)
Income from Continuing Operations Before Taxes$3,583 $5,266 $12,931 $9,970 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A and R&D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing arrangements.
Pharmaceutical segment profits increased 11% and 26% in the third quarter and first nine months of 2022, respectively, reflecting higher sales, partially offset by higher administrative and promotional costs, as well as the unfavorable effect of foreign exchange. Animal Health segment profits grew 2% in the third quarter of 2022 reflecting favorable product mix, partially offset by the unfavorable effect of foreign exchange. Animal Health segment profits grew 3% in the first nine months of 2022 reflecting higher sales, partially offset by higher selling and administrative costs and the unfavorable effect of foreign exchange.

- 42 -

Taxes on Income
The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related to the settlement of certain federal income tax matters as discussed below.
In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.
Non-GAAP Income and Non-GAAP EPS from Continuing Operations
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP).
In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results no longer exclude charges related to these items. Prior periods have been recast to conform to the current presentation.

- 43 -

A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions except per share amounts)2022202120222021
Income from continuing operations before taxes as reported under GAAP$3,583 $5,266 $12,931 $9,970 
Increase (decrease) for excluded items:
Acquisition and divestiture-related costs
1,344 445 2,512 1,445 
Restructuring costs
175 168 559 630 
Loss (income) from investments in equity securities, net350 (684)1,268 (1,503)
Other items:
Charges for the discontinuation of COVID-19 development programs— — — 225 
Non-GAAP income from continuing operations before taxes5,452 5,195 17,270 10,767 
Taxes on income from continuing operations as reported under GAAP330 695 1,423 1,436 
Estimated tax benefit (provision) on excluded items (1)
414 (29)965 84 
Net tax benefit from the settlement of certain federal income tax matters— — — 207 
Non-GAAP taxes on income from continuing operations744 666 2,388 1,727 
Non-GAAP net income from continuing operations4,708 4,529 14,882 9,040 
Less: Net income attributable to noncontrolling interests as reported under GAAP5 4 6 9 
Non-GAAP net income from continuing operations attributable to Merck & Co., Inc.$4,703 $4,525 $14,876 $9,031 
EPS assuming dilution from continuing operations as reported under GAAP$1.28 $1.80 $4.53 $3.36 
EPS difference0.57 (0.02)1.33 0.20 
Non-GAAP EPS assuming dilution from continuing operations$1.85 $1.78 $5.86 $3.56 
(1) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Income and Losses from Investments in Equity Securities
Non-GAAP income and non-GAAP EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2021 are charges related to the discontinuation of COVID-19 development programs (see Note 3 to the condensed consolidated financial statements) and a net tax benefit related to the settlement of certain federal income tax matters (see Note 13 to the condensed consolidated financial statements).

- 44 -

Research and Development Update
The Company currently has several candidates under regulatory review in the U.S. and internationally.
MK-4482, Lagevrio, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing Lagevrio in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for Lagevrio in December 2021; last reissued in October 2022, to authorize Lagevrio for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. Lagevrio is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. Lagevrio has also received Conditional Marketing Authorization in the UK and Special Approval for Emergency in Japan. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for Lagevrio, which is intended to support national decision-making on the possible use of Lagevrio prior to marketing authorization. In October 2021, the EMA initiated a rolling review for Lagevrio for the treatment of COVID-19 in adults. Merck plans to work with the Committee for Medicinal Products for Human Use of the EMA to complete the rolling review process to facilitate initiating the formal review of the Marketing Authorization Application. Applications to other regulatory bodies are underway. Lagevrio is also being evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy and safety of Lagevrio for the prevention of COVID-19 in adults who reside with a person with COVID-19.
In October 2022, Merck provided an update on new clinical and non-clinical studies of Lagevrio. A preliminary analysis of the University of Oxford’s PANORAMIC study, conducted in the UK in highly-vaccinated adults mostly over 65 years of age, showed no evidence of a difference between Lagevrio added to usual care compared to usual care alone for the reduction of hospitalizations and deaths through Day 28 (primary endpoint was not met); the incidence of hospitalizations and death through Day 28 was very low overall. The main secondary endpoint (time to first self-reported recovery) in the PANORAMIC study was 6 days shorter with the Lagevrio group compared to the usual care group; in addition, the use of Lagevrio also was associated with earlier recovery across a wide range of other symptom measures, as compared to the usual care group. Additionally, an analysis of real-world data from a separate study conducted by investigators in Israel (known as the Clalit study) showed that in a cohort of non-hospitalized, high-risk patients, Lagevrio reduced hospitalizations and mortality due to COVID-19 in patients 65 years and above; no evidence of benefit was found in younger adults ages 40 to 64 years. Also, Merck reported results from a separate, non-clinical 6-month carcinogenicity study in transgenic mice, which demonstrated that Lagevrio was not carcinogenic at any dose tested.
MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA and EMA. The marketing applications for gefapixant are based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application (NDA) for gefapixant. In the CRL, the FDA requested additional information related to the cough counting system that was used to assess efficacy. The CRL was not related to the safety of gefapixant. The Company is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023 in response to the CRL. The review period in the EU has been extended pending the receipt of additional information from the Company. The Company plans to submit the information to the EMA in the first half of 2023.
MK-3475, Keytruda, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,650 clinical trials, including more than 1,200 trials that combine Keytruda with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
Keytruda is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from the KEYNOTE-240 and KEYNOTE-224 trials. Keytruda is approved for this indication in the U.S. under the FDA’s accelerated approval process. This submission is to convert the accelerated approval to full (regular) approval.
Keytruda is also under review by the FDA for the adjuvant treatment of patients with stage IB (≥4 centimeters), II or IIIA NSCLC following complete surgical resection. The supplemental Biologics License Application is based on data from the pivotal Phase 3 KEYNOTE-091 trial, also known as EORTC-1416-LCG/ETOP-8-15 – PEARLS. The FDA set a Prescription
- 45 -

Drug User Fee Act (PDUFA) date of January 29, 2023, however, further data may be provided during the review process that may delay this date. Keytruda is also under review for this indication in the EU.
In July 2022, Merck announced that the Phase 3 KEYNOTE-412 trial evaluating Keytruda with concurrent chemoradiation therapy (CRT) followed by Keytruda as maintenance therapy (the Keytruda regimen) did not meet its primary endpoint of event-free survival for the treatment of patients with unresected locally advanced HNSCC. At the final analysis of the study, there was an improvement in event-free survival for patients who received the Keytruda regimen compared to placebo plus CRT; however, these results did not meet statistical significance per the pre-specified statistical plan. Results were presented at the 2022 European Society for Medical Oncology (ESMO) congress.
In August 2022, Merck announced that the Phase 3 KEYNOTE-921 trial evaluating Keytruda in combination with chemotherapy (docetaxel) compared to chemotherapy alone did not meet its dual primary endpoints of overall survival and radiographic progression-free survival for the treatment of patients with metastatic castration-resistant prostate cancer. In the study, there were modest trends toward an improvement in both overall survival and radiographic progression-free survival for patients who received Keytruda plus chemotherapy compared with chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. Results will be presented at an upcoming medical meeting.
MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca.
In August 2022, the FDA granted priority review for a supplemental NDA for Lynparza in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. The supplemental NDA was based on results from the Phase 3 PROpel trial, which were presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and later published in NEJM Evidence. The FDA set a PDUFA date in the fourth quarter of 2022. Lynparza is also under review in the EU and Japan for the treatment of certain patients with metastatic castration-resistant prostate cancer based on the PROpel clinical trial.
In March 2022, Merck announced that it would stop the Phase 3 KEYLYNK-010 trial investigating Keytruda in combination with Lynparza for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. Merck has discontinued the study following the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed data from a planned interim analysis. At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival, one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide. The trial’s other dual primary endpoint, radiographic progression free survival, was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. Results from the study were presented at the 2022 ESMO congress.
In July 2022, Merck announced it will stop the Phase 3 LYNK-003 trial investigating Lynparza with or without bevacizumab for the treatment of patients with unresectable or metastatic colorectal cancer who have not progressed following first-line induction. This action follows the recommendation of an independent DMC, after the DMC reviewed the data from a planned interim analysis. At the pre-specified interim analysis for progression-free survival, the efficacy of Lynparza as a monotherapy and in combination with bevacizumab relative to control met the criteria for futility by the DMC and accordingly, both experimental arms were discontinued. Data from this study will be shared in a future scientific forum.
MK-7902, Lenvima, is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai. Merck and Eisai are studying the Keytruda plus Lenvima combination through the LEAP (LEnvatinib And Pembrolizumab) clinical program.
In August 2022, Merck and Eisai announced that the Phase 3 LEAP-002 trial investigating Keytruda plus Lenvima versus Lenvima monotherapy did not meet its dual primary endpoints of overall survival and progression-free survival as a first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC). There were trends toward improvement in overall survival and progression-free survival for patients who received Keytruda plus Lenvima versus Lenvima monotherapy; however, these results did not meet statistical significance per the pre-specified statistical plan. Results were presented at the 2022 ESMO congress.
In July 2020, Merck and Eisai announced that the FDA issued a CRL regarding Merck’s and Eisai’s applications seeking accelerated approval of Keytruda plus Lenvima for the first-line treatment of patients with uHCC based on data from the Phase 1b KEYNOTE-524/Study 116 trial. Given the results of the LEAP-002 trial noted above, Merck no longer intends to pursue the application.
In October 2022, Merck announced positive top-line results from the pivotal Phase 3 STELLAR trial evaluating the safety and efficacy of sotatercept, an investigational activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein being evaluated as an add-on to stable background therapy for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization [WHO] Group 1). The trial met its primary efficacy outcome measure, demonstrating a statistically significant and
- 46 -

clinically meaningful improvement in 6-minute walk distance (6MWD, which measures how far patients can walk in 6 minutes). Eight of nine secondary efficacy outcome measures achieved statistical significance, including the outcome measure of proportion of participants achieving multicomponent improvement (defined as improvement in 6MWD, improvement in N-terminal pro-B-type natriuretic peptide level, and either improvement in WHO Functional Class [FC] or maintenance of WHO FC II), and the outcome measure of time to death or the first occurrence of a clinical worsening event. The Cognitive/Emotional Impacts domain score of PAH-SYMPACT®, which was assessed as the ninth and final secondary outcome measure, did not achieve statistical significance. Results from the study will be presented at an upcoming scientific congress.
In September 2022, Merck announced it will initiate a new Phase 3 clinical program with once-daily islatravir for the treatment of people with HIV-1 infection. These new Phase 3 studies will evaluate a once-daily oral combination of doravirine 100 mg and a lower dose of islatravir (DOR/ISL). One study will evaluate DOR/ISL in previously untreated adults with HIV-1 infection and two studies will evaluate DOR/ISL as a switch in antiretroviral therapy in adults with HIV-1 infection who are virologically suppressed. The investigational new drug application for the once-daily oral DOR/ISL treatment program remains under a partial clinical hold for any studies that would use doses higher than the dose to be studied in the new Phase 3 program. The Phase 2 clinical trial evaluating an investigational oral once-weekly combination treatment regimen of islatravir and Gilead Sciences’ lenacapavir in adults with HIV-1 infection who are virologically suppressed will resume under an amended protocol with a lower dose of islatravir. The investigational new drug application under which the islatravir + lenacapavir once-weekly treatment regimen is being investigated remains under a partial clinical hold for any studies that would use weekly oral islatravir doses higher than the doses considered for the revised clinical program. Additionally, Merck announced it will discontinue the development of once-monthly oral islatravir for pre-exposure prophylaxis (PrEP).
In June 2022, Merck announced the presentation of positive results from a Phase 1/2 study evaluating the safety, tolerability and immunogenicity of V116, the Company’s investigational 21-valent pneumococcal conjugate vaccine (PCV), in pneumococcal vaccine-naïve adults 18-49 years of age (Phase 1) and 50 years of age and older (Phase 2). In both populations, V116 met the primary immunogenicity objectives and was well-tolerated with an overall safety profile generally comparable to Pneumovax 23 across age groups. In April 2022, Merck announced that V116 received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. The Breakthrough Therapy Designation is an FDA program designed to expedite the development and review of products intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must indicate that the product may demonstrate substantial improvement over currently available options on at least one clinically significant endpoint. Enrollment in several Phase 3 trials evaluating V116 is ongoing.
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties.
The charts below reflect the Company’s research pipeline as of November 3, 2022. Candidates shown in Phase 3 include the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
- 47 -

Phase 2
Cancer
MK-0482(2)
     Non-Small-Cell Lung
MK-1026 (nemtabrutinib)
     Hematological Malignancies
MK-1308 (quavonlimab)(2)
Non-Small-Cell Lung
MK-1308A (quavonlimab+pembrolizumab)
Colorectal
Hepatocellular
Melanoma
Small-Cell Lung
MK-2140 (zilovertamab vedotin)
Breast
Gastric
Hematological Malignancies
Non-Small-Cell Lung
Ovarian
Pancreatic
MK-2870(1)(3)
Neoplasm Malignant
MK-3475 Keytruda
Advanced Solid Tumors
MK-4280 (favezelimab)(2)
    Non-Small-Cell Lung
MK-4280A (favezelimab+pembrolizumab)
     Esophageal
     Renal Cell
     Small-Cell Lung
MK-4830(2)
        Colorectal
     Esophageal
     Melanoma
Non-Small-Cell Lung
Ovarian
Renal Cell
     Small-Cell Lung
MK-5684(1)
Prostate
MK-5890 (boserolimab)(2)
     Non-Small-Cell Lung
     Small-Cell Lung



Cancer
MK-6440 (ladiratuzumab vedotin)(1)(3)
Breast
Esophageal
Gastric
Head and Neck
Melanoma
Non-Small-Cell Lung
Prostate
Small-Cell Lung
MK-6482 Welireg(3)
Biliary
Colorectal
Endometrial
Esophageal
Hepatocellular
Pancreatic
Rare cancers
Von Hippel-Lindau Disease-Associated Tumors (EU)
MK-7119 Tukysa(1)
Advanced Solid Tumors
Biliary
Bladder
Cervical
Endometrial
Gastric
Non-Small-Cell Lung
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684 (vibostolimab)(2)
Melanoma
MK-7684A (vibostolimab+pembrolizumab)
Biliary
Breast
Cervical
Colorectal
Endometrial
Esophageal
Head and Neck
Hematological Malignancies
Hepatocellular
Prostate

Cancer
MK-7902 Lenvima(1)(2)
Biliary
Glioblastoma
Pancreatic
Prostate
Small-Cell Lung
V940(1)
Melanoma
Chikungunya Virus Vaccine
V184
Dengue Fever Virus Vaccine
V181
HIV-1 Infection
MK-8591B (islatravir+MK-8507)(4)
MK-8591D (islatravir+lenacapavir)(1)(5)
Hypercholesterolemia
MK-0616
Nonalcoholic Steatohepatitis (NASH)
MK-3655
MK-6024
Overgrowth Syndrome
MK-7075 (miransertib)
Pulmonary Arterial Hypertension
MK-5475
Pulmonary Hypertension Due To Left Heart Disease
MK-7962 (sotatercept)
Schizophrenia
MK-8189(6)
Thrombosis
MK-2060
Treatment Resistant Depression
MK-1942

- 48 -

Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
     MK-4482 Lagevrio (U.S.) (May 2021)(1)(7)
Cancer
MK-1308A (quavonlimab+pembrolizumab)
Renal Cell (April 2021)
MK-3475 Keytruda
Biliary (September 2019)
Cutaneous Squamous Cell (August 2019) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017)
MK-3475 (pembrolizumab subcutaneous)
Non-Small-Cell Lung (August 2021)
MK-4280A (favezelimab+pembrolizumab)
Colorectal (November 2021)
Hematological Malignancies (October 2022)
MK-6482 Welireg(3)
Renal Cell (February 2020)
MK-7119 Tukysa(1)
Breast (October 2019)
Colorectal (August 2022)
MK-7339 Lynparza(1)(3)
Non-Small-Cell Lung (June 2019)
Small-Cell Lung (December 2020)
MK-7684A (vibostolimab+pembrolizumab)
Non-Small-Cell Lung (April 2021)
Small-Cell Lung (March 2022)
MK-7902 Lenvima(1)(2)
Colorectal (April 2021)
Esophageal (July 2021)
Gastric (December 2020)
Head and Neck (February 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
HIV-1 Infection
     MK-8591A (doravirine+islatravir) (February 2020)(5)
Pneumococcal Vaccine Adult
V116 (July 2022)
Pulmonary Arterial Hypertension
MK-7962 (sotatercept) (January 2021)
Respiratory Syncytial Virus
MK-1654 (clesrovimab) (November 2021)
New Molecular Entities/Vaccines
Antiviral COVID-19
MK-4482 Lagevrio (EU)(1)
Cough
MK-7264 (gefapixant) (U.S.)(8) (EU)






Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• Second-Line Hepatocellular Cancer
(KEYNOTE-394) (U.S.)
• Adjuvent Non-Small-Cell Lung Cancer
(KEYNOTE-091) (U.S.) (EU)

MK-7339 Lynparza(1)
• First-Line Metastatic Prostate Cancer
(PROpel) (U.S.) (EU) (JPN)



Footnotes:
(1) Being developed in a collaboration.
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and/or in combination with Keytruda.
(4) On FDA clinical hold.
(5) On FDA partial clinical hold.
(6) Phase 2b development costs are being co-funded.
(7) Available in the U.S. under Emergency Use Authorization.
(8) In response to the CRL received from the FDA for this application in January 2022, Merck is performing additional analyses and anticipates submitting this information to the FDA in the first half of 2023.


Liquidity and Capital Resources
($ in millions)September 30, 2022December 31, 2021
Cash and investments$12,232 $8,466 
Working capital10,563 6,394 
Total debt to total liabilities and equity28.4 %31.3 %
Cash provided by operating activities of continuing operations was $14.7 billion in the first nine months of 2022 compared with $8.0 billion in the first nine months of 2021 reflecting stronger operating performance, including the impact of Lagevrio (see Note 4 to the condensed consolidated financial statements). Cash provided by operating activities of continuing operations in the first nine months of 2022 was reduced by $1.8 billion of milestone payments related to collaborations compared with $432 million of milestone and option payments related to collaborations in the first nine months of 2021. Cash provided by operating activities of continuing operations continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance capital expenditures, dividends paid to shareholders and treasury stock purchases. As a result of the mandatory change in R&D capitalization rules that are effective for tax years beginning after December 31, 2021 (related to the Tax Cuts and Jobs Act of 2017), the Company has paid higher taxes in the U.S. in the first nine months of 2022 compared with the same prior year period.
Cash used in investing activities of continuing operations was $3.2 billion in the first nine months of 2022 compared with $4.4 billion in the first nine months of 2021. The lower use of cash in investing activities of continuing operations was primarily due to lower cash used for acquisitions and higher proceeds from the sale of securities and other investments, partially offset by higher purchases of securities and other investments.
- 49 -

Cash used in financing activities of continuing operations was $7.6 billion in the first nine months of 2022 compared with $2.1 billion in the first nine months of 2021. The increase in cash used in financing activities of continuing operations was primarily due to the cash distribution in 2021 received from Organon in connection with the spin-off (see Note 2 to the condensed consolidated financial statements) coupled with higher payments on long-term debt and higher dividends paid to shareholders in the current period. The increase in cash used in financing activities was partially offset by net repayments of short-term borrowings and treasury stock purchases in the prior year period that did not occur in the current period.
Capital expenditures totaled $3.2 billion in both the first nine months of 2022 and the first nine months of 2021.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable at September 30, 2022 and December 31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.
Dividends paid to stockholders were $5.3 billion and $5.0 billion for the first nine months of 2022 and 2021, respectively. In May 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company’s stock for the third quarter that was paid in July 2022. In July 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company’s stock for the fourth quarter that was paid in October 2022.
In February 2022, the Company’s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In September 2022, the Company’s $1.0 billion, 2.40% notes matured in accordance with their terms and were repaid. In January 2021, the Company’s $1.15 billion, 3.875% notes matured in accordance with their terms and were repaid.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company did not purchase any shares of its common stock during the first nine months of 2022. As of September 30, 2022, the Company’s remaining share repurchase authorization was $5.0 billion.
The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Estimates
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2021 included in Merck’s Form 10‑K filed on February 25, 2022. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2022. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December 31, 2021.
Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2021 Form 10-K filed on February 25, 2022.
The economy of Turkey was recently determined to be hyperinflationary. Consequently, in accordance with U.S. GAAP, the Company’s monetary assets and liabilities that are subject to remeasurement as a result of the changes in the Turkish lira changed beginning in the second quarter of 2022. This change had an immaterial impact to Merck’s condensed consolidated financial statements.
- 50 -


Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2022, the Company’s disclosure controls and procedures are effective. For the third quarter of 2022, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and may include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2021, filed on February 25, 2022, in the Company’s Form 10-Q for the quarterly period ended March 31, 2022, filed on May 5, 2022, the Company’s Form 10-Q for the quarterly period ended June 30, 2022, filed on August 5, 2022, and in this Form 10-Q, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 9 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on Form 10-K, except as follows:
The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company’s business, results of operations and financial condition.
The ongoing war between Russia and Ukraine, and the financial and economic sanctions imposed by the U.S., the European Union and other countries in response, are having pervasive direct and indirect effects on the global economy, and may adversely affect the Company’s business, results of operations and financial condition. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials.
For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck is donating profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as
- 51 -

planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products.
The financial impacts of the war between Russia and Ukraine were immaterial to the Company’s consolidated financial statements for the third quarter and first nine months of 2022. However, the degree to which the war and related disruptions will impact the Company’s results for the remainder of 2022 or beyond is difficult to predict and will depend on developments outside of the Company’s control, including, but not limited to, the duration and severity of the war, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets. Such developments may negatively impact the Company directly or indirectly as well as the parties with which the Company conducts business. In addition, the effects of the war between Russia and Ukraine could heighten other risks disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which could materially adversely affect the Company’s business, results of operations and financial condition.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended September 30, 2022 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
July 1 - July 31— $0.00— $5,047
August 1 - August 31— $0.00— $5,047
September 1 - September 30— $0.00— $5,047
Total— $0.00— 
(1) The Company did not purchase any shares during the three months ended September 30, 2022 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.
Item 6. Exhibits
Number  Description
3.1—
3.2—
31.1 —
31.2 —
32.1 —
32.2 —
101.INS—XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH—XBRL Taxonomy Extension Schema Document.
101.CAL—XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF—XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB—XBRL Taxonomy Extension Label Linkbase Document.
101.PRE—XBRL Taxonomy Extension Presentation Linkbase Document.
104 —Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 52 -




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 MERCK & CO., INC.
Date: November 3, 2022 /s/ Jennifer Zachary
 JENNIFER ZACHARY
 Executive Vice President and General Counsel
Date: November 3, 2022 /s/ Rita A. Karachun
 RITA A. KARACHUN
 Senior Vice President Finance - Global Controller
- 53 -
 EX-31.1 2 exhibit311-rule13ax14a15dx.htm EXHIBIT-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO Document

Exhibit 31.1
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 3, 2022
 
By:     /s/ Robert M. Davis
ROBERT M. DAVIS
Chief Executive Officer and President

 EX-31.2 3 exhibit312-rule13ax14a15dx.htm EXHIBIT-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO Document

Exhibit 31.2
CERTIFICATION
I, Caroline Litchfield, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   November 3, 2022
By:      /s/ Caroline Litchfield
CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer

 EX-32.1 4 exhibit321-section1350cert.htm EXHIBIT-32.1 SECTION 1350 CERTIFICATION OF CEO Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
 
 
 
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 3, 2022
/s/ Robert M. Davis
Name:
Title:		ROBERT M. DAVIS
Chief Executive Officer and President



 EX-32.2 5 exhibit322-section1350cert.htm EXHIBIT-32.2 SECTION 1350 CERTIFICATION OF CFO Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer



Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 3, 2022
/s/ Caroline Litchfield
Name:
Title:		CAROLINE LITCHFIELD
Executive Vice President, Chief Financial Officer




 EX-101.SCH 6 mrk-20220930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Spin-Off of Organon & Co. link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Other Intangibles link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Spin-Off of Organon & Co. (Tables) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) link:presentationLink link:calculationLink link:definitionLink 0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 0000039 - Disclosure - Collaborative Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 0000041 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 0000043 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 0000044 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000054 - Disclosure - Inventories - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 0000055 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000056 - Disclosure - Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 0000057 - Disclosure - Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 0000058 - Disclosure - Equity - Rollforward Reconciliations (Details) link:presentationLink link:calculationLink link:definitionLink 0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) link:presentationLink link:calculationLink link:definitionLink 0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000063 - Disclosure - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 0000065 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000066 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 0000067 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000068 - Disclosure - Segment Reporting - Sales from Products (Details) link:presentationLink link:calculationLink link:definitionLink 0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrk-20220930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mrk-20220930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mrk-20220930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Inventory [Axis] Inventory [Axis] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Loss contingency, pending claims Loss Contingency, Pending Claims, Number Compensation earned Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Entity Address, Postal Zip Code Entity Address, Postal Zip Code Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Investments Debt Securities, Trading, and Equity Securities, FV-NI Schedule of Equity Schedule of Stockholders Equity [Table Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Foreign exchange contracts Foreign Exchange Contract [Member] Revenue related to the sale of the marketing rights Proceeds from Sale of Intangible Assets Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Sales Disposal Group, Including Discontinued Operation, Revenue Lagevrio Lagevrio [Member] Lagevrio Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Financial Instruments Financial Instruments [Domain] Other Payments for (Proceeds from) Other Investing Activities Statistical Measurement [Domain] Statistical Measurement [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Depreciation Depreciation Depreciation Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Location and Amount of Pretax Gains and Losses of Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Other current assets Other Current Assets [Member] Other paid-in capital Additional Paid in Capital, Common Stock Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Domestic Tax Authority Domestic Tax Authority [Member] Other Other Noncash Income (Expense) Derivative Liability, Statement of Financial Position [Extensible Enumeration] Derivative Liability, Statement of Financial Position [Extensible Enumeration] Bayer AG Bayer AG [Member] Bayer AG [Member] Income taxes paid Income Taxes Paid Milestone payments accrued but not yet paid Milestone Payments Accrued Sales Based Milestone Payments Accrued Sales Based Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net income attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Antidilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Other Intangible Assets Other Intangible Assets [Member] Amortization of unrecognized prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Subsequent Event Type [Axis] Subsequent Event Type [Axis] Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member] Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Equity Component [Domain] Equity Component [Domain] Net cash provided by operating activities Cash Provided by (Used in) Operating Activities, Discontinued Operations Subsequent Event Type [Domain] Subsequent Event Type [Domain] Scenario [Axis] Scenario [Axis] Total assets Assets, Fair Value Disclosure Number of interest rate swaps held (in interest rate swaps) Number of Interest Rate Derivatives Held Cases Company Agreed To Toll Statute Of Limitations Cases Company Agreed ToToll Statute Of Limitations [Member] Cases Company Agreed To Toll Statute Of Limitations[Member] Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021 Treasury Stock, Common, Value Debt securities, fair value Investments Debt Securities, Available-for-Sale Hedging Designation [Domain] Hedging Designation [Domain] Income from Continuing Operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Derivative Instrument [Axis] Derivative Instrument [Axis] Number of operating segments Number of Operating Segments Sales discounts Sales Discounts Sales Discounts Payables included in Other Noncurrent Liabilities Liabilities, Noncurrent AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Other Comprehensive (Loss) Income Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Operating Activities [Domain] Operating Activities [Domain] Tax benefit recognized related to settlement Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Fair Value of Derivative, Asset Gross amounts recognized in the consolidated balance sheet, asset Derivative assets Derivative Asset In Process Research and Development In Process Research and Development [Member] Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Additional funding by others, development costs subject to funding Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding Related Party Transaction [Domain] Related Party Transaction [Domain] Costs, Expenses and Other Costs and Expenses [Abstract] Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Animal Health Animal Health segment Animal Health segment [Member] Animal Health segment [Member] Legal Entity [Axis] Legal Entity [Axis] Raw materials and work in process Inventory, Work in Process and Raw Materials Long-Term Debt Long-Term Debt, Excluding Current Maturities Liabilities Liabilities Cash Flows from Discontinued Operations Net Cash Provided by (Used in) Discontinued Operations [Abstract] Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo Geographical [Axis] Geographical [Axis] Cash Flows from Investing Activities of Continuing Operations Net Cash Provided by (Used in) Investing Activities [Abstract] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Collaboration Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Collaborative Arrangement, Transaction with Party to Collaborative Arrangement Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] Income from Discontinued Operations (in dollars per share) Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share Factored accounts receivable Accounts Receivable, Sale Document Type Document Type Acquisition of Pandion Therapeutics, Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Accounts Payable and Accrued Liabilities Accounts Payable and Accrued Liabilities [Member] Restructuring Type [Axis] Restructuring Type [Axis] Segments [Axis] Segments [Axis] Asset Acquisition [Axis] Asset Acquisition [Axis] Product and Service [Domain] Product and Service [Domain] Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Entity Shell Company Entity Shell Company Deferred income taxes Deferred Income Tax Expense (Benefit) Financial Instrument Financial Instrument [Axis] Capitalized milestone payment Milestone Payments Made to Collaborative Partner Milestone Payments Made to Collaborative Partner Amount of gain (loss) recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Financial Instruments Financial Instruments Disclosure [Text Block] Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Consolidation Items [Domain] Consolidation Items [Domain] Subsequent Event Subsequent Event [Member] Document Period End Date Document Period End Date Income Tax Examination [Table] Income Tax Examination [Table] Januvia Januvia [Member] Januvia [Member] . Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Alliance revenue - profit sharing Collaborative Arrangement, Profit Sharing Collaborative Arrangement, Profit Sharing Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Total Assets Assets Milestone payments to be made to a collaborative partner Milestone Payments to be Made to a Collaborative Partner Milestone Payments to be Made to a Collaborative Partner Net Cash Used in Financing Activities of Continuing Operations Net Cash Provided by (Used in) Financing Activities, Continuing Operations Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Currency options Foreign Exchange Option [Member] Publicly traded equity securities, fair value Publicly traded equity securities Equity Securities, FV-NI, Current Other current assets Deferred Income Taxes and Other Assets, Current [Member] Deferred Income Taxes and Other Assets, Current Interest rate swap contracts Interest rate swaps Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Artiva Biotherapeutics, Inc. Artiva Biotherapeutics, Inc. [Member] Artiva Biotherapeutics, Inc. 2.40% Notes Due 2022 2.40% Notes Due 2022 [Member] 2.40% Notes Due 2022 [Member] Reclassification adjustments, net of taxes Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Merck & Co., Inc. Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Income from Continuing Operations Before Taxes Profits Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest RotaTeq Rotateq [Member] RotaTeq [Member] Maximum average period of maturities of contracts in years (less than) Derivative, Average Remaining Maturity Segments [Domain] Segments [Domain] Transition services agreement Transition services agreement [Member] Transition services agreement Amounts Recorded on Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Net assets Asset Acquisition, Other Assets and Liabilities Recognized, Net Asset Acquisition, Other Assets and Liabilities Recognized, Net Earnings Per Share Earnings Per Share [Text Block] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Interest cost Defined Benefit Plan, Interest Cost Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Loss contingency, claims settled Loss Contingency, Claims Settled, Number Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Net cash used in investing activities Cash Provided by (Used in) Investing Activities, Discontinued Operations Other pharmaceutical Other Pharmaceutical [Member] Other pharmaceutical. Finished goods Inventory, Finished Goods, Gross Derivative Contract [Domain] Derivative Contract [Domain] Number of research programs Collaborative Arrangement, Number Of Research Programs Collaborative Arrangement, Number Of Research Programs Entity Registrant Name Entity Registrant Name COLOMBIA COLOMBIA China CHINA Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Foreign Currency Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Patents Patents [Member] Entity Address, City or Town Entity Address, City or Town Belsomra Belsomra [Member] Belsomra [Member] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Europe, Middle East and Africa EMEA [Member] Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Total equity Equity, beginning balance Equity, ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] Lenvima Alliance revenue - Lenvima Lenvima [Member] Lenvima [Member] Legal Costs Legal Costs, Policy [Policy Text Block] Minimum Minimum [Member] Noncontrolling Interests Stockholders' Equity Attributable to Noncontrolling Interest Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Income Tax Examination [Line Items] Income Tax Examination [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table]   Treasury Stock Treasury Stock, Common [Member] Pension Plans Pension Plan [Member] Trading Symbol Trading Symbol Entity File Number Entity File Number Other Intangibles Intangible Assets Disclosure [Text Block] 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] [Line Items] for Stockholders Equity [Table] Treasury stock (in shares) Treasury stock, beginning balance (in shares) Treasury stock, ending balance (in shares) Treasury Stock, Common, Shares Tax Reclassification from AOCI, Current Period, Tax Operating Activities [Axis] Operating Activities [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Loss contingency, claims on appeal Loss Contingency, Claims on Appeal, Number Loss Contingency, Claims on Appeal, Number Research and development Research and development Research and Development Expense Supplies Other Inventory, Supplies, Gross Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Probable contingent payments Probable Contingent Payments Collaborative Arrangement Probable Contingent Payments Collaborative Arrangement Restricted cash Restricted Cash and Cash Equivalents Entity Information [Line Items] Entity Information [Line Items] Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Costs, Expenses and Other Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract] Due from related parties, current Due from Related Parties, Current Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) COVID-19 COVID-19 [Member] COVID-19 Sales Sales Revenues Inventory [Table] Inventory [Table] Inventory [Table] Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Taxes on Income Income Tax Disclosure [Text Block] Revenue from related party Revenue from Related Parties Net Income from Continuing Operations Attributable to Merck & Co., Inc. Net Income from Continuing Operations Attributable to Merck & Co., Inc. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Amortization of intangible assets Amortization of Intangible Assets Net Income (in dollars per share) Net Income (in dollars per share) Earnings Per Share, Basic Debt, carrying amount Debt, Long-Term and Short-Term, Combined Amount Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Recognized as: Recognized As [Abstract] Recognized as. Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Corporate, Non-Segment Corporate, Non-Segment Corporate, Non-Segment [Member] Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Primaxin Primaxin [Member] Primaxin [Member]. License option payment related to collaborative arrangement License option payment related to collaborative arrangement License option payment related to collaborative arrangement Counterparty Name [Domain] Counterparty Name [Domain] Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Upfront and milestone payments Upfront And Milestone Payments Made To Collaborative Partner Upfront and milestone payments made to partner as part of collaborative arrangement. Total Merck & Co., Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Asset acquisition costs Asset Acquisition, Consideration Transferred, Transaction Cost Estimate of cumulative pre tax costs that will result in cash outlays Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense). Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Interactive Data Current Entity Interactive Data Current Vaqta Vaqta [Member] Vaqta [Member] Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other Remaining minimum courses committed (in courses) Supply Commitment, Remaining Minimum Courses Committed Supply Commitment, Remaining Minimum Courses Committed Research and development payments to be made to a collaborative partner (up to) Research and Development Payments to be Made to a Collaborative Partner Research and Development Payments to be Made to a Collaborative Partner Information About the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Retained Earnings Retained Earnings [Member] Development Milestones Development Milestones [Member] Development Milestones [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Cash dividends declared on common stock Dividends, Common Stock, Cash Other (income) expense, net Other Nonoperating Income (Expense) [Member] Potential future sales-based milestone payments Potential Future Milestone Payments Sales-Based Potential Future Milestone Payments Sales-Based Noxafil Noxafil [Member] Noxafil [Member]. Litigation Status [Domain] Litigation Status [Domain] Common Stock ($0.50 par value)    Common Stock Common Stock [Member] Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive income (loss) before reclassification adjustments, net of taxes OCI, before Reclassifications, Net of Tax, Attributable to Parent Purchases of treasury stock Payments for Repurchase of Common Stock Net changes in assets and liabilities Increase (Decrease) in Operating Capital Contingent consideration Fair value, beginning balance Fair value, ending balance Business Combination, Contingent Consideration, Liability Class of Stock [Axis] Class of Stock [Axis] Disposal Groups, Including Discontinued Operations Disposal Groups, Including Discontinued Operations [Table Text Block] Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Receivables included in Other current assets Receivables, Net, Current Investments Marketable Securities, Noncurrent Document Quarterly Report Document Quarterly Report Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Current Assets Assets, Current [Abstract] Benefit plan net (loss) gain and prior service (cost) credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Statistical Measurement [Axis] Statistical Measurement [Axis] Charge for the acquisition of Pandion Therapeutics, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off Treasury stock shares purchased (in shares) Treasury Stock, Shares, Acquired Asset Acquisition [Domain] Asset Acquisition [Domain] Less: Income of discontinued operations attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest Januvia and Janumet Januvia and Janumet [Member] Januvia and Janumet Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Related Party Transaction [Axis] Related Party Transaction [Axis] Retained earnings Retained Earnings (Accumulated Deficit) ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Cash equivalents Cash Equivalents, at Carrying Value Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021) Accounts Receivable, after Allowance for Credit Loss, Current Purchases of securities and other investments Payments to Acquire Marketable Securities Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Litigation Case [Domain] Litigation Case [Domain] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Document Fiscal Year Focus Document Fiscal Year Focus International Foreign Plan [Member] Other (income) expense, net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Disposal Group, Including Discontinued Operation, Other Income (Expense), Net Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Cash Flows from Operating Activities of Continuing Operations Net Cash Provided by (Used in) Operating Activities [Abstract] Simponi Simponi [Member] Simponi [Member]. Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Consideration received Disposal Group, Including Discontinued Operation, Consideration Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] Current liability Business Combination, Contingent Consideration, Liability, Current Loss contingency, recovery from third party, bench trial period Loss Contingency, Recovery From Third Party, Bench Trial Period Loss Contingency, Recovery From Third Party, Bench Trial Period Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Selling, general and administrative Selling, General and Administrative Expense Loss Contingencies [Table] Loss Contingencies [Table] Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Debt securities, unrealized losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Reclassification adjustments, pretax Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Loans payable and current portion of long-term debt Long Term Debt, Current Maturities [Member] Long Term Debt, Current Maturities [Member] Non-cash activity Restructuring Reserve, Increase (Decrease) Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Cumulative unrealized losses on investments Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Discontinued Operations Discontinued Operations [Member] Fosamax Fosamax [Member] Fosamax [Member]. Capital expenditures Payments to Acquire Productive Assets Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Type of Restructuring [Domain] Type of Restructuring [Domain] Document Transition Report Document Transition Report Local Phone Number Local Phone Number Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Litigation Status [Axis] Litigation Status [Axis] Keytruda Keytruda [Member] Keytruda [Member] Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Loss contingency, trial period Loss Contingency, Trial Period Loss Contingency, Trial Period Total (approximates current cost) Inventory, Gross Goodwill Goodwill Accrued and other current liabilities Other Current Liabilities [Member] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Total liabilities Liabilities, Fair Value Disclosure Equity Funds Equity Funds [Member] Alliance revenue - Adempas/Verquvo Alliance revenue - Adempas/Verquvo [Member] Alliance revenue - Adempas/Verquvo Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Taxes on Income from Continuing Operations Income Tax Expense (Benefit) Geographical [Domain] Geographical [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Deferred Income Taxes Deferred Income Tax Liabilities, Net Income Statement [Abstract] Income Statement [Abstract] Other Paid-In Capital Additional Paid-in Capital [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Licensing Agreements Licensing Agreements [Member] Document Fiscal Period Focus Document Fiscal Period Focus Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Earnings Per Share, Basic [Abstract] Cost of sales Cost of Goods and Services Sold Average common shares outstanding assuming dilution (in shares) Weighted Average Number of Shares Outstanding, Diluted Derivative [Line Items] Derivative [Line Items] Cash collateral received, liability Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Fair Value of Derivative, Liability Gross amounts recognized in the consolidated balance sheet, liability Derivative liabilities Derivative Liability Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Inventories Schedule of Inventory, Current [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Equity securities, noncurrent Equity Securities, FV-NI, Noncurrent Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Collaborative Arrangement Collaborative Arrangement [Member] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Manufacturing and supply agreements Manufacturing and supply agreements [Member] Manufacturing and supply agreements Information on Investments in Debt and Equity Securities Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 Common Stock, Value, Issued Restructuring costs Restructuring Charges [Member] Related party amount in cost of sales Related Parties Amount in Cost of Sales Income from Discontinued Operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Lynparza Lynparza [Member] Lynparza [Member] Asia Pacific (other than China and Japan) Asia Pacific [Member] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Operating Segments Operating Segments Operating Segments [Member] Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. Cost of sales Disposal Group, Including Discontinued Operation, Costs of Goods Sold Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Zetia antitrust litigation Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Acquisitions, Research Collaborations and License Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, divestitures, research collaborations and license agreements. Contingencies Commitments and Contingencies Disclosure [Text Block] Additional funding by others, percentage of development costs Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs Current Liabilities Liabilities, Current [Abstract] Net income attributable to Merck & Co., Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Proceeds from exercise of stock options Proceeds from Stock Options Exercised Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Common stock, issued (in shares) Common stock, beginning balance (in shares) Common stock, ending balance (in shares) Common Stock, Shares, Issued Patent Infringement Lawsuit Against Zydus Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd. [Member] Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd. 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Exchange losses Foreign Currency Transaction Gain (Loss), before Tax Retirement Plan Type [Domain] Retirement Plan Type [Domain] Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Income Statement Location [Domain] Income Statement Location [Domain] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Alliance Revenue - Reblozyl Alliance Revenue - Reblozyl [Member] Alliance Revenue - Reblozyl Amendment Flag Amendment Flag Net amounts, asset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Face amount of debt Debt Instrument, Face Amount Other Assets Deferred Income Taxes and Other Assets, Noncurrent Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Investment Type [Axis] Investment Type [Axis] Income from discontinued operations before taxes Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Loss contingency, new claims filed Loss Contingency, New Claims Filed, Number Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Cancidas Cancidas [Member] Cancidas [Member]. Litigation Case [Axis] Litigation Case [Axis] Net Cash Provided by Operating Activities of Continuing Operations Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net Cash Used in Investing Activities of Continuing Operations Net Cash Provided by (Used in) Investing Activities, Continuing Operations Potential future regulatory milestone payments Potential Future Milestone Payments Regulatory Potential Future Milestone Payments Regulatory Debt securities, unrealized gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Accrued and other current liabilities Other Liabilities, Current Other assets Other Assets, Noncurrent Ridgeback Biotherapeutics LP Ridgeback Biotherapeutics LP [Member] Ridgeback Biotherapeutics LP First Commercial Sale Milestones First Commercial Sale Milestones [Member] First Commercial Sale Milestones Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent (Payments) receipts, net Payments for Restructuring Total Costs, Expenses and Other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Bristol Myers Squibb Bristol Myers Squibb [Member] Bristol Myers Squibb Japan JAPAN Royalties Royalty Income, Nonoperating Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Royalty rate Royalty Rate, Percentage Royalty Rate, Percentage Counterparty Name [Axis] Counterparty Name [Axis] Derivative [Table] Derivative [Table] Increase to pension liabilities due to remeasurement Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Distribution from Organon & Co. Disposal Group Incl. Discontinued Operations Distribution Received Disposal Group Incl. Discontinued Operations Distribution Received Femur Fracture Litigation Femur Fracture Litigation [Member] Femur Fracture litigation. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Share-based compensation plans and other Stockholders' Equity, Other Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021 Property, Plant and Equipment, Net Entities [Table] Entities [Table] Payments on debt Repayments of Long-Term Debt Domestic Plan Domestic Plan [Member] Other Other Countries [Member] Other Countries [Member] Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] Operating expenses Disposal Group, Including Discontinued Operation, Operating Expense Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Balance Sheet Location [Axis] Balance Sheet Location [Axis] Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Restructuring Restructuring and Related Activities Disclosure [Text Block] Common stock, authorized (shares) Common Stock, Shares Authorized Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income taxes payable Accrued Income Taxes, Current Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Maximum Maximum [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Sales from Products Revenue from External Customers by Products and Services [Table Text Block] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Consolidated Sales by Geographic Area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Inventory [Domain] Inventory [Domain] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Net Cash Flows Provided by Discontinued Operations Net Cash Provided by (Used in) Discontinued Operations Loss (income) from investments in equity securities, net Loss (income) from investments in equity securities, net Equity Securities, FV-NI, Gain (Loss) Total current assets Assets, Current Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Small Business Entity Small Business Net unrealized gain on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Measurement Frequency [Domain] Measurement Frequency [Domain] Equity Stockholders' Equity Note Disclosure [Text Block] Cash dividends declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Net Benefit Costs Schedule of Net Benefit Costs [Table Text Block] Finite-lived intangible assets Finite-Lived Intangible Assets, Net Net Income from Continuing Operations Net income from continuing operations Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Distributions attributable to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Prevymis Prevymis [Member] Prevymis [Member] Verquvo Verquvo [Member] Verquvo Federal Federal [Member] Federal. Title of 12(b) Security Title of 12(b) Security 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Proceeds from sales of securities and other investments Proceeds from Sale, Maturity and Collection of Investments Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Short-term investments Short-Term Investments Sales-based milestone payments Milestone Payments Sales-Based Milestone Payments Sales-Based Net cash used in financing activities Cash Provided by (Used in) Financing Activities, Discontinued Operations Business Combination and Asset Acquisition [Abstract] Restructuring costs Disposal Group, Including Discontinued Operations, Restructuring Costs Disposal Group, Including Discontinued Operations, Restructuring Costs U.S. government and agency securities US Government Agencies Debt Securities [Member] Segment Reporting Segment Reporting Disclosure [Text Block] Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Liabilities and Equity Liabilities and Equity [Abstract] Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Debt securities, amortized cost Debt Securities, Available-for-Sale, Amortized Cost Cumulative unrealized gains on investments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Other comprehensive income (loss) before reclassification adjustments, pretax OCI, before Reclassifications, before Tax, Attributable to Parent Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7) Inventories Inventory, Net Trade accounts payable Accounts Payable, Current Restructuring costs Restructuring costs Restructuring Charges Income Tax Authority [Axis] Income Tax Authority [Axis] Period of continuing involvement after disposal Discontinued Operation, Period of Continuing Involvement after Disposal Royalty rate, deduction Royalty Rate, Deduction, Percentage Royalty Rate, Deduction, Percentage Income from Continuing Operations (in dollars per share) Income (Loss) from Continuing Operations, Per Basic Share Hedging Designation [Axis] Hedging Designation [Axis] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Entity Filer Category Entity Filer Category Average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Bridion Bridion [Member] Bridion [Member]. U.S. United States UNITED STATES Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Liabilities Liabilities, Fair Value Disclosure [Abstract] Eisai Eisai [Member] Eisai [Member] Consideration transferred, asset acquisition Asset Acquisition, Consideration Transferred Security Exchange Name Security Exchange Name Net amounts, liability Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Int’l International [Member] International [Member] Total swap notional amount U.S Dollar Notional Amount Derivative, Notional Amount Increase (decrease) in Sales as a result of AOCL reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Restricted cash Restricted Cash, Current Segment Reconciling Items Segment Reconciling Items [Member] Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Other current assets Deferred Income Taxes and Other Assets, Current Service cost Defined Benefit Plan, Service Cost Number of collaboration targets Collaborative Arrangement, Number Of Collaboration Targets Collaborative Arrangement, Number Of Collaboration Targets Loans payable and current portion of long-term debt Debt, Current Cover [Abstract] Cover [Abstract] Pending Litigation Pending Litigation [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Pharmaceutical Pharmaceutical segment Pharmaceutical segment [Member] Pharmaceutical segment. Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Other Assets Deferred Income Taxes And Other Assets, Noncurrent [Member] Deferred Income Taxes And Other Assets, Noncurrent Segment Reporting [Abstract] Segment Reporting [Abstract] Non- controlling Interests Noncontrolling Interest [Member] Investments [Domain] Investments [Domain] Total pretax restructuring costs Expense Restructuring and Related Cost, Incurred Cost Forecast Forecast [Member] Net loss amortization Defined Benefit Plan, Amortization of Gain (Loss) Liabilities and Equity Liabilities and Equity Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Share-based compensation plans and other (in shares) Stockholders' Equity, Other Shares Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Earnings Per Share, Diluted [Abstract] Non-US Non-US [Member] Revenue Sales Sales [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Milestone payment to be made to a collaborative partner Milestone Payment to be Made to a Collaborative Partner Milestone Payment to be Made to a Collaborative Partner Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Other acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Level 2 Fair Value, Inputs, Level 2 [Member] Reconciliation of Segment Profits to Income before Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Amount paid for investment Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Net income attributable to Merck & Co., Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Other Intangibles, Net Intangible assets Intangible Assets, Net (Excluding Goodwill) Net Income (in dollars per share) Net Income (in dollars per share) Earnings Per Share, Diluted Spin-off of Organon & Co. Stockholders' Equity Note, Spinoff Transaction Inventory [Line Items] Inventory [Line Items] Selling, general and administrative Disposal Group, Including Discontinued Operation, General and Administrative Expense Stock conversion ratio Stockholders' Equity Note, Stock Split, Conversion Ratio Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Consolidation Items [Axis] Consolidation Items [Axis] Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Total current liabilities Payables included in Accrued and other liabilities Liabilities, Current Other Other Restructuring [Member] Remicade Remicade [Member] Remicade [Member]. Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] Publicly traded equity securities Equity Securities [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Spin-Off of Organon & Co. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Janumet Janumet [Member] Janumet [Member]. Corporate notes and bonds Corporate Debt Securities [Member] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Unrealized net (gains) losses Equity Securities, FV-NI, Unrealized Gain (Loss) Income from discontinued operations, net of taxes Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amortization Amortization Amortization Foreign government bonds Debt Security, Government, Non-US [Member] Upfront and milestone payments to be made Upfront and Milestone Payments to be Made to Collaborative Partner Upfront and Milestone Payments to be Made to Collaborative Partner Entity Address, Address Line One Entity Address, Address Line One Income Tax Authority [Domain] Income Tax Authority [Domain] Other Proceeds from (Payments for) Other Financing Activities Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Impairment charge Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill) Product and Service [Axis] Product and Service [Axis] Dificid Dificid [Member] Dificid Component of Other Income / Expense of Nonoperating [Line Items] Component of Other Income / Expense of Nonoperating [Line Items] [Line Items] for Component of Other Income / Expense of Nonoperating [Table] Loss contingency, claims dismissed Loss Contingency, Claims Dismissed, Number Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Net change in short-term borrowings Proceeds from (Repayments of) Short-Term Debt Class of Stock [Domain] Class of Stock [Domain] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Cash collateral received from counterparties Cash collateral received, asset Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset Interest expense Interest expense Interest Expense Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Retirement Plan Type [Axis] Retirement Plan Type [Axis] Inventories classified in Other assets Other assets Inventory, Noncurrent Inventories Inventory Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Adempas Adempas [Member] Adempas Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Disposal group, other expense Disposal Group, Including Discontinued Operation, Other Expense Entity Tax Identification Number Entity Tax Identification Number Decrease to LIFO cost Inventory, LIFO Reserve Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Other Noncurrent Assets Other Noncurrent Assets [Member] Alliance revenue - Lynparza Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] nemtabrutinib nemtabrutinib [Member] nemtabrutinib Livestock Livestock [Member] Livestock [Member] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Number of markets (more than) Supply Commitment, Minimum, Number of Markets Supply Commitment, Minimum, Number of Markets Dividends payable Dividends Payable, Current Inventories Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Foreign Exchange Future Foreign Exchange Future [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Currency Swap Currency Swap [Member] Net Increase in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Common shares issuable (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Contingent consideration, measurement input, discount rate Business Combination, Contingent Consideration, Liability, Measurement Input Commercial paper Commercial Paper [Member] Entity Central Index Key Entity Central Index Key Interest income Interest income Investment Income, Interest Measurement Frequency [Axis] Measurement Frequency [Axis] Latin America Latin America [Member] Orna Therapeutics Orna Therapeutics [Member] Orna Therapeutics Tax benefit resulting from acquisition Unrecognized Tax Benefits, Increase Resulting from Acquisition Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Separation Costs One-time Termination Benefits [Member] Pandion Therapeutics Pandion Therapeutics [Member] Pandion Therapeutics Legal defense costs reserve Estimated Litigation Liability Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity [Domain] Entity [Domain] 2.35% Notes Due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 [Member] City Area Code City Area Code Assets Assets [Abstract] Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Companion Animals Companion Animals [Member] Companion Animals [Member] Income tax benefit Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period Research and development Disposal Group, Including Discontinued Operations, Research and Development Expenses Disposal Group, Including Discontinued Operations, Research and Development Expenses Due to related parties, current Due to Related Parties, Current Cash Flows from Financing Activities of Continuing Operations Net Cash Provided by (Used in) Financing Activities [Abstract] Contingent milestone payments collaborative arrangement Contingent Payments Collaborative Arrangement Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. Share-based compensation Share-Based Payment Arrangement, Noncash Expense Invanz Invanz [Member] Invanz [Member]. Orion Corporation Orion Corporation [Member] Orion Corporation Charges related to program discontinuation Charges related to program discontinuation Charges related to program discontinuation Other Noncurrent Liabilities Other Liabilities, Noncurrent Interest Rate Contract Interest Rate Contract [Member] Continuing Operations Continuing Operations [Member] Research and development Research and Development Expense [Member] Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Organon & Co. Organon & Co. [Member] Organon & Co. Cost of sales Cost of sales Cost of Sales [Member] Net sales by Merck Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Other Postretirement Benefit Plans Other Postretirement Benefits Plan [Member] Less: Net Income Attributable to Noncontrolling Interests Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest EX-101.PRE 10 mrk-20220930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2022
Oct. 31, 2022
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2022  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 126 East Lincoln Avenue  
Entity Address, City or Town Rahway  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07065  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,535,395,974
Amendment Flag false  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
Common Stock ($0.50 par value)    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
0.500% Notes due 2024    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2024  
Trading Symbol MRK 24  
Security Exchange Name NYSE  
1.875% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Trading Symbol MRK/26  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Statement [Abstract]        
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183
Costs, Expenses and Other        
Cost of sales 3,934 3,450 13,530 9,752
Selling, general and administrative 2,520 2,336 7,355 6,804
Research and development 4,399 2,445 9,773 9,177
Restructuring costs 94 107 288 487
Other (income) expense, net 429 (450) 1,576 (1,007)
Total Costs, Expenses and Other 11,376 7,888 32,522 25,213
Income from Continuing Operations Before Taxes 3,583 5,266 12,931 9,970
Taxes on Income from Continuing Operations 330 695 1,423 1,436
Net Income from Continuing Operations 3,253 4,571 11,508 8,534
Less: Net Income Attributable to Noncontrolling Interests 5 4 6 9
Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,248 4,567 11,502 8,525
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 0 0 766
Net Income Attributable to Merck & Co., Inc. $ 3,248 $ 4,567 $ 11,502 $ 9,291
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) $ 1.28 $ 1.81 $ 4.55 $ 3.37
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) 1.28 1.81 4.55 3.67
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) 1.28 1.80 4.53 3.36
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) $ 1.28 $ 1.80 $ 4.53 $ 3.66
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Statement of Comprehensive Income [Abstract]        
Net Income Attributable to Merck & Co., Inc. $ 3,248 $ 4,567 $ 11,502 $ 9,291
Other Comprehensive (Loss) Income Net of Taxes:        
Net unrealized gain on derivatives, net of reclassifications 338 84 584 324
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization (186) 38 92 1,522
Cumulative translation adjustment (568) (84) (990) (251)
Other comprehensive income (loss), net of taxes (416) 38 (314) 1,595
Comprehensive Income Attributable to Merck & Co., Inc. $ 2,832 $ 4,605 $ 11,188 $ 10,886
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current Assets    
Cash and cash equivalents $ 11,145 $ 8,096
Short-term investments 103 0
Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021) 9,482 9,230
Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note 7) 5,614 5,953
Other current assets 7,217 6,987
Total current assets 33,561 30,266
Investments 984 370
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021 20,424 19,279
Goodwill 21,160 21,264
Other Intangibles, Net 21,368 22,933
Other Assets 9,584 11,582
Total Assets 107,081 105,694
Current Liabilities    
Loans payable and current portion of long-term debt 1,936 2,412
Trade accounts payable 3,371 4,609
Accrued and other current liabilities 14,222 13,859
Income taxes payable 1,698 1,224
Dividends payable 1,771 1,768
Total current liabilities 22,998 23,872
Long-Term Debt 28,482 30,690
Deferred Income Taxes 2,417 3,441
Other Noncurrent Liabilities 8,660 9,434
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021 1,788 1,788
Other paid-in capital 44,243 44,238
Retained earnings 59,928 53,696
Accumulated other comprehensive loss (4,743) (4,429)
Stockholders' equity before deduction for treasury stock 101,216 95,293
Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021 56,758 57,109
Total Merck & Co., Inc. stockholders’ equity 44,458 38,184
Noncontrolling Interests 66 73
Total equity 44,524 38,257
Liabilities and Equity $ 107,081 $ 105,694
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 77 $ 62
Inventories classified in Other assets 2,641 2,194
Accumulated depreciation $ 17,921 $ 18,192
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, authorized (shares) 6,500,000,000 6,500,000,000
Common stock, issued (in shares) 3,577,103,522 3,577,103,522
Treasury stock (in shares) 1,043,697,097 1,049,499,023
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash Flows from Operating Activities of Continuing Operations    
Net income from continuing operations $ 11,508 $ 8,534
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:    
Amortization 1,623 1,231
Depreciation 1,394 1,148
Intangible asset impairment charges 910 0
Loss (income) from investments in equity securities, net 1,361 (1,535)
Charge for the acquisition of Pandion Therapeutics, Inc. 0 1,556
Deferred income taxes (1,261) 28
Share-based compensation 396 360
Other 1,169 499
Net changes in assets and liabilities (2,435) (3,794)
Net Cash Provided by Operating Activities of Continuing Operations 14,665 8,027
Cash Flows from Investing Activities of Continuing Operations    
Capital expenditures (3,239) (3,240)
Purchases of securities and other investments (710) (1)
Proceeds from sales of securities and other investments 709 497
Acquisition of Pandion Therapeutics, Inc., net of cash acquired 0 (1,554)
Other acquisitions, net of cash acquired (121) (89)
Other 149 15
Net Cash Used in Investing Activities of Continuing Operations (3,212) (4,372)
Cash Flows from Financing Activities of Continuing Operations    
Net change in short-term borrowings 0 (3,983)
Payments on debt (2,250) (1,153)
Distribution from Organon & Co. 0 9,000
Purchases of treasury stock 0 (822)
Dividends paid to stockholders (5,262) (4,967)
Proceeds from exercise of stock options 119 68
Other (172) (253)
Net Cash Used in Financing Activities of Continuing Operations (7,565) (2,110)
Cash Flows from Discontinued Operations    
Net cash provided by operating activities 0 1,051
Net cash used in investing activities 0 (134)
Net cash used in financing activities 0 (504)
Net Cash Flows Provided by Discontinued Operations 0 413
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash (776) (65)
Net Increase in Cash, Cash Equivalents and Restricted Cash 3,112 1,893
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets) 8,167 8,153
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September 30, 2022 and 2021, respectively, included in Other current assets) $ 11,279 $ 10,046
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Statement of Cash Flows [Abstract]        
Restricted cash $ 134 $ 71 $ 30 $ 103
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).
Recently Adopted Accounting Standards
In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2.2
Spin-Off of Organon & Co.
 9 Months Ended
Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Spin-Off of Organon & Co. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100 million and $293 million and related cost of sales of $104 million and $312 million for the three and nine months ended September 30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September 30, 2022 and September 30, 2021.
The amounts due from Organon under all of the above agreements were $567 million and $964 million at September 30, 2022 and December 31, 2021, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $333 million and $400 million at September 30, 2022 and December 31, 2021, respectively, and are included in Accrued and other current liabilities.
The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s condensed consolidated statement of income as Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million for the nine months ended September 30, 2021 related to the spin-off of Organon, which are also included in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees.
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
 Nine Months Ended September 30,
($ in millions)
2021 (1)
Sales$2,512 
Costs, Expenses and Other
Cost of sales789 
Selling, general and administrative877 
Research and development103 
Restructuring costs1 
Other (income) expense, net(15)
1,755 
Income from discontinued operations before taxes757 
Income tax benefit(12)
Income from discontinued operations, net of taxes769 
Less: Income of discontinued operations attributable to noncontrolling interests3 
$766 
(1)    Reflects amounts through the June 2, 2021 spin-off date.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Research Collaborations and License Agreements
 9 Months Ended
Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]  
Acquisitions, Research Collaborations and License Agreements Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
2022 Transactions
In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties.
In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge in Research and development expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration.
In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties
ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in the fourth quarter of 2022.
In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved.
Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in Research and development expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with Keytruda for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in Research and development expenses in the first nine months of 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $101 million to fund Kelun-Biotech’s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.
2021 Transactions
In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and Research and development expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.
In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in Research and development expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.
As part of Merck’s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in the first nine months of 2021, which are reflected in Cost of sales and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements
 9 Months Ended
Sep. 30, 2022
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. As of September 30, 2022, sales-based milestone payments accrued but not yet paid totaled $600 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lynparza$284 $246 $825 $721 
Alliance revenue - Koselugo10 6 43 20 
Total alliance revenue$294 $252 $868 $741 
Cost of sales (1)
64 42 425 125 
Selling, general and administrative45 44 135 127 
Research and development28 27 79 87 
($ in millions)September 30, 2022December 31, 2021
Receivables from AstraZeneca included in Other current assets
$290 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
12 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1) Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2) Includes accrued milestone payments.
Eisai
In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in Research and development expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of Keytruda and Lenvima.
Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September 30, 2022 and is included in Other Intangibles, Net. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lenvima$202 $188 $660 $498 
Cost of sales (1)
53 49 159 143 
Selling, general and administrative42 34 115 88 
Research and development24 43 128 165 
($ in millions)September 30, 2022December 31, 2021
Receivables from Eisai included in Other current assets
$202 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
1 625 
(1) Represents amortization of capitalized milestone payments.
(2) Amount as of December 31, 2021 includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.
The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September 30, 2022 and are included in Other Intangibles, Net. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Adempas/Verquvo$88 $100 $258 $248 
Net sales of Adempas recorded by Merck57 59 181 188 
Net sales of Verquvo recorded by Merck6 2 15 3 
Total sales$151 $161 $454 $439 
Cost of sales (1)
55 53 158 328 
Selling, general and administrative42 31 107 84 
Research and development18 16 52 36 
($ in millions)September 30, 2022December 31, 2021
Receivables from Bayer included in Other current assets
$144 $114 
Payables to Bayer included in Accrued and other current liabilities (2)
75 472 
(1) Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
(2) Amount as of December 31, 2021 includes accrued milestone payment.
Ridgeback Biotherapeutics LP
In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop Lagevrio (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize Lagevrio and related molecules.
Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within Cost of sales. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to Research and development expenses.
Lagevrio has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for Lagevrio in more than 40 markets. As of September 30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Lagevrio sales
$436 $— $4,859 $— 
Cost of sales (1)
234 4 2,580 56 
Selling, general and administrative41 6 105 13 
Research and development 8 58 29 167 
($ in millions)September 30, 2022December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2)
$193 $283 
(1) Includes royalty expense and amortization of capitalized milestone payments.
(2) Includes accrued royalty and milestone payments.
Bristol Myers Squibb
Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $39 million (consisting of royalties) within Sales in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104 million, as well as the receipt of a regulatory approval milestone payment of $20 million.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested.
The Company recorded total pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to
restructuring program activities. Since inception of the Restructuring Program through September 30, 2022, Merck has recorded total pretax accumulated costs of approximately $3.2 billion. For the full year of 2022, the Company expects to record charges of approximately $600 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $16 $38 $54 $— $51 $116 $167 
Selling, general and administrative— 5 21 26 — 17 57 74 
Research and development— — 1 1 — 29 1 30 
Restructuring costs65 — 29 94 197 — 91 288 
$65 $21 $89 $175 $197 $97 $265 $559 
 Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $11 $37 $48 $— $32 $81 $113 
Selling, general and administrative— 4 1 5 — 8 1 9 
Research and development— 7 1 8 — 20 1 21 
Restructuring costs17 — 90 107 310 — 177 487 
$17 $22 $129 $168 $310 $60 $260 $630 
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 11) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2022:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2022
$596 $— $41 $637 
Expense197 97 265 559 
(Payments) receipts, net(303)— (458)(761)
Non-cash activity— (97)183 86 
Restructuring reserves September 30, 2022 (1)
$490 $— $31 $521 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated Other Comprehensive Loss (AOCL) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCL until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20222021202220212022202120222021
Net Investment Hedging Relationships
Foreign exchange contracts
$(1)$1 $(47)$(27)$— $(4)$(2)$(12)
Euro-denominated notes(250)(77)(431)(199)— — — — 
(1) No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk.
In February 2022, five interest rate swap contracts with a total notional amount of $1.25 billion matured. These swaps effectively converted the Company’s $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt. In September 2022, four interest rate swap contracts with a total notional amount of $1.0 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.40% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2022December 31, 2021September 30, 2022December 31, 2021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$— $2,263 $— $13 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2022December 31, 2021
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Balance Sheet Caption
Interest rate swap contractsOther current assets$— $— $— $14 $— $2,250 
Foreign exchange contractsOther current assets826 — 7,250 271 — 6,778 
Foreign exchange contractsOther Assets85 — 1,408 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities— 1 37 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities— 1 93 — 1 43 
  $911 $2 $8,788 $328 $25 $12,245 
Derivatives Not Designated as Hedging Instruments
Balance Sheet Caption      
Foreign exchange contractsOther current assets$597 $— $9,523 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities— 240 7,715 — 96 10,640 
  $597 $240 $17,238 $221 $96 $20,713 
  $1,508 $242 $26,026 $549 $121 $32,958 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master
netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2022December 31, 2021
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$1,508 $242 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(217)(217)(110)(110)
Cash collateral received(794)— (164)— 
Net amounts$497 $25 $275 $11 
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)202220212022202120222021202220212022202120222021
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,959 $13,154 $429 $(450)$(416)$38 $45,453 $35,183 $1,576 $(1,007)$(314)$1,595 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — 1 (9)— — — — (13)(29)— — 
Derivatives designated as hedging instruments
— — — (1)— — — — 4 (1)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
— — — — 682 72 — — — — 1,233 193 
Increase (decrease) in Sales as a result of AOCL reclassifications
253 (36)— — (253)36 491 (219)— — (491)219 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)— — — — — (2)(2)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)— — — — — (2)(2)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2022202120222021
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(41)$18 $(77)$234 
Foreign exchange contracts (2)
Sales(4)(4)(42)6 
(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
At September 30, 2022, the Company estimates $864 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCL to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2022December 31, 2021
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$67 $— $— $67 $80 $— $— $80 
Commercial paper4 — — 4 — — — — 
Corporate notes and bonds3 — — 3 4 — — 4 
Foreign government bonds2 — — 2 2 — — 2 
Total debt securities$76 $— $— $76 $86 $— $— $86 
Publicly traded equity securities (1)
1,334 1,647 
Total debt and publicly traded equity securities
$1,410 $1,733 
(1) Unrealized net losses of $221 million and $415 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022. Unrealized net (gains) losses of $(90) million and $109 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2021, respectively, on equity securities still held at September 30, 2021.
At September 30, 2022 and September 30, 2021, the Company also had $705 million and $578 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in Other (income) expense, net. During the first nine months of 2022, the Company recorded unrealized gains of $21 million and unrealized net losses of $12 million related to certain of these equity investments still held at September 30, 2022. During the first nine months of 2021, the Company recorded unrealized gains of $104 million and unrealized losses of $1 million related to certain of these investments still held at September 30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September 30, 2022 were $255 million and $19 million, respectively.
At September 30, 2022 and September 30, 2021, the Company also had $655 million and $1.2 billion, respectively, recorded in Other Assets for equity securities held through ownership interests in investment funds. Losses (gains) recorded in Other (income) expense, net relating to these investment funds were $141 million and $(391) million for the third quarter of 2022 and 2021, respectively, and were $952 million and $(893) million for the first nine months of 2022 and 2021, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest:
Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;
Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities;
Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation.
If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2022December 31, 2021
Assets
Investments
Commercial paper$— $4 $— $4 $— $— $— $— 
Foreign government bonds— 2 — 2 — 2 — 2 
Publicly traded equity securities1,081 — — 1,081 368 — — 368 
 1,081 6 — 1,087 368 2 — 370 
Other assets (1)
U.S. government and agency securities67 — — 67 80 — — 80 
Corporate notes and bonds3 — — 3 4 — — 4 
Publicly traded equity securities253 — — 253 1,279 — — 1,279 
323 — — 323 1,363 — — 1,363 
Derivative assets (2)
Forward exchange contracts— 945 — 945 — 351 — 351 
Purchased currency options— 563 — 563 — 184 — 184 
Interest rate swaps— — — — — 14 — 14 
 — 1,508 — 1,508 — 549 — 549 
Total assets$1,404 $1,514 $— $2,918 $1,731 $551 $— $2,282 
Liabilities
Other liabilities
Contingent consideration$— $— $499 $499 $— $— $777 $777 
Derivative liabilities (2)
Forward exchange contracts— 242 — 242 — 120 — 120 
Written currency options— — — — — 1 — 1 
— 242 — 242 — 121 — 121 
Total liabilities$— $242 $499 $741 $— $121 $777 $898 
(1) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of September 30, 2022 and December 31, 2021, Cash and cash equivalents included $10.0 billion and $6.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(156)73 
Payments(119)— 
Other(3)(12)
Fair value September 30 (2)
$499 $902 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) At September 30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.
The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2022, was $25.9 billion compared with a carrying value of $30.4 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable as of September 30, 2022 and December 31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September 30, 2022 and December 31, 2021, the Company had collected $55 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in Other current assets and the related obligation to remit the cash within Accrued and other current liabilities. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $794 million and $164 million at September 30, 2022 and December 31, 2021, respectively. The obligation to return such collateral is recorded in Accrued and other current liabilities.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)September 30, 2022December 31, 2021
Finished goods$1,683 $1,747 
Raw materials and work in process6,532 6,220 
Supplies227 196 
Total (approximates current cost)8,442 8,163 
Decrease to LIFO cost(187)(16)
 $8,255 $8,147 
Recognized as:
Inventories$5,614 $5,953 
Other assets2,641 2,194 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At September 30, 2022 and December 31, 2021, these amounts included $2.2 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $417 million and $256 million at September 30, 2022 and December 31, 2021, respectively, of inventories produced in preparation for product launches.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Intangibles
 9 Months Ended
Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangibles Other IntangiblesIn the third quarter of 2022, the Company recorded $887 million of impairment charges within Research and development expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $807 million represents an in-process research and development (IPR&D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&D impairment charge noted above. The remaining IPR&D intangible asset related to nemtabrutinib is $1.2 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingencies
 9 Months Ended
Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September 30, 2022, approximately 3,450 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck’s motion and ruled that plaintiffs’ failure to warn claims are preempted as a matter of law to the extent they
assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court’s preemption ruling to the Third Circuit.
Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Januvia (sitagliptin) and/or Janumet (sitagliptin and metformin HCl).
Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants’ summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants’ motions to exclude plaintiffs’ expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court’s judgment is now final and no longer appealable with respect to remaining claims.
Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants’ summary judgment motions and also granting defendants’ motions to exclude plaintiffs’ expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.
Gardasil/Gardasil 9
Merck is a defendant in product liability lawsuits in the U.S. involving Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September 30, 2022, approximately 65 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with Gardasil or Gardasil 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that Gardasil/Gardasil 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.
Governmental Proceedings
As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.
In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.
In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.
On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.
In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene.
On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.
340B Program Litigation
Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.
Bridion — As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if
any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a one-day trial on December 19, 2022 on this remaining patent term extension calculation defense.
The Company has settled with five generic companies providing that these generic companies can bring their generic versions of Bridion to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of Bridion to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.
Januvia, Janumet, Janumet XR — As previously disclosed, the FDA has granted pediatric exclusivity with respect to Januvia, Janumet, and Janumet XR (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, Januvia, Janumet, and Janumet XR contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the Janumet formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.
Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.
In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of Januvia and Janumet to the market in May 2026 or earlier under certain circumstances, and their generic versions of Janumet XR to the market in July 2026 or earlier under certain circumstances.
Additionally, in 2019, Mylan filed a petition for inter partes review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision.
In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a three-day bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.
Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for Janumet in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the Janumet SPCs in Europe. In June 2021, a German court decided that the SPC for Janumet is invalid, which decision the Company has appealed. The validity of the Janumet SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided
that the SPC for Janumet was invalid in a first instance decision. In August 2022, the validity of the SPC for Janumet was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: ex-parte preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be prima facie valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for ex parte preliminary injunctions were refused in Portugal.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2022 and December 31, 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Equity Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20213,577 $1,788 $44,039 $48,777 $(4,628)1,044 $(56,682)$94 $33,388 
Net income attributable to Merck & Co., Inc.— — — 4,567 — — — — 4,567 
Other comprehensive income, net of taxes— — — — 38 — — — 38 
Cash dividends declared on common stock ($0.65 per share)
— — — (1,653)— — — — (1,653)
Treasury stock shares purchased— — — — — 8 (583)— (583)
Share-based compensation plans and other— — 110 — — — 21 — 131 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at July 1, 20223,577 $1,788 $44,115 $58,437 $(4,327)1,044 $(56,770)$75 $43,318 
Net income attributable to Merck & Co., Inc.— — — 3,248 — — — — 3,248 
Other comprehensive loss, net of taxes— — — — (416)— — — (416)
Cash dividends declared on common stock ($0.69 per share)
— — — (1,757)— — — — (1,757)
Share-based compensation plans and other— — 128 — — — 12 — 140 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Distributions attributable to noncontrolling interests— — — — — — — (14)(14)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20213,577 $1,788 $39,588 $47,362 $(6,634)1,047 $(56,787)$87 $25,404 
Net income attributable to Merck & Co., Inc.— — — 9,291 — — — — 9,291 
Other comprehensive income, net of taxes— — — — 1,595 — — — 1,595 
Cash dividends declared on common stock ($1.95 per share)
— — — (4,962)— — — — (4,962)
Treasury stock shares purchased— — — — — 11 (822)— (822)
Spin-off of Organon & Co.— — 4,643 — 449 — — (1)5,091 
Share-based compensation plans and other— — (82)— — (6)365 — 283 
Net income attributable to noncontrolling interests— — — — — — — 12 12 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 11,502 — — — — 11,502 
Other comprehensive loss, net of taxes— — — — (314)— — — (314)
Cash dividends declared on common stock ($2.07 per share)
— — — (5,270)— — — — (5,270)
Share-based compensation plans and other— — 5 — — (5)351 — 356 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests— — — — — — — (13)(13)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Pension and Other Postretirement Benefit Plans
 9 Months Ended
Sep. 30, 2022
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$91 $66 $104 $75 $289 $213 $302 $254 
Interest cost123 35 102 33 330 110 305 92 
Expected return on plan assets(182)(93)(188)(105)(576)(292)(568)(313)
Amortization of unrecognized prior service credit
(8)(3)(9)(3)(24)(10)(29)(12)
Net loss amortization10 24 75 32 122 73 218 110 
Termination benefits1 — 2 — 2 1 54 3 
Curtailments3 — (1)— 11 — 15 (27)
Settlements79 — 139 — 180 — 139 2 
 $117 $29 $224 $32 $334 $95 $436 $109 
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Service cost$11 $11 $36 $37 
Interest cost11 12 34 34 
Expected return on plan assets(21)(20)(64)(59)
Amortization of unrecognized prior service credit(14)(16)(42)(48)
Net gain amortization(11)(12)(32)(30)
Termination benefits— — — 37 
Curtailments— (1)(1)(29)
 $(24)$(26)$(69)$(58)
Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.
In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company’s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $296 million to net pension liabilities and also resulted in a related adjustment to AOCL. Remeasurements during the first nine months of 2022 have resulted in a net increase of $131 million to net pension liabilities with related adjustments to AOCL.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests if related to the spin-off of Organon (each as noted above).
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense, Net
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Interest income$(40)$(7)$(62)$(27)
Interest expense244 196 727 597 
Exchange losses96 46 220 202 
Loss (income) from investments in equity securities, net (1)
371 (683)1,361 (1,535)
Net periodic defined benefit plan (credit) cost other than service cost(60)40 (208)(159)
Other, net(182)(42)(462)(85)
 $429 $(450)$1,576 $(1,007)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
Interest paid for the nine months ended September 30, 2022 and 2021 was $660 million and $570 million, respectively.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2.2
Taxes on Income
 9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on Income
The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related to the settlement of certain federal income tax matters as discussed below.
In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2022202120222021
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $8,525 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests— — — 766 
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Average common shares outstanding2,533 2,530 2,531 2,531 
Common shares issuable (1)
9 6 9 8 
Average common shares outstanding assuming dilution 2,542 2,536 2,540 2,539 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.81 $4.55 $3.37 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.81 $4.55 $3.67 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.80 $4.53 $3.36 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.80 $4.53 $3.66 
(1)Issuable primarily under share-based compensation plans.
For the third quarter of 2022 and 2021, 2 million and 8 million, respectively, and for the first nine months of 2022 and 2021, 5 million and 10 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance July 1, 2021, net of taxes$(26)$(3,028)$(1,574)$(4,628)
Other comprehensive income (loss) before reclassification adjustments, pretax72 (24)(96)(48)
Tax(16)16 12 12 
Other comprehensive income (loss) before reclassification adjustments, net of taxes56 (8)(84)(36)
Reclassification adjustments, pretax36 
(1)
68 
(2)
— 104 
Tax(8)(22)— (30)
Reclassification adjustments, net of taxes28 

46 

— 74 
Other comprehensive income (loss), net of taxes84 38 (84)38 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance July 1, 2022, net of taxes$390 $(2,465)$(2,252)$(4,327)
Other comprehensive income (loss) before reclassification adjustments, pretax682 (294)(618)(230)
Tax(143)62 50 (31)
Other comprehensive income (loss) before reclassification adjustments, net of taxes539 (232)(568)(261)
Reclassification adjustments, pretax(254)
(1)
77 
(2)
— (177)
Tax53 (31)— 22 
Reclassification adjustments, net of taxes(201)

46 

— (155)
Other comprehensive income (loss), net of taxes338 (186)(568)(416)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
Nine Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2021, net of taxes$(266)$(4,540)$(1,828)$(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax193 1,739 (167)1,765 
Tax(41)(385)(84)(510)
Other comprehensive income (loss) before reclassification adjustments, net of taxes152 1,354 (251)1,255 
Reclassification adjustments, pretax218 
(1)
210 
(2)
— 428 
Tax(46)(42)— (88)
Reclassification adjustments, net of taxes172 168 — 340 
Other comprehensive income (loss), net of taxes324 1,522 (251)1,595 
Spin-off of Organon (see Note 2)
— 28 421 449 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax1,233 (125)(1,001)107 
Tax(259)25 11 (223)
Other comprehensive income (loss) before reclassification adjustments, net of taxes974 (100)(990)(116)
Reclassification adjustments, pretax(493)
(1)
266 
(2)
— (227)
Tax103 (74)— 29 
Reclassification adjustments, net of taxes(390)192 — (198)
Other comprehensive income (loss), net of taxes584 92 (990)(314)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
(1) Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a product basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,331 $2,095 $5,426 $2,580 $1,954 $4,534 $9,307 $6,180 $15,487 $7,108 $5,501 $12,609 
Alliance revenue-Lynparza (1)
144 140 284 129 117 246 427 397 825 371 350 721 
Alliance revenue-Lenvima (1)
142 60 202 114 74 188 426 235 660 287 211 498 
Alliance revenue-Reblozyl (2)
32 7 39 — — — 87 37 124 — — — 
Vaccines
Gardasil/Gardasil 9
957 1,337 2,294 839 1,154 1,993 1,803 3,624 5,428 1,605 2,539 4,144 
ProQuad/M-M-R II/Varivax
532 136 668 537 125 661 1,337 379 1,716 1,255 371 1,626 
RotaTeq154 102 256 135 92 227 427 218 644 364 229 593 
Pneumovax 23
68 63 131 181 97 277 280 177 457 354 247 600 
Vaqta27 36 64 32 16 48 72 62 134 80 58 138 
Hospital Acute Care
Bridion233 190 423 181 188 369 665 579 1,244 545 551 1,096 
Prevymis49 64 114 39 57 96 136 174 310 111 159 270 
Dificid72 6 77 52 2 54 184 12 196 108 7 115 
Primaxin— 63 63 — 69 70 1 185 185 — 194 194 
Noxafil13 49 62 19 45 64 39 141 180 48 149 197 
Invanz2 48 50 (2)55 53 4 144 148 (2)159 157 
Cancidas1 42 43 1 56 56 5 133 138 4 164 168 
Zerbaxa24 19 43 (1)(1)(2)64 55 120 (5)(6)(11)
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
85 3 88 73 27 100 244 14 258 222 26 248 
Adempas— 57 57 — 59 59 — 181 181 — 188 188 
Virology
Lagevrio— 436 436 — — — 1,523 3,336 4,859 — — — 
Isentress/Isentress HD
68 93 161 77 112 189 196 270 466 222 368 590 
Neuroscience
Belsomra20 42 62 23 58 81 60 139 199 56 183 238 
Immunology
Simponi— 173 173 — 203 203 — 540 540 — 619 619 
Remicade— 49 49 — 73 73 — 163 163 — 233 233 
Diabetes
Januvia332 385 717 365 487 852 958 1,294 2,252 997 1,448 2,445 
Janumet90 327 417 86 401 487 258 1,089 1,347 244 1,205 1,449 
Other pharmaceutical (4)
244 321 564 210 306 518 616 949 1,565 637 950 1,589 
Total Pharmaceutical segment sales6,620 6,343 12,963 5,670 5,826 11,496 19,119 20,707 39,826 14,611 16,103 30,714 
Animal Health:
Livestock186 643 829 190 675 864 521 1,965 2,486 508 1,996 2,503 
Companion Animals289 253 542 277 276 553 904 929 1,834 855 948 1,804 
Total Animal Health segment sales475 896 1,371 467 951 1,417 1,425 2,894 4,320 1,363 2,944 4,307 
Total segment sales7,095 7,239 14,334 6,137 6,777 12,913 20,544 23,601 44,146 15,974 19,047 35,021 
Other (5)
227 398 625 139 101 241 383 925 1,307 192 (30)162 
 $7,322 $7,637 $14,959 $6,276 $6,878 $13,154 $20,927 $24,526 $45,453 $16,166 $19,017 $35,183 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2022 and 2021 also includes $156 million and $191 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.3 billion and $3.1 billion for the three months ended September 30, 2022 and 2021, respectively, and $9.1 billion for both the nine months ended September 30, 2022 and 2021.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
United States$7,322 $6,276 $20,927 $16,166 
Europe, Middle East and Africa3,286 3,342 11,228 9,912 
China1,442 1,307 3,957 3,004 
Japan673 638 2,776 1,929 
Asia Pacific (other than China and Japan)854 613 2,792 1,782 
Latin America684 599 1,933 1,631 
Other698 379 1,840 759 
 $14,959 $13,154 $45,453 $35,183 
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Segment profits:
Pharmaceutical segment$9,590 $8,606 $28,263 $22,450 
Animal Health segment515 505 1,672 1,629 
Total segment profits10,105 9,111 29,935 24,079 
Other profits377 141 831 29 
Unallocated:
Interest income40 7 62 27 
Interest expense(244)(196)(727)(597)
Amortization(460)(360)(1,623)(1,231)
Depreciation(448)(358)(1,257)(1,031)
Research and development(4,277)(2,312)(9,374)(8,775)
Restructuring costs(94)(107)(288)(487)
Other unallocated, net(1,416)(660)(4,628)(2,044)
 $3,583 $5,266 $12,931 $9,970 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2.2
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted
Recently Adopted Accounting Standards
In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
Legal Costs Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2.2
Spin-Off of Organon & Co. (Tables)
 9 Months Ended
Sep. 30, 2022
Discontinued Operations and Disposal Groups [Abstract]  
Disposal Groups, Including Discontinued Operations
Details of Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests are as follows:
 Nine Months Ended September 30,
($ in millions)
2021 (1)
Sales$2,512 
Costs, Expenses and Other
Cost of sales789 
Selling, general and administrative877 
Research and development103 
Restructuring costs1 
Other (income) expense, net(15)
1,755 
Income from discontinued operations before taxes757 
Income tax benefit(12)
Income from discontinued operations, net of taxes769 
Less: Income of discontinued operations attributable to noncontrolling interests3 
$766 
(1)    Reflects amounts through the June 2, 2021 spin-off date.
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2022
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lynparza$284 $246 $825 $721 
Alliance revenue - Koselugo10 6 43 20 
Total alliance revenue$294 $252 $868 $741 
Cost of sales (1)
64 42 425 125 
Selling, general and administrative45 44 135 127 
Research and development28 27 79 87 
($ in millions)September 30, 2022December 31, 2021
Receivables from AstraZeneca included in Other current assets
$290 $271 
Payables to AstraZeneca included in Trade accounts payable and Accrued and other current liabilities (2)
12 415 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
600 — 
(1) Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Lenvima$202 $188 $660 $498 
Cost of sales (1)
53 49 159 143 
Selling, general and administrative42 34 115 88 
Research and development24 43 128 165 
($ in millions)September 30, 2022December 31, 2021
Receivables from Eisai included in Other current assets
$202 $200 
Payables to Eisai included in Accrued and other current liabilities (2)
1 625 
(1) Represents amortization of capitalized milestone payments.
(2) Amount as of December 31, 2021 includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Alliance revenue - Adempas/Verquvo$88 $100 $258 $248 
Net sales of Adempas recorded by Merck57 59 181 188 
Net sales of Verquvo recorded by Merck6 2 15 3 
Total sales$151 $161 $454 $439 
Cost of sales (1)
55 53 158 328 
Selling, general and administrative42 31 107 84 
Research and development18 16 52 36 
($ in millions)September 30, 2022December 31, 2021
Receivables from Bayer included in Other current assets
$144 $114 
Payables to Bayer included in Accrued and other current liabilities (2)
75 472 
(1) Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.
(2) Amount as of December 31, 2021 includes accrued milestone payment.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Lagevrio sales
$436 $— $4,859 $— 
Cost of sales (1)
234 4 2,580 56 
Selling, general and administrative41 6 105 13 
Research and development 8 58 29 167 
($ in millions)September 30, 2022December 31, 2021
Payables to Ridgeback included in Accrued and other current liabilities (2)
$193 $283 
(1) Includes royalty expense and amortization of capitalized milestone payments.
(2) Includes accrued royalty and milestone payments.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2022
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2022Nine Months Ended September 30, 2022
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $16 $38 $54 $— $51 $116 $167 
Selling, general and administrative— 5 21 26 — 17 57 74 
Research and development— — 1 1 — 29 1 30 
Restructuring costs65 — 29 94 197 — 91 288 
$65 $21 $89 $175 $197 $97 $265 $559 
 Three Months Ended September 30, 2021Nine Months Ended September 30, 2021
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $11 $37 $48 $— $32 $81 $113 
Selling, general and administrative— 4 1 5 — 8 1 9 
Research and development— 7 1 8 — 20 1 21 
Restructuring costs17 — 90 107 310 — 177 487 
$17 $22 $129 $168 $310 $60 $260 $630 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2022:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2022
$596 $— $41 $637 
Expense197 97 265 559 
(Payments) receipts, net(303)— (458)(761)
Non-cash activity— (97)183 86 
Restructuring reserves September 30, 2022 (1)
$490 $— $31 $521 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20222021202220212022202120222021
Net Investment Hedging Relationships
Foreign exchange contracts
$(1)$1 $(47)$(27)$— $(4)$(2)$(12)
Euro-denominated notes(250)(77)(431)(199)— — — — 
(1) No amounts were reclassified from AOCL into income related to the sale of a subsidiary.
Amounts Recorded on Balance Sheet Related to Fair Value Hedges
The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2022December 31, 2021September 30, 2022December 31, 2021
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$— $2,263 $— $13 
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2022December 31, 2021
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)AssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Balance Sheet Caption
Interest rate swap contractsOther current assets$— $— $— $14 $— $2,250 
Foreign exchange contractsOther current assets826 — 7,250 271 — 6,778 
Foreign exchange contractsOther Assets85 — 1,408 43 — 1,551 
Foreign exchange contractsAccrued and other current liabilities— 1 37 — 24 1,623 
Foreign exchange contractsOther Noncurrent Liabilities— 1 93 — 1 43 
  $911 $2 $8,788 $328 $25 $12,245 
Derivatives Not Designated as Hedging Instruments
Balance Sheet Caption      
Foreign exchange contractsOther current assets$597 $— $9,523 $221 $— $10,073 
Foreign exchange contractsAccrued and other current liabilities— 240 7,715 — 96 10,640 
  $597 $240 $17,238 $221 $96 $20,713 
  $1,508 $242 $26,026 $549 $121 $32,958 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master
netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2022December 31, 2021
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$1,508 $242 $549 $121 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(217)(217)(110)(110)
Cash collateral received(794)— (164)— 
Net amounts$497 $25 $275 $11 
Location and Amount of Pretax Gains and Losses of Derivatives
The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)202220212022202120222021202220212022202120222021
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are RecordedSales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
$14,959 $13,154 $429 $(450)$(416)$38 $45,453 $35,183 $1,576 $(1,007)$(314)$1,595 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — 1 (9)— — — — (13)(29)— — 
Derivatives designated as hedging instruments
— — — (1)— — — — 4 (1)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of gain recognized in OCI on derivatives
— — — — 682 72 — — — — 1,233 193 
Increase (decrease) in Sales as a result of AOCL reclassifications
253 (36)— — (253)36 491 (219)— — (491)219 
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)— — — — — (2)(2)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)— — — — — (2)(2)
(1) Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)2022202120222021
Derivatives Not Designated as Hedging InstrumentsIncome Statement Caption
Foreign exchange contracts (1)
Other (income) expense, net$(41)$18 $(77)$234 
Foreign exchange contracts (2)
Sales(4)(4)(42)6 
(1) These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2022December 31, 2021
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$67 $— $— $67 $80 $— $— $80 
Commercial paper4 — — 4 — — — — 
Corporate notes and bonds3 — — 3 4 — — 4 
Foreign government bonds2 — — 2 2 — — 2 
Total debt securities$76 $— $— $76 $86 $— $— $86 
Publicly traded equity securities (1)
1,334 1,647 
Total debt and publicly traded equity securities
$1,410 $1,733 
(1) Unrealized net losses of $221 million and $415 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022. Unrealized net (gains) losses of $(90) million and $109 million were recorded in Other (income) expense, net in the third quarter and first nine months of 2021, respectively, on equity securities still held at September 30, 2021.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2022December 31, 2021
Assets
Investments
Commercial paper$— $4 $— $4 $— $— $— $— 
Foreign government bonds— 2 — 2 — 2 — 2 
Publicly traded equity securities1,081 — — 1,081 368 — — 368 
 1,081 6 — 1,087 368 2 — 370 
Other assets (1)
U.S. government and agency securities67 — — 67 80 — — 80 
Corporate notes and bonds3 — — 3 4 — — 4 
Publicly traded equity securities253 — — 253 1,279 — — 1,279 
323 — — 323 1,363 — — 1,363 
Derivative assets (2)
Forward exchange contracts— 945 — 945 — 351 — 351 
Purchased currency options— 563 — 563 — 184 — 184 
Interest rate swaps— — — — — 14 — 14 
 — 1,508 — 1,508 — 549 — 549 
Total assets$1,404 $1,514 $— $2,918 $1,731 $551 $— $2,282 
Liabilities
Other liabilities
Contingent consideration$— $— $499 $499 $— $— $777 $777 
Derivative liabilities (2)
Forward exchange contracts— 242 — 242 — 120 — 120 
Written currency options— — — — — 1 — 1 
— 242 — 242 — 121 — 121 
Total liabilities$— $242 $499 $741 $— $121 $777 $898 
(1) Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(2)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:
($ in millions)20222021
Fair value January 1$777 $841 
Changes in estimated fair value (1)
(156)73 
Payments(119)— 
Other(3)(12)
Fair value September 30 (2)
$499 $902 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) At September 30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2022
Inventory Disclosure [Abstract]  
Inventories
Inventories consisted of:
($ in millions)September 30, 2022December 31, 2021
Finished goods$1,683 $1,747 
Raw materials and work in process6,532 6,220 
Supplies227 196 
Total (approximates current cost)8,442 8,163 
Decrease to LIFO cost(187)(16)
 $8,255 $8,147 
Recognized as:
Inventories$5,614 $5,953 
Other assets2,641 2,194 
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Schedule of Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20213,577 $1,788 $44,039 $48,777 $(4,628)1,044 $(56,682)$94 $33,388 
Net income attributable to Merck & Co., Inc.— — — 4,567 — — — — 4,567 
Other comprehensive income, net of taxes— — — — 38 — — — 38 
Cash dividends declared on common stock ($0.65 per share)
— — — (1,653)— — — — (1,653)
Treasury stock shares purchased— — — — — 8 (583)— (583)
Share-based compensation plans and other— — 110 — — — 21 — 131 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at July 1, 20223,577 $1,788 $44,115 $58,437 $(4,327)1,044 $(56,770)$75 $43,318 
Net income attributable to Merck & Co., Inc.— — — 3,248 — — — — 3,248 
Other comprehensive loss, net of taxes— — — — (416)— — — (416)
Cash dividends declared on common stock ($0.69 per share)
— — — (1,757)— — — — (1,757)
Share-based compensation plans and other— — 128 — — — 12 — 140 
Net income attributable to noncontrolling interests— — — — — — — 5 5 
Distributions attributable to noncontrolling interests— — — — — — — (14)(14)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20213,577 $1,788 $39,588 $47,362 $(6,634)1,047 $(56,787)$87 $25,404 
Net income attributable to Merck & Co., Inc.— — — 9,291 — — — — 9,291 
Other comprehensive income, net of taxes— — — — 1,595 — — — 1,595 
Cash dividends declared on common stock ($1.95 per share)
— — — (4,962)— — — — (4,962)
Treasury stock shares purchased— — — — — 11 (822)— (822)
Spin-off of Organon & Co.— — 4,643 — 449 — — (1)5,091 
Share-based compensation plans and other— — (82)— — (6)365 — 283 
Net income attributable to noncontrolling interests— — — — — — — 12 12 
Distributions attributable to noncontrolling interests— — — — — — — (29)(29)
Balance at September 30, 20213,577 $1,788 $44,149 $51,691 $(4,590)1,052 $(57,244)$69 $35,863 
Balance at January 1, 20223,577 $1,788 $44,238 $53,696 $(4,429)1,049 $(57,109)$73 $38,257 
Net income attributable to Merck & Co., Inc.— — — 11,502 — — — — 11,502 
Other comprehensive loss, net of taxes— — — — (314)— — — (314)
Cash dividends declared on common stock ($2.07 per share)
— — — (5,270)— — — — (5,270)
Share-based compensation plans and other— — 5 — — (5)351 — 356 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests— — — — — — — (13)(13)
Balance at September 30, 20223,577 $1,788 $44,243 $59,928 $(4,743)1,044 $(56,758)$66 $44,524 
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2.2
Pension and Other Postretirement Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2022
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$91 $66 $104 $75 $289 $213 $302 $254 
Interest cost123 35 102 33 330 110 305 92 
Expected return on plan assets(182)(93)(188)(105)(576)(292)(568)(313)
Amortization of unrecognized prior service credit
(8)(3)(9)(3)(24)(10)(29)(12)
Net loss amortization10 24 75 32 122 73 218 110 
Termination benefits1 — 2 — 2 1 54 3 
Curtailments3 — (1)— 11 — 15 (27)
Settlements79 — 139 — 180 — 139 2 
 $117 $29 $224 $32 $334 $95 $436 $109 
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Net Benefit Costs
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Service cost$11 $11 $36 $37 
Interest cost11 12 34 34 
Expected return on plan assets(21)(20)(64)(59)
Amortization of unrecognized prior service credit(14)(16)(42)(48)
Net gain amortization(11)(12)(32)(30)
Termination benefits— — — 37 
Curtailments— (1)(1)(29)
 $(24)$(26)$(69)$(58)
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense, Net (Tables)
 9 Months Ended
Sep. 30, 2022
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Interest income$(40)$(7)$(62)$(27)
Interest expense244 196 727 597 
Exchange losses96 46 220 202 
Loss (income) from investments in equity securities, net (1)
371 (683)1,361 (1,535)
Net periodic defined benefit plan (credit) cost other than service cost(60)40 (208)(159)
Other, net(182)(42)(462)(85)
 $429 $(450)$1,576 $(1,007)
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag.
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2022
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2022202120222021
Net Income from Continuing Operations Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $8,525 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests— — — 766 
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Average common shares outstanding2,533 2,530 2,531 2,531 
Common shares issuable (1)
9 6 9 8 
Average common shares outstanding assuming dilution 2,542 2,536 2,540 2,539 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.81 $4.55 $3.37 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.81 $4.55 $3.67 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.80 $4.53 $3.36 
Income from Discontinued Operations— — — 0.30 
Net Income$1.28 $1.80 $4.53 $3.66 
(1)Issuable primarily under share-based compensation plans.
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Changes in AOCI by Component
Changes in each component of other comprehensive income (loss) are as follows:
Three Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance July 1, 2021, net of taxes$(26)$(3,028)$(1,574)$(4,628)
Other comprehensive income (loss) before reclassification adjustments, pretax72 (24)(96)(48)
Tax(16)16 12 12 
Other comprehensive income (loss) before reclassification adjustments, net of taxes56 (8)(84)(36)
Reclassification adjustments, pretax36 
(1)
68 
(2)
— 104 
Tax(8)(22)— (30)
Reclassification adjustments, net of taxes28 

46 

— 74 
Other comprehensive income (loss), net of taxes84 38 (84)38 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance July 1, 2022, net of taxes$390 $(2,465)$(2,252)$(4,327)
Other comprehensive income (loss) before reclassification adjustments, pretax682 (294)(618)(230)
Tax(143)62 50 (31)
Other comprehensive income (loss) before reclassification adjustments, net of taxes539 (232)(568)(261)
Reclassification adjustments, pretax(254)
(1)
77 
(2)
— (177)
Tax53 (31)— 22 
Reclassification adjustments, net of taxes(201)

46 

— (155)
Other comprehensive income (loss), net of taxes338 (186)(568)(416)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
Nine Months Ended September 30,
($ in millions)DerivativesEmployee
Benefit
Plans		Foreign Currency
Translation
Adjustment		Accumulated Other
Comprehensive
Loss
Balance January 1, 2021, net of taxes$(266)$(4,540)$(1,828)$(6,634)
Other comprehensive income (loss) before reclassification adjustments, pretax193 1,739 (167)1,765 
Tax(41)(385)(84)(510)
Other comprehensive income (loss) before reclassification adjustments, net of taxes152 1,354 (251)1,255 
Reclassification adjustments, pretax218 
(1)
210 
(2)
— 428 
Tax(46)(42)— (88)
Reclassification adjustments, net of taxes172 168 — 340 
Other comprehensive income (loss), net of taxes324 1,522 (251)1,595 
Spin-off of Organon (see Note 2)
— 28 421 449 
Balance September 30, 2021, net of taxes$58 $(2,990)$(1,658)$(4,590)
Balance January 1, 2022, net of taxes$144 $(2,743)$(1,830)$(4,429)
Other comprehensive income (loss) before reclassification adjustments, pretax1,233 (125)(1,001)107 
Tax(259)25 11 (223)
Other comprehensive income (loss) before reclassification adjustments, net of taxes974 (100)(990)(116)
Reclassification adjustments, pretax(493)
(1)
266 
(2)
— (227)
Tax103 (74)— 29 
Reclassification adjustments, net of taxes(390)192 — (198)
Other comprehensive income (loss), net of taxes584 92 (990)(314)
Balance September 30, 2022, net of taxes$728 $(2,651)$(2,820)$(4,743)
(1) Primarily relates to foreign currency cash flow hedges that were reclassified from AOCL to Sales.
(2) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2022
Segment Reporting [Abstract]  
Sales from Products
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$3,331 $2,095 $5,426 $2,580 $1,954 $4,534 $9,307 $6,180 $15,487 $7,108 $5,501 $12,609 
Alliance revenue-Lynparza (1)
144 140 284 129 117 246 427 397 825 371 350 721 
Alliance revenue-Lenvima (1)
142 60 202 114 74 188 426 235 660 287 211 498 
Alliance revenue-Reblozyl (2)
32 7 39 — — — 87 37 124 — — — 
Vaccines
Gardasil/Gardasil 9
957 1,337 2,294 839 1,154 1,993 1,803 3,624 5,428 1,605 2,539 4,144 
ProQuad/M-M-R II/Varivax
532 136 668 537 125 661 1,337 379 1,716 1,255 371 1,626 
RotaTeq154 102 256 135 92 227 427 218 644 364 229 593 
Pneumovax 23
68 63 131 181 97 277 280 177 457 354 247 600 
Vaqta27 36 64 32 16 48 72 62 134 80 58 138 
Hospital Acute Care
Bridion233 190 423 181 188 369 665 579 1,244 545 551 1,096 
Prevymis49 64 114 39 57 96 136 174 310 111 159 270 
Dificid72 6 77 52 2 54 184 12 196 108 7 115 
Primaxin— 63 63 — 69 70 1 185 185 — 194 194 
Noxafil13 49 62 19 45 64 39 141 180 48 149 197 
Invanz2 48 50 (2)55 53 4 144 148 (2)159 157 
Cancidas1 42 43 1 56 56 5 133 138 4 164 168 
Zerbaxa24 19 43 (1)(1)(2)64 55 120 (5)(6)(11)
Cardiovascular
Alliance revenue-Adempas/Verquvo (3)
85 3 88 73 27 100 244 14 258 222 26 248 
Adempas— 57 57 — 59 59 — 181 181 — 188 188 
Virology
Lagevrio— 436 436 — — — 1,523 3,336 4,859 — — — 
Isentress/Isentress HD
68 93 161 77 112 189 196 270 466 222 368 590 
Neuroscience
Belsomra20 42 62 23 58 81 60 139 199 56 183 238 
Immunology
Simponi— 173 173 — 203 203 — 540 540 — 619 619 
Remicade— 49 49 — 73 73 — 163 163 — 233 233 
Diabetes
Januvia332 385 717 365 487 852 958 1,294 2,252 997 1,448 2,445 
Janumet90 327 417 86 401 487 258 1,089 1,347 244 1,205 1,449 
Other pharmaceutical (4)
244 321 564 210 306 518 616 949 1,565 637 950 1,589 
Total Pharmaceutical segment sales6,620 6,343 12,963 5,670 5,826 11,496 19,119 20,707 39,826 14,611 16,103 30,714 
Animal Health:
Livestock186 643 829 190 675 864 521 1,965 2,486 508 1,996 2,503 
Companion Animals289 253 542 277 276 553 904 929 1,834 855 948 1,804 
Total Animal Health segment sales475 896 1,371 467 951 1,417 1,425 2,894 4,320 1,363 2,944 4,307 
Total segment sales7,095 7,239 14,334 6,137 6,777 12,913 20,544 23,601 44,146 15,974 19,047 35,021 
Other (5)
227 398 625 139 101 241 383 925 1,307 192 (30)162 
 $7,322 $7,637 $14,959 $6,276 $6,878 $13,154 $20,927 $24,526 $45,453 $16,166 $19,017 $35,183 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).
(2)    Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note 4).
(3)    Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).
(4)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(5)    Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2022 and 2021 also includes $156 million and $191 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements.
Consolidated Sales by Geographic Area
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
United States$7,322 $6,276 $20,927 $16,166 
Europe, Middle East and Africa3,286 3,342 11,228 9,912 
China1,442 1,307 3,957 3,004 
Japan673 638 2,776 1,929 
Asia Pacific (other than China and Japan)854 613 2,792 1,782 
Latin America684 599 1,933 1,631 
Other698 379 1,840 759 
 $14,959 $13,154 $45,453 $35,183 
Reconciliation of Segment Profits to Income before Taxes
A reconciliation of segment profits to Income from Continuing Operations Before Taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2022202120222021
Segment profits:
Pharmaceutical segment$9,590 $8,606 $28,263 $22,450 
Animal Health segment515 505 1,672 1,629 
Total segment profits10,105 9,111 29,935 24,079 
Other profits377 141 831 29 
Unallocated:
Interest income40 7 62 27 
Interest expense(244)(196)(727)(597)
Amortization(460)(360)(1,623)(1,231)
Depreciation(448)(358)(1,257)(1,031)
Research and development(4,277)(2,312)(9,374)(8,775)
Restructuring costs(94)(107)(288)(487)
Other unallocated, net(1,416)(660)(4,628)(2,044)
 $3,583 $5,266 $12,931 $9,970 
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2.2
Spin-Off of Organon & Co. - Narrative (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Jun. 02, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Consideration received $ 9,000          
Disposal group, other expense         $ 556  
Organon & Co.            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Stock conversion ratio 0.1          
Revenue from related party   $ 100 $ 0 $ 293 0  
Related party amount in cost of sales   104 $ 0 312 $ 0  
Due from related parties, current   567   567   $ 964
Due to related parties, current   $ 333   $ 333   $ 400
Minimum | Transition services agreement            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Period of continuing involvement after disposal 25 months          
Minimum | Manufacturing and supply agreements            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Period of continuing involvement after disposal 4 years          
Maximum | Transition services agreement            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Period of continuing involvement after disposal 31 months          
Maximum | Manufacturing and supply agreements            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Period of continuing involvement after disposal 10 years          
Organon & Co.            
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]            
Face amount of debt $ 9,500          
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]        
Sales       $ 2,512
Costs, Expenses and Other        
Cost of sales       789
Selling, general and administrative       877
Research and development       103
Restructuring costs       1
Other (income) expense, net       (15)
Operating expenses       1,755
Income from discontinued operations before taxes       757
Income tax benefit       (12)
Income from discontinued operations, net of taxes       769
Less: Income of discontinued operations attributable to noncontrolling interests       3
Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests $ 0 $ 0 $ 0 $ 766
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2.2
Acquisitions, Research Collaborations and License Agreements (Details)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2022
USD ($)
Aug. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Apr. 30, 2021
USD ($)
Jan. 31, 2021
USD ($)
research_program
collaboration_target
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Business Acquisition [Line Items]                      
Upfront and milestone payments               $ 250.0   $ 250.0  
Research and development               $ 4,399.0 $ 2,445.0 $ 9,773.0 $ 9,177.0
Subsequent Event                      
Business Acquisition [Line Items]                      
Compensation earned $ 50.0                    
Additional funding by others, percentage of development costs 50.00%                    
Additional funding by others, development costs subject to funding $ 375.0                    
Pandion Therapeutics                      
Business Acquisition [Line Items]                      
Research and development                     1,700.0
Consideration transferred, asset acquisition         $ 1,900.0            
Asset acquisition costs         147.0            
Net assets         $ 156.0            
Orna Therapeutics | Subsequent Event                      
Business Acquisition [Line Items]                      
Amount paid for investment             $ 100.0        
Orna Therapeutics | Licensing Agreements                      
Business Acquisition [Line Items]                      
Upfront and milestone payments   $ 150.0                  
Orna Therapeutics | Licensing Agreements | Development Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement   440.0                  
Orna Therapeutics | Licensing Agreements | Regulatory Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement   675.0                  
Orna Therapeutics | Licensing Agreements | Sales-Based Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement   $ 2,400.0                  
Orion Corporation | Licensing Agreements                      
Business Acquisition [Line Items]                      
Upfront and milestone payments     $ 290.0                
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements                      
Business Acquisition [Line Items]                      
Upfront and milestone payments     35.0 $ 30.0              
Milestone payments to be made to a collaborative partner       30.0              
Milestone payment to be made to a collaborative partner       25.0              
Research and development payments to be made to a collaborative partner (up to)       101.0              
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Development Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement     82.0 90.0              
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Regulatory Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement     334.0                
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | Sales-Based Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement     $ 485.0 780.0              
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Licensing Agreements | First Commercial Sale Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement       $ 290.0              
Artiva Biotherapeutics, Inc. | Licensing Agreements                      
Business Acquisition [Line Items]                      
Upfront and milestone payments           $ 30.0          
Upfront and milestone payments to be made           $ 15.0          
Number of research programs | research_program           3          
Number of collaboration targets | collaboration_target           3          
Artiva Biotherapeutics, Inc. | Licensing Agreements | Minimum                      
Business Acquisition [Line Items]                      
Royalty rate           7.00%          
Artiva Biotherapeutics, Inc. | Licensing Agreements | Maximum                      
Business Acquisition [Line Items]                      
Royalty rate           14.00%          
Artiva Biotherapeutics, Inc. | Licensing Agreements | Development Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement           $ 217.5          
Artiva Biotherapeutics, Inc. | Licensing Agreements | Regulatory Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement           570.0          
Artiva Biotherapeutics, Inc. | Licensing Agreements | Sales-Based Milestones                      
Business Acquisition [Line Items]                      
Contingent milestone payments collaborative arrangement           $ 1,050.0          
COVID-19                      
Business Acquisition [Line Items]                      
Charges related to program discontinuation                     $ 207.0
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements - Narrative (Details)
course in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2022
USD ($)
Mar. 31, 2021
USD ($)
Sep. 30, 2022
USD ($)
course
Mar. 31, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
market
course
Sep. 30, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Amortization           $ 1,623 $ 1,231
Number of markets (more than) | market           40  
Remaining minimum courses committed (in courses) | course     0.8     0.8  
Sales     $ 14,959   $ 13,154 $ 45,453 35,183
Operating Segments              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     14,334   12,913 44,146 35,021
Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     12,963   11,496 39,826 30,714
Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Amortization       $ 250      
Lynparza | Other Noncurrent Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     1,500     1,500  
Lenvima | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     202   188 660 498
Lenvima | Other Noncurrent Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     867     867  
Verquvo | Other Intangible Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     53     53  
Adempas | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     57   59 181 188
Adempas | Other Intangible Assets              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Finite-lived intangible assets     597     597  
Alliance Revenue - Reblozyl | Operating Segments | Pharmaceutical              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales     39   $ 0 124 $ 0
AstraZeneca | Sales-Based Milestones | Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Probable contingent payments       600      
Liabilities       $ 600      
Milestone payments accrued but not yet paid     600     600  
AstraZeneca | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lynparza              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments           400  
Potential future sales-based milestone payments     2,100     2,100  
Capitalized milestone payment           250  
Potential future regulatory milestone payments     1,200     1,200  
Eisai              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
License option payment related to collaborative arrangement   $ 125          
Eisai | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Lenvima              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments           600  
Potential future sales-based milestone payments     $ 2,600     2,600  
Capitalized milestone payment           $ 50  
Bayer AG | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Sales-based milestone payments $ 400            
Bristol Myers Squibb | Licensing Agreements              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate, deduction           0.50  
Royalties           $ 104  
Bristol Myers Squibb | Licensing Agreements | Sales-Based Milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments collaborative arrangement           80  
Bristol Myers Squibb | Licensing Agreements | Regulatory Milestones              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Contingent milestone payments collaborative arrangement           $ 20  
Bristol Myers Squibb | Licensing Agreements | Minimum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate           20.00%  
Bristol Myers Squibb | Licensing Agreements | Maximum              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Royalty rate           24.00%  
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2.2
Collaborative Arrangements - Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183  
Cost of sales 3,934 3,450 13,530 9,752  
Selling, general and administrative 2,520 2,336 7,355 6,804  
Research and development 4,399 2,445 9,773 9,177  
Payables included in Accrued and other liabilities 22,998   22,998   $ 23,872
Other current assets | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 290   290   271
Other current assets | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 202   202   200
Other current assets | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables included in Other current assets 144   144   114
Accounts Payable and Accrued Liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 12   12   415
Accounts Payable and Accrued Liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 1   1   625
Accounts Payable and Accrued Liabilities | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 75   75   472
Accounts Payable and Accrued Liabilities | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Accrued and other liabilities 193   193   283
Other Noncurrent Liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables included in Other Noncurrent Liabilities 600   600   $ 0
Revenue | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 294 252 868 741  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 284 246 825 721  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 10 6 43 20  
Revenue | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 202 188 660 498  
Revenue | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 88 100 258 248  
Sales 151 161 454 439  
Revenue | Bayer AG | Collaborative Arrangement | Adempas          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net sales by Merck 57 59 181 188  
Revenue | Bayer AG | Collaborative Arrangement | Verquvo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Net sales by Merck 6 2 15 3  
Revenue | Ridgeback Biotherapeutics LP | Collaborative Arrangement | Lagevrio          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales 436 0 4,859 0  
Cost of sales | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 64 42 425 125  
Amortization of intangible assets     250    
Cost of sales | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 53 49 159 143  
Cost of sales | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 55 53 158 328  
Amortization of intangible assets       153  
Cost of sales | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 234 4 2,580 56  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 45 44 135 127  
Selling, general and administrative | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 42 34 115 88  
Selling, general and administrative | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 42 31 107 84  
Selling, general and administrative | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 41 6 105 13  
Research and development | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 28 27 79 87  
Research and development | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 24 43 128 165  
Research and development | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 18 16 52 36  
Research and development | Ridgeback Biotherapeutics LP | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development $ 8 $ 58 $ 29 $ 167  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]          
Expected restructuring and related cost $ 3,500   $ 3,500    
Estimate of cumulative pre tax costs that will result in cash outlays     70.00%    
Estimate of cumulative pre tax costs that will be noncash     30.00%    
Total pretax restructuring costs 175 $ 168 $ 559 $ 630  
Cumulative costs since program inception $ 3,200   $ 3,200    
Forecast          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring and related cost         $ 600
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 175 $ 168 $ 559 $ 630
Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 65 17 197 310
Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 21 22 97 60
Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 89 129 265 260
Cost of sales        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 54 48 167 113
Cost of sales | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Cost of sales | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 16 11 51 32
Cost of sales | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 38 37 116 81
Selling, general and administrative        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 26 5 74 9
Selling, general and administrative | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Selling, general and administrative | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 5 4 17 8
Selling, general and administrative | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 21 1 57 1
Research and development        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 1 8 30 21
Research and development | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Research and development | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 7 29 20
Research and development | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 1 1 1 1
Restructuring costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 94 107 288 487
Restructuring costs | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 65 17 197 310
Restructuring costs | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Restructuring costs | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 29 $ 90 $ 91 $ 177
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     $ 637  
Expense $ 175 $ 168 559 $ 630
(Payments) receipts, net     (761)  
Non-cash activity     86  
Restructuring reserve, ending balance 521   521  
Separation Costs        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     596  
Expense 65 17 197 310
(Payments) receipts, net     (303)  
Non-cash activity     0  
Restructuring reserve, ending balance 490   490  
Accelerated Depreciation        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     0  
Expense 21 22 97 60
(Payments) receipts, net     0  
Non-cash activity     (97)  
Restructuring reserve, ending balance 0   0  
Other        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     41  
Expense 89 $ 129 265 $ 260
(Payments) receipts, net     (458)  
Non-cash activity     183  
Restructuring reserve, ending balance $ 31   $ 31  
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Narrative (Details)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
interest_rate_swap
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
interest_rate_swap
Sep. 30, 2021
USD ($)
Dec. 31, 2021
USD ($)
Feb. 28, 2022
USD ($)
interest_rate_swap
Derivative [Line Items]            
Total swap notional amount $ 26,026,000,000   $ 26,026,000,000   $ 32,958,000,000  
Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales     864,000,000      
Equity investments without readily determinable fair values 705,000,000 $ 578,000,000 705,000,000 $ 578,000,000    
Unrealized gains recognized on investments in equity securities without readily determinable fair value     21,000,000 104,000,000    
Unrealized losses recognized on investments in equity securities without readily determinable fair values     12,000,000 1,000,000    
Cumulative unrealized gains on investments 255,000,000   255,000,000      
Cumulative unrealized losses on investments 19,000,000   19,000,000      
Equity securities, noncurrent 655,000,000 1,200,000,000 655,000,000 1,200,000,000    
Loss (income) from investments in equity securities, net 371,000,000 (683,000,000) 1,361,000,000 (1,535,000,000)    
Fair value of loans payable and long-term debt, including current portion 25,900,000,000   25,900,000,000   35,700,000,000  
Debt, carrying amount 30,400,000,000   30,400,000,000   33,100,000,000  
Factored accounts receivable 2,300,000,000       2,800,000,000  
Restricted cash 55,000,000   55,000,000   62,000,000  
Cash collateral received from counterparties 794,000,000   794,000,000   164,000,000  
2.40% Notes Due 2022            
Derivative [Line Items]            
Face amount of debt 1,000,000,000   1,000,000,000      
Equity Funds            
Derivative [Line Items]            
Loss (income) from investments in equity securities, net 141,000,000 $ (391,000,000) 952,000,000 $ (893,000,000)    
Level 2            
Derivative [Line Items]            
Cash equivalents $ 10,000,000,000   $ 10,000,000,000   6,800,000,000  
2.35% Notes Due 2022            
Derivative [Line Items]            
Face amount of debt           $ 1,250,000,000
Stated interest rate           2.35%
2.40% Notes Due 2022            
Derivative [Line Items]            
Stated interest rate 2.40%   2.40%      
Interest rate swap contracts            
Derivative [Line Items]            
Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap 4   4     5
Interest rate swap contracts | 2.35% Notes Due 2022            
Derivative [Line Items]            
Total swap notional amount           $ 1,250,000,000
Interest rate swap contracts | 2.40% Notes Due 2022            
Derivative [Line Items]            
Total swap notional amount $ 1,000,000,000   $ 1,000,000,000      
Derivatives Designated as Hedging Instruments            
Derivative [Line Items]            
Total swap notional amount 8,788,000,000   8,788,000,000   12,245,000,000  
Derivatives Not Designated as Hedging Instruments            
Derivative [Line Items]            
Total swap notional amount $ 17,238,000,000   $ 17,238,000,000   $ 20,713,000,000  
Maximum | Derivatives Designated as Hedging Instruments            
Derivative [Line Items]            
Maximum average period of maturities of contracts in years (less than)     2 years      
Maximum | Derivatives Not Designated as Hedging Instruments            
Derivative [Line Items]            
Maximum average period of maturities of contracts in years (less than)     1 year      
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ (1) $ 1 $ (47) $ (27)
Foreign exchange contracts | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing 0 (4) (2) (12)
Euro-denominated notes        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (250) (77) (431) (199)
Euro-denominated notes | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0 $ 0 $ 0
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Fair Value Hedges (Details) - Loans payable and current portion of long-term debt - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Carrying Amount of Hedged Liabilities $ 0 $ 2,263
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount $ 0 $ 13
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 1,508 $ 549
Fair Value of Derivative, Liability 242 121
U.S Dollar Notional Amount 26,026 32,958
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 911 328
Fair Value of Derivative, Liability 2 25
U.S Dollar Notional Amount 8,788 12,245
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 597 221
Fair Value of Derivative, Liability 240 96
U.S Dollar Notional Amount 17,238 20,713
Interest Rate Contract | Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 0 $ 14
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Interest Rate Contract | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
U.S Dollar Notional Amount $ 0 $ 2,250
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 826 $ 271
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
U.S Dollar Notional Amount $ 7,250 $ 6,778
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 85 $ 43
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other Assets Other Assets
U.S Dollar Notional Amount $ 1,408 $ 1,551
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 1 $ 24
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
U.S Dollar Notional Amount $ 37 $ 1,623
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability $ 1 $ 1
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Other Noncurrent Liabilities Other Noncurrent Liabilities
U.S Dollar Notional Amount $ 93 $ 43
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 597 $ 221
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other current assets Other current assets
Fair Value of Derivative, Liability $ 240 $ 96
Derivative Liability, Statement of Financial Position [Extensible Enumeration] Accrued and other current liabilities Accrued and other current liabilities
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
U.S Dollar Notional Amount $ 9,523 $ 10,073
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
U.S Dollar Notional Amount $ 7,715 $ 10,640
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 1,508 $ 549
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (217) (110)
Cash collateral received, asset (794) (164)
Net amounts, asset 497 275
Gross amounts recognized in the consolidated balance sheet, liability 242 121
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (217) (110)
Cash collateral received, liability 0 0
Net amounts, liability $ 25 $ 11
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]        
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183
Other (income) expense, net 429 (450) 1,576 (1,007)
Other comprehensive income (loss) $ (416) $ 38 $ (314) $ 1,595
Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Other (income) expense, net Other (income) expense, net Other (income) expense, net Other (income) expense, net
Interest rate swap contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain (loss) recognized in OCI on derivatives $ (1) $ 0 $ (2) $ (2)
Amount of gain recognized in Other (income) expense, net on derivatives (1) 0 (2) (2)
Interest rate swap contracts | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Hedged items 1 (9) (13) (29)
Derivatives designated as hedging instruments 0 (1) 4 (1)
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of gain (loss) recognized in OCI on derivatives 682 72 1,233 193
Increase (decrease) in Sales as a result of AOCL reclassifications (253) 36 (491) 219
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest        
Derivative Instruments, Gain (Loss) [Line Items]        
Sales $ 253 $ (36) $ 491 $ (219)
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Currency Swap | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (41) $ 18 $ (77) $ 234
Foreign Exchange Future | Sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (4) $ (4) $ (42) $ 6
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost $ 76   $ 76   $ 86
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 76   76   86
Publicly traded equity securities, fair value 1,334   1,334   1,647
Total debt and publicly traded equity securities, fair value 1,410   1,410   1,733
Unrealized net (gains) losses 221 $ (90) 415 $ 109  
U.S. government and agency securities          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 67   67   80
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 67   67   80
Commercial paper          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 4   4   0
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 4   4   0
Corporate notes and bonds          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 3   3   4
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 3   3   4
Foreign government bonds          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 2   2   2
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value $ 2   $ 2   $ 2
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Sep. 30, 2021
Dec. 31, 2020
Assets        
Investments $ 76 $ 86    
Publicly traded equity securities 1,334 1,647    
Derivative assets 1,508 549    
Liabilities        
Contingent consideration 499 777 $ 902 $ 841
Derivative liabilities 242 121    
Commercial paper        
Assets        
Investments 4 0    
Foreign government bonds        
Assets        
Investments 2 2    
U.S. government and agency securities        
Assets        
Investments 67 80    
Corporate notes and bonds        
Assets        
Investments 3 4    
Fair Value, Measurements, Recurring        
Assets        
Investments 1,087 370    
Other assets 323 1,363    
Derivative assets 1,508 549    
Total assets 2,918 2,282    
Liabilities        
Contingent consideration 499 777    
Derivative liabilities 242 121    
Total liabilities 741 898    
Fair Value, Measurements, Recurring | Foreign exchange contracts        
Assets        
Derivative assets 945 351    
Liabilities        
Derivative liabilities 242 120    
Fair Value, Measurements, Recurring | Interest rate swaps        
Assets        
Derivative assets 0 14    
Fair Value, Measurements, Recurring | Currency options        
Assets        
Derivative assets 563 184    
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Level 1        
Assets        
Investments 1,081 368    
Other assets 323 1,363    
Derivative assets 0 0    
Total assets 1,404 1,731    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 0 0    
Total liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swaps        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 1 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 2        
Assets        
Investments 6 2    
Other assets 0 0    
Derivative assets 1,508 549    
Total assets 1,514 551    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 242 121    
Total liabilities 242 121    
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts        
Assets        
Derivative assets 945 351    
Liabilities        
Derivative liabilities 242 120    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swaps        
Assets        
Derivative assets 0 14    
Fair Value, Measurements, Recurring | Level 2 | Currency options        
Assets        
Derivative assets 563 184    
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Derivative assets 0 0    
Total assets 0 0    
Liabilities        
Contingent consideration 499 777    
Derivative liabilities 0 0    
Total liabilities 499 777    
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swaps        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 3 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Commercial paper        
Assets        
Investments 4 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 2        
Assets        
Investments 4 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds        
Assets        
Investments 2 2    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 2        
Assets        
Investments 2 2    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities        
Assets        
Publicly traded equity securities 1,081 368    
Other assets 253 1,279    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1        
Assets        
Publicly traded equity securities 1,081 368    
Other assets 253 1,279    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities        
Assets        
Other assets 67 80    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1        
Assets        
Other assets 67 80    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2        
Assets        
Other assets 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3        
Assets        
Other assets 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds        
Assets        
Other assets 3 4    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1        
Assets        
Other assets 3 4    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2        
Assets        
Other assets 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3        
Assets        
Other assets $ 0 $ 0    
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.2.2
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, beginning balance $ 777 $ 841
Changes in estimated fair value (156) 73
Payments (119) 0
Other (3) (12)
Fair value, ending balance 499 902
Contingent consideration 499 $ 902
Current liability 139  
Sanofi Pasteur    
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Fair value, ending balance 358  
Contingent consideration $ 358  
Contingent consideration, measurement input, discount rate 0.115  
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories - Schedule of Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory Disclosure [Abstract]    
Finished goods $ 1,683 $ 1,747
Raw materials and work in process 6,532 6,220
Supplies 227 196
Total (approximates current cost) 8,442 8,163
Decrease to LIFO cost (187) (16)
Total current and noncurrent inventories 8,255 8,147
Recognized as:    
Inventories 5,614 5,953
Other assets $ 2,641 $ 2,194
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.22.2.2
Inventories - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Inventory [Line Items]    
Inventories classified in Other assets $ 2,641 $ 2,194
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in Other assets 2,200 1,900
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in Other assets $ 417 $ 256
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Intangibles (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2022
Dec. 31, 2021
Indefinite-Lived Intangible Assets [Line Items]    
Intangible assets $ 21,368 $ 22,933
In Process Research and Development    
Indefinite-Lived Intangible Assets [Line Items]    
Impairment charge 887  
nemtabrutinib | In Process Research and Development    
Indefinite-Lived Intangible Assets [Line Items]    
Impairment charge 807  
Intangible assets $ 1,200  
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.22.2.2
Contingencies (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Jan. 09, 2023
Dec. 19, 2022
Jun. 30, 2022
claim
Mar. 31, 2014
case
Sep. 30, 2022
USD ($)
case
claim
Dec. 31, 2021
USD ($)
Aug. 31, 2020
claim
Legal Defense Costs              
Loss Contingencies [Line Items]              
Legal defense costs reserve | $         $ 230 $ 230  
Zetia antitrust litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | claim             35
Zetia antitrust litigation | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, new claims filed | claim     23        
Patent Infringement Lawsuit Against Zydus | Pending Litigation | Forecast              
Loss Contingencies [Line Items]              
Loss contingency, recovery from third party, bench trial period 3 days            
Fosamax              
Loss Contingencies [Line Items]              
Loss contingency, pending claims         3,450    
Fosamax | Femur Fracture Litigation | Federal              
Loss Contingencies [Line Items]              
Loss contingency, claims dismissed       650      
Loss contingency, claims on appeal       515      
Januvia | Cases Company Agreed To Toll Statute Of Limitations              
Loss Contingencies [Line Items]              
Loss contingency, pending claims | claim         50    
Gardasil/Gardasil 9 | U.S.              
Loss Contingencies [Line Items]              
Loss contingency, pending claims         65    
Gardasil/Gardasil 9 | Non-US              
Loss Contingencies [Line Items]              
Loss contingency, pending claims         15    
Gardasil/Gardasil 9 | COLOMBIA              
Loss Contingencies [Line Items]              
Loss contingency, pending claims         1    
Bridion | Patents              
Loss Contingencies [Line Items]              
Loss contingency, claims settled         5    
Bridion | Patents | Pending Litigation              
Loss Contingencies [Line Items]              
Loss contingency, pending claims         2    
Bridion | Patents | Pending Litigation | Forecast              
Loss Contingencies [Line Items]              
Loss contingency, trial period   1 day          
Januvia and Janumet | Patents              
Loss Contingencies [Line Items]              
Loss contingency, claims settled         22    
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.22.2.2
Equity - Rollforward Reconciliations (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock, beginning balance (in shares)     3,577,103,522  
Treasury stock, beginning balance (in shares)     1,049,499,023  
Equity, beginning balance $ 43,318 $ 33,388 $ 38,257 $ 25,404
Net income attributable to Merck & Co., Inc. 3,248 4,567 11,502 9,291
Other comprehensive income (loss), net of taxes (416) 38 (314) 1,595
Cash dividends declared on common stock (1,757) (1,653) (5,270) (4,962)
Treasury stock shares purchased   (583)   (822)
Spin-off of Organon & Co.       5,091
Share-based compensation plans and other 140 131 356 283
Net income attributable to noncontrolling interests 5 4 6 12
Distributions attributable to noncontrolling interests $ (14) (29) $ (13) (29)
Common stock, ending balance (in shares) 3,577,103,522   3,577,103,522  
Treasury stock, ending balance (in shares) 1,043,697,097   1,043,697,097  
Equity, ending balance $ 44,524 $ 35,863 $ 44,524 $ 35,863
Cash dividends declared on common stock (in dollars per share) $ 0.69 $ 0.65 $ 2.07 $ 1.95
   Common Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock, beginning balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Common stock, ending balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Other Paid-In Capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 44,115 44,039 44,238 39,588
Spin-off of Organon & Co.       4,643
Share-based compensation plans and other 128 110 5 (82)
Equity, ending balance 44,243 44,149 44,243 44,149
Retained Earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 58,437 48,777 53,696 47,362
Net income attributable to Merck & Co., Inc. 3,248 4,567 11,502 9,291
Cash dividends declared on common stock (1,757) (1,653) (5,270) (4,962)
Equity, ending balance 59,928 51,691 59,928 51,691
Accumulated Other Comprehensive Loss        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance (4,327) (4,628) (4,429) (6,634)
Other comprehensive income (loss), net of taxes (416) 38 (314) 1,595
Spin-off of Organon & Co.       449
Equity, ending balance $ (4,743) $ (4,590) $ (4,743) $ (4,590)
  Treasury Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Treasury stock, beginning balance (in shares) 1,044,000,000 1,044,000,000 1,049,000,000 1,047,000,000
Equity, beginning balance $ (56,770) $ (56,682) $ (57,109) $ (56,787)
Treasury stock shares purchased (in shares)   8,000,000   11,000,000
Treasury stock shares purchased   $ (583)   $ (822)
Share-based compensation plans and other (in shares)     (5,000,000) (6,000,000)
Share-based compensation plans and other $ 12 $ 21 $ 351 $ 365
Treasury stock, ending balance (in shares) 1,044,000,000 1,052,000,000 1,044,000,000 1,052,000,000
Equity, ending balance $ (56,758) $ (57,244) $ (56,758) $ (57,244)
Non- controlling Interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 75 94 73 87
Spin-off of Organon & Co.       (1)
Net income attributable to noncontrolling interests 5 4 6 12
Distributions attributable to noncontrolling interests (14) (29) (13) (29)
Equity, ending balance $ 66 $ 69 $ 66 $ 69
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.22.2.2
Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Other Postretirement Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost $ 11 $ 11 $ 36 $ 37
Interest cost 11 12 34 34
Expected return on plan assets (21) (20) (64) (59)
Amortization of unrecognized prior service credit (14) (16) (42) (48)
Net loss amortization (11) (12) (32) (30)
Termination benefits 0 0 0 37
Curtailments 0 (1) (1) (29)
Net periodic benefit cost (24) (26) (69) (58)
U.S. | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 91 104 289 302
Interest cost 123 102 330 305
Expected return on plan assets (182) (188) (576) (568)
Amortization of unrecognized prior service credit (8) (9) (24) (29)
Net loss amortization 10 75 122 218
Termination benefits 1 2 2 54
Curtailments 3 (1) 11 15
Settlements 79 139 180 139
Net periodic benefit cost 117 224 334 436
International | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 66 75 213 254
Interest cost 35 33 110 92
Expected return on plan assets (93) (105) (292) (313)
Amortization of unrecognized prior service credit (3) (3) (10) (12)
Net loss amortization 24 32 73 110
Termination benefits 0 0 1 3
Curtailments 0 0 0 (27)
Settlements 0 0 0 2
Net periodic benefit cost $ 29 $ 32 $ 95 $ 109
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.22.2.2
Pension and Other Postretirement Benefit Plans - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2022
Retirement Benefits [Abstract]    
Increase to pension liabilities due to remeasurement $ 296 $ 131
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Component of Other Income / Expense of Nonoperating [Line Items]        
Interest income $ (40) $ (7) $ (62) $ (27)
Interest expense 244 196 727 597
Exchange losses 96 46 220 202
Loss (income) from investments in equity securities, net 371 (683) 1,361 (1,535)
Net periodic defined benefit plan (credit) cost other than service cost (60) 40 (208) (159)
Other, net (182) (42) (462) (85)
Other (income) expense, net 429 (450) 1,576 (1,007)
Unrealized net (gains) losses $ 221 $ (90) $ 415 $ 109
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Other Income and Expenses [Abstract]    
Interest paid $ 660 $ 570
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.22.2.2
Taxes on Income (Details) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2022
Sep. 30, 2021
Income Tax Examination [Line Items]          
Effective income tax rate 9.20% 13.20%   11.00% 14.40%
Tax benefit resulting from acquisition   $ 0     $ 0
Internal Revenue Service (IRS) | Domestic Tax Authority          
Income Tax Examination [Line Items]          
Tax benefit recognized related to settlement         236,000,000
Income taxes paid     $ 190,000,000    
Internal Revenue Service (IRS) | Domestic Tax Authority | Continuing Operations          
Income Tax Examination [Line Items]          
Tax benefit recognized related to settlement         207,000,000
Income taxes paid     172,000,000    
Internal Revenue Service (IRS) | Domestic Tax Authority | Discontinued Operations          
Income Tax Examination [Line Items]          
Tax benefit recognized related to settlement         $ 29,000,000
Income taxes paid     $ 18,000,000    
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share - Calculations of Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]        
Net Income from Continuing Operations Attributable to Merck & Co., Inc. $ 3,248 $ 4,567 $ 11,502 $ 8,525
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 0 0 0 766
Net income attributable to Merck & Co., Inc., basic 3,248 4,567 11,502 9,291
Net income attributable to Merck & Co., Inc., diluted $ 3,248 $ 4,567 $ 11,502 $ 9,291
Average common shares outstanding (in shares) 2,533 2,530 2,531 2,531
Common shares issuable (in shares) 9 6 9 8
Average common shares outstanding assuming dilution (in shares) 2,542 2,536 2,540 2,539
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) $ 1.28 $ 1.81 $ 4.55 $ 3.37
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) 1.28 1.81 4.55 3.67
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:        
Income from Continuing Operations (in dollars per share) 1.28 1.80 4.53 3.36
Income from Discontinued Operations (in dollars per share) 0 0 0 0.30
Net Income (in dollars per share) $ 1.28 $ 1.80 $ 4.53 $ 3.66
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.22.2.2
Earnings Per Share - Narrative (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Earnings Per Share [Abstract]        
Antidilutive shares (in shares) 2 8 5 10
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.22.2.2
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance $ 43,318 $ 33,388 $ 38,257 $ 25,404
Other comprehensive income (loss) before reclassification adjustments, pretax (230) (48) 107 1,765
Tax (31) 12 (223) (510)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (261) (36) (116) 1,255
Reclassification adjustments, pretax (177) 104 (227) 428
Tax 22 (30) 29 (88)
Reclassification adjustments, net of taxes (155) 74 (198) 340
Other comprehensive income (loss), net of taxes (416) 38 (314) 1,595
Spin-off of Organon & Co.       5,091
Equity, ending balance 44,524 35,863 44,524 35,863
Derivatives        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance 390 (26) 144 (266)
Other comprehensive income (loss) before reclassification adjustments, pretax 682 72 1,233 193
Tax (143) (16) (259) (41)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 539 56 974 152
Reclassification adjustments, pretax (254) 36 (493) 218
Tax 53 (8) 103 (46)
Reclassification adjustments, net of taxes (201) 28 (390) 172
Other comprehensive income (loss), net of taxes 338 84 584 324
Spin-off of Organon & Co.       0
Equity, ending balance 728 58 728 58
Employee Benefit Plans        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (2,465) (3,028) (2,743) (4,540)
Other comprehensive income (loss) before reclassification adjustments, pretax (294) (24) (125) 1,739
Tax 62 16 25 (385)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (232) (8) (100) 1,354
Reclassification adjustments, pretax 77 68 266 210
Tax (31) (22) (74) (42)
Reclassification adjustments, net of taxes 46 46 192 168
Other comprehensive income (loss), net of taxes (186) 38 92 1,522
Spin-off of Organon & Co.       28
Equity, ending balance (2,651) (2,990) (2,651) (2,990)
Foreign Currency Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (2,252) (1,574) (1,830) (1,828)
Other comprehensive income (loss) before reclassification adjustments, pretax (618) (96) (1,001) (167)
Tax 50 12 11 (84)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (568) (84) (990) (251)
Reclassification adjustments, pretax 0 0 0 0
Tax 0 0 0 0
Reclassification adjustments, net of taxes 0 0 0 0
Other comprehensive income (loss), net of taxes (568) (84) (990) (251)
Spin-off of Organon & Co.       421
Equity, ending balance (2,820) (1,658) (2,820) (1,658)
Accumulated Other Comprehensive Loss        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (4,327) (4,628) (4,429) (6,634)
Spin-off of Organon & Co.       449
Equity, ending balance $ (4,743) $ (4,590) $ (4,743) $ (4,590)
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting - Narrative (Details)
$ in Billions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2022
USD ($)
segment
Sep. 30, 2021
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     2  
Sales discounts | $ $ 3.3 $ 3.1 $ 9.1 $ 9.1
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting - Sales from Products (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183
Revenue related to the sale of the marketing rights     156 191
U.S.        
Segment Reporting Information [Line Items]        
Sales 7,322 6,276 20,927 16,166
Int’l        
Segment Reporting Information [Line Items]        
Sales 7,637 6,878 24,526 19,017
Operating Segments        
Segment Reporting Information [Line Items]        
Sales 14,334 12,913 44,146 35,021
Operating Segments | U.S.        
Segment Reporting Information [Line Items]        
Sales 7,095 6,137 20,544 15,974
Operating Segments | Int’l        
Segment Reporting Information [Line Items]        
Sales 7,239 6,777 23,601 19,047
Corporate, Non-Segment        
Segment Reporting Information [Line Items]        
Sales 625 241 1,307 162
Corporate, Non-Segment | U.S.        
Segment Reporting Information [Line Items]        
Sales 227 139 383 192
Corporate, Non-Segment | Int’l        
Segment Reporting Information [Line Items]        
Sales 398 101 925 (30)
Pharmaceutical | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 12,963 11,496 39,826 30,714
Pharmaceutical | Operating Segments | U.S.        
Segment Reporting Information [Line Items]        
Sales 6,620 5,670 19,119 14,611
Pharmaceutical | Operating Segments | Int’l        
Segment Reporting Information [Line Items]        
Sales 6,343 5,826 20,707 16,103
Pharmaceutical | Operating Segments | Keytruda        
Segment Reporting Information [Line Items]        
Sales 5,426 4,534 15,487 12,609
Pharmaceutical | Operating Segments | Keytruda | U.S.        
Segment Reporting Information [Line Items]        
Sales 3,331 2,580 9,307 7,108
Pharmaceutical | Operating Segments | Keytruda | Int’l        
Segment Reporting Information [Line Items]        
Sales 2,095 1,954 6,180 5,501
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza        
Segment Reporting Information [Line Items]        
Sales 284 246 825 721
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S.        
Segment Reporting Information [Line Items]        
Sales 144 129 427 371
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l        
Segment Reporting Information [Line Items]        
Sales 140 117 397 350
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima        
Segment Reporting Information [Line Items]        
Sales 202 188 660 498
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S.        
Segment Reporting Information [Line Items]        
Sales 142 114 426 287
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l        
Segment Reporting Information [Line Items]        
Sales 60 74 235 211
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl        
Segment Reporting Information [Line Items]        
Sales 39 0 124 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S.        
Segment Reporting Information [Line Items]        
Sales 32 0 87 0
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l        
Segment Reporting Information [Line Items]        
Sales 7 0 37 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9        
Segment Reporting Information [Line Items]        
Sales 2,294 1,993 5,428 4,144
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S.        
Segment Reporting Information [Line Items]        
Sales 957 839 1,803 1,605
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l        
Segment Reporting Information [Line Items]        
Sales 1,337 1,154 3,624 2,539
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax        
Segment Reporting Information [Line Items]        
Sales 668 661 1,716 1,626
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S.        
Segment Reporting Information [Line Items]        
Sales 532 537 1,337 1,255
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l        
Segment Reporting Information [Line Items]        
Sales 136 125 379 371
Pharmaceutical | Operating Segments | RotaTeq        
Segment Reporting Information [Line Items]        
Sales 256 227 644 593
Pharmaceutical | Operating Segments | RotaTeq | U.S.        
Segment Reporting Information [Line Items]        
Sales 154 135 427 364
Pharmaceutical | Operating Segments | RotaTeq | Int’l        
Segment Reporting Information [Line Items]        
Sales 102 92 218 229
Pharmaceutical | Operating Segments | Pneumovax 23        
Segment Reporting Information [Line Items]        
Sales 131 277 457 600
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S.        
Segment Reporting Information [Line Items]        
Sales 68 181 280 354
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l        
Segment Reporting Information [Line Items]        
Sales 63 97 177 247
Pharmaceutical | Operating Segments | Vaqta        
Segment Reporting Information [Line Items]        
Sales 64 48 134 138
Pharmaceutical | Operating Segments | Vaqta | U.S.        
Segment Reporting Information [Line Items]        
Sales 27 32 72 80
Pharmaceutical | Operating Segments | Vaqta | Int’l        
Segment Reporting Information [Line Items]        
Sales 36 16 62 58
Pharmaceutical | Operating Segments | Bridion        
Segment Reporting Information [Line Items]        
Sales 423 369 1,244 1,096
Pharmaceutical | Operating Segments | Bridion | U.S.        
Segment Reporting Information [Line Items]        
Sales 233 181 665 545
Pharmaceutical | Operating Segments | Bridion | Int’l        
Segment Reporting Information [Line Items]        
Sales 190 188 579 551
Pharmaceutical | Operating Segments | Prevymis        
Segment Reporting Information [Line Items]        
Sales 114 96 310 270
Pharmaceutical | Operating Segments | Prevymis | U.S.        
Segment Reporting Information [Line Items]        
Sales 49 39 136 111
Pharmaceutical | Operating Segments | Prevymis | Int’l        
Segment Reporting Information [Line Items]        
Sales 64 57 174 159
Pharmaceutical | Operating Segments | Dificid        
Segment Reporting Information [Line Items]        
Sales 77 54 196 115
Pharmaceutical | Operating Segments | Dificid | U.S.        
Segment Reporting Information [Line Items]        
Sales 72 52 184 108
Pharmaceutical | Operating Segments | Dificid | Int’l        
Segment Reporting Information [Line Items]        
Sales 6 2 12 7
Pharmaceutical | Operating Segments | Primaxin        
Segment Reporting Information [Line Items]        
Sales 63 70 185 194
Pharmaceutical | Operating Segments | Primaxin | U.S.        
Segment Reporting Information [Line Items]        
Sales 0 0 1 0
Pharmaceutical | Operating Segments | Primaxin | Int’l        
Segment Reporting Information [Line Items]        
Sales 63 69 185 194
Pharmaceutical | Operating Segments | Noxafil        
Segment Reporting Information [Line Items]        
Sales 62 64 180 197
Pharmaceutical | Operating Segments | Noxafil | U.S.        
Segment Reporting Information [Line Items]        
Sales 13 19 39 48
Pharmaceutical | Operating Segments | Noxafil | Int’l        
Segment Reporting Information [Line Items]        
Sales 49 45 141 149
Pharmaceutical | Operating Segments | Invanz        
Segment Reporting Information [Line Items]        
Sales 50 53 148 157
Pharmaceutical | Operating Segments | Invanz | U.S.        
Segment Reporting Information [Line Items]        
Sales 2 (2) 4 (2)
Pharmaceutical | Operating Segments | Invanz | Int’l        
Segment Reporting Information [Line Items]        
Sales 48 55 144 159
Pharmaceutical | Operating Segments | Cancidas        
Segment Reporting Information [Line Items]        
Sales 43 56 138 168
Pharmaceutical | Operating Segments | Cancidas | U.S.        
Segment Reporting Information [Line Items]        
Sales 1 1 5 4
Pharmaceutical | Operating Segments | Cancidas | Int’l        
Segment Reporting Information [Line Items]        
Sales 42 56 133 164
Pharmaceutical | Operating Segments | Zerbaxa        
Segment Reporting Information [Line Items]        
Sales 43 (2) 120 (11)
Pharmaceutical | Operating Segments | Zerbaxa | U.S.        
Segment Reporting Information [Line Items]        
Sales 24 (1) 64 (5)
Pharmaceutical | Operating Segments | Zerbaxa | Int’l        
Segment Reporting Information [Line Items]        
Sales 19 (1) 55 (6)
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo        
Segment Reporting Information [Line Items]        
Sales 88 100 258 248
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S.        
Segment Reporting Information [Line Items]        
Sales 85 73 244 222
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l        
Segment Reporting Information [Line Items]        
Sales 3 27 14 26
Pharmaceutical | Operating Segments | Adempas        
Segment Reporting Information [Line Items]        
Sales 57 59 181 188
Pharmaceutical | Operating Segments | Adempas | U.S.        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Pharmaceutical | Operating Segments | Adempas | Int’l        
Segment Reporting Information [Line Items]        
Sales 57 59 181 188
Pharmaceutical | Operating Segments | Lagevrio        
Segment Reporting Information [Line Items]        
Sales 436 0 4,859 0
Pharmaceutical | Operating Segments | Lagevrio | U.S.        
Segment Reporting Information [Line Items]        
Sales 0 0 1,523 0
Pharmaceutical | Operating Segments | Lagevrio | Int’l        
Segment Reporting Information [Line Items]        
Sales 436 0 3,336 0
Pharmaceutical | Operating Segments | Isentress/Isentress HD        
Segment Reporting Information [Line Items]        
Sales 161 189 466 590
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S.        
Segment Reporting Information [Line Items]        
Sales 68 77 196 222
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l        
Segment Reporting Information [Line Items]        
Sales 93 112 270 368
Pharmaceutical | Operating Segments | Belsomra        
Segment Reporting Information [Line Items]        
Sales 62 81 199 238
Pharmaceutical | Operating Segments | Belsomra | U.S.        
Segment Reporting Information [Line Items]        
Sales 20 23 60 56
Pharmaceutical | Operating Segments | Belsomra | Int’l        
Segment Reporting Information [Line Items]        
Sales 42 58 139 183
Pharmaceutical | Operating Segments | Simponi        
Segment Reporting Information [Line Items]        
Sales 173 203 540 619
Pharmaceutical | Operating Segments | Simponi | U.S.        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Pharmaceutical | Operating Segments | Simponi | Int’l        
Segment Reporting Information [Line Items]        
Sales 173 203 540 619
Pharmaceutical | Operating Segments | Remicade        
Segment Reporting Information [Line Items]        
Sales 49 73 163 233
Pharmaceutical | Operating Segments | Remicade | U.S.        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Pharmaceutical | Operating Segments | Remicade | Int’l        
Segment Reporting Information [Line Items]        
Sales 49 73 163 233
Pharmaceutical | Operating Segments | Januvia        
Segment Reporting Information [Line Items]        
Sales 717 852 2,252 2,445
Pharmaceutical | Operating Segments | Januvia | U.S.        
Segment Reporting Information [Line Items]        
Sales 332 365 958 997
Pharmaceutical | Operating Segments | Januvia | Int’l        
Segment Reporting Information [Line Items]        
Sales 385 487 1,294 1,448
Pharmaceutical | Operating Segments | Janumet        
Segment Reporting Information [Line Items]        
Sales 417 487 1,347 1,449
Pharmaceutical | Operating Segments | Janumet | U.S.        
Segment Reporting Information [Line Items]        
Sales 90 86 258 244
Pharmaceutical | Operating Segments | Janumet | Int’l        
Segment Reporting Information [Line Items]        
Sales 327 401 1,089 1,205
Pharmaceutical | Operating Segments | Other pharmaceutical        
Segment Reporting Information [Line Items]        
Sales 564 518 1,565 1,589
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S.        
Segment Reporting Information [Line Items]        
Sales 244 210 616 637
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l        
Segment Reporting Information [Line Items]        
Sales 321 306 949 950
Animal Health | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 1,371 1,417 4,320 4,307
Animal Health | Operating Segments | U.S.        
Segment Reporting Information [Line Items]        
Sales 475 467 1,425 1,363
Animal Health | Operating Segments | Int’l        
Segment Reporting Information [Line Items]        
Sales 896 951 2,894 2,944
Animal Health | Operating Segments | Livestock        
Segment Reporting Information [Line Items]        
Sales 829 864 2,486 2,503
Animal Health | Operating Segments | Livestock | U.S.        
Segment Reporting Information [Line Items]        
Sales 186 190 521 508
Animal Health | Operating Segments | Livestock | Int’l        
Segment Reporting Information [Line Items]        
Sales 643 675 1,965 1,996
Animal Health | Operating Segments | Companion Animals        
Segment Reporting Information [Line Items]        
Sales 542 553 1,834 1,804
Animal Health | Operating Segments | Companion Animals | U.S.        
Segment Reporting Information [Line Items]        
Sales 289 277 904 855
Animal Health | Operating Segments | Companion Animals | Int’l        
Segment Reporting Information [Line Items]        
Sales $ 253 $ 276 $ 929 $ 948
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting - Consolidated Sales by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue from External Customer [Line Items]        
Sales $ 14,959 $ 13,154 $ 45,453 $ 35,183
United States        
Revenue from External Customer [Line Items]        
Sales 7,322 6,276 20,927 16,166
Europe, Middle East and Africa        
Revenue from External Customer [Line Items]        
Sales 3,286 3,342 11,228 9,912
China        
Revenue from External Customer [Line Items]        
Sales 1,442 1,307 3,957 3,004
Japan        
Revenue from External Customer [Line Items]        
Sales 673 638 2,776 1,929
Asia Pacific (other than China and Japan)        
Revenue from External Customer [Line Items]        
Sales 854 613 2,792 1,782
Latin America        
Revenue from External Customer [Line Items]        
Sales 684 599 1,933 1,631
Other        
Revenue from External Customer [Line Items]        
Sales $ 698 $ 379 $ 1,840 $ 759
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.22.2.2
Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Segment Reporting Information [Line Items]        
Profits $ 3,583 $ 5,266 $ 12,931 $ 9,970
Interest income 40 7 62 27
Interest expense (244) (196) (727) (597)
Amortization     (1,623) (1,231)
Depreciation     (1,394) (1,148)
Research and development (4,399) (2,445) (9,773) (9,177)
Restructuring costs (94) (107) (288) (487)
Operating Segments        
Segment Reporting Information [Line Items]        
Profits 10,105 9,111 29,935 24,079
Operating Segments | Pharmaceutical segment        
Segment Reporting Information [Line Items]        
Profits 9,590 8,606 28,263 22,450
Operating Segments | Animal Health segment        
Segment Reporting Information [Line Items]        
Profits 515 505 1,672 1,629
Corporate, Non-Segment        
Segment Reporting Information [Line Items]        
Profits 377 141 831 29
Segment Reconciling Items        
Segment Reporting Information [Line Items]        
Interest income 40 7 62 27
Interest expense (244) (196) (727) (597)
Amortization (460) (360) (1,623) (1,231)
Depreciation (448) (358) (1,257) (1,031)
Research and development (4,277) (2,312) (9,374) (8,775)
Restructuring costs (94) (107) (288) (487)
Other unallocated, net $ (1,416) $ (660) $ (4,628) $ (2,044)
XML 81 mrk-20220930_htm.xml IDEA: XBRL DOCUMENT 0000310158 2022-01-01 2022-09-30 0000310158 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0000310158 mrk:A0.500Notesdue2024Member 2022-01-01 2022-09-30 0000310158 mrk:A1.875Notesdue2026Member 2022-01-01 2022-09-30 0000310158 mrk:A2.500Notesdue2034Member 2022-01-01 2022-09-30 0000310158 mrk:A1.375Notesdue2036Member 2022-01-01 2022-09-30 0000310158 2022-10-31 0000310158 2022-07-01 2022-09-30 0000310158 2021-07-01 2021-09-30 0000310158 2021-01-01 2021-09-30 0000310158 2022-09-30 0000310158 2021-12-31 0000310158 2020-12-31 0000310158 2021-09-30 0000310158 mrk:OrganonCoMember 2021-06-02 0000310158 2021-06-02 0000310158 srt:MinimumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:TransitionServicesAgreementMember 2021-06-02 2021-06-02 0000310158 srt:MinimumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 srt:MaximumMember mrk:ManufacturingAndSupplyAgreementsMember 2021-06-02 2021-06-02 0000310158 mrk:OrganonCoMember 2022-07-01 2022-09-30 0000310158 mrk:OrganonCoMember 2022-01-01 2022-09-30 0000310158 mrk:OrganonCoMember 2022-09-30 0000310158 mrk:OrganonCoMember 2021-12-31 0000310158 mrk:OrganonCoMember 2021-06-02 2021-06-02 0000310158 mrk:OrganonCoMember 2021-07-01 2021-09-30 0000310158 mrk:OrganonCoMember 2021-01-01 2021-09-30 0000310158 us-gaap:SubsequentEventMember 2022-10-01 2022-10-31 0000310158 mrk:OrnaTherapeuticsMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 mrk:OrnaTherapeuticsMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-08-01 2022-08-31 0000310158 us-gaap:SubsequentEventMember mrk:OrnaTherapeuticsMember 2022-10-01 2022-12-31 0000310158 mrk:OrionCorporationMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-07-01 2022-07-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:FirstCommercialSaleMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-05-01 2022-05-31 0000310158 mrk:PandionTherapeuticsMember 2021-04-01 2021-04-30 0000310158 mrk:PandionTherapeuticsMember 2021-04-30 0000310158 mrk:PandionTherapeuticsMember 2021-01-01 2021-09-30 0000310158 mrk:ArtivaBiotherapeuticsIncMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:DevelopmentMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:ArtivaBiotherapeuticsIncMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-01-31 0000310158 mrk:COVID19Member 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-03-31 0000310158 mrk:LynparzaMember 2022-01-01 2022-03-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-09-30 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:EisaiMember 2021-03-01 2021-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:EisaiMember mrk:LenvimaMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-09-30 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2022-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember 2022-01-01 2022-01-31 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2022-09-30 0000310158 mrk:VerquvoMember us-gaap:OtherIntangibleAssetsMember 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember mrk:AdempasMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember mrk:VerquvoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:BayerAGMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember mrk:LagevrioMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-07-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2021-01-01 2021-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2022-09-30 0000310158 mrk:RidgebackBiotherapeuticsLPMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2021-12-31 0000310158 mrk:BristolMyersSquibbMember srt:MinimumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0000310158 mrk:BristolMyersSquibbMember srt:MaximumMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0000310158 mrk:BristolMyersSquibbMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0000310158 mrk:BristolMyersSquibbMember mrk:SalesBasedMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 mrk:BristolMyersSquibbMember mrk:RegulatoryMilestonesMember us-gaap:LicensingAgreementsMember 2022-01-01 2022-09-30 0000310158 srt:ScenarioForecastMember 2022-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2022-07-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2022-07-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2022-07-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember 2022-07-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember 2022-01-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2022-07-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2022-07-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2022-07-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2022-07-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2022-07-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2022-07-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2022-01-01 2022-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2022-07-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2022-07-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2022-07-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember 2022-07-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2022-01-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2022-01-01 2022-09-30 0000310158 us-gaap:RestructuringChargesMember 2022-01-01 2022-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-07-01 2022-09-30 0000310158 mrk:AcceleratedDepreciationMember 2022-07-01 2022-09-30 0000310158 us-gaap:OtherRestructuringMember 2022-07-01 2022-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-01-01 2022-09-30 0000310158 mrk:AcceleratedDepreciationMember 2022-01-01 2022-09-30 0000310158 us-gaap:OtherRestructuringMember 2022-01-01 2022-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2021-07-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2021-07-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2021-07-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember 2021-07-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-09-30 0000310158 us-gaap:CostOfSalesMember 2021-01-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2021-07-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2021-07-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2021-07-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-07-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2021-07-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2021-07-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2021-07-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2021-07-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2021-01-01 2021-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2021-07-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2021-07-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2021-07-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember 2021-07-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2021-01-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2021-01-01 2021-09-30 0000310158 us-gaap:RestructuringChargesMember 2021-01-01 2021-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2021-07-01 2021-09-30 0000310158 mrk:AcceleratedDepreciationMember 2021-07-01 2021-09-30 0000310158 us-gaap:OtherRestructuringMember 2021-07-01 2021-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2021-01-01 2021-09-30 0000310158 mrk:AcceleratedDepreciationMember 2021-01-01 2021-09-30 0000310158 us-gaap:OtherRestructuringMember 2021-01-01 2021-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2021-12-31 0000310158 mrk:AcceleratedDepreciationMember 2021-12-31 0000310158 us-gaap:OtherRestructuringMember 2021-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2022-09-30 0000310158 mrk:AcceleratedDepreciationMember 2022-09-30 0000310158 us-gaap:OtherRestructuringMember 2022-09-30 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-01-01 2022-09-30 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2022-07-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2021-07-01 2021-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2021-01-01 2021-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0000310158 mrk:EurodominatedNotesMember 2022-07-01 2022-09-30 0000310158 mrk:EurodominatedNotesMember 2021-07-01 2021-09-30 0000310158 mrk:EurodominatedNotesMember 2022-01-01 2022-09-30 0000310158 mrk:EurodominatedNotesMember 2021-01-01 2021-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0000310158 us-gaap:InterestRateSwapMember 2022-02-28 0000310158 us-gaap:InterestRateSwapMember mrk:A2.35NotesDue2022Member 2022-02-28 0000310158 mrk:A2.35NotesDue2022Member 2022-02-28 0000310158 us-gaap:InterestRateSwapMember 2022-09-30 0000310158 us-gaap:InterestRateSwapMember mrk:A2.40NotesDue2022Member 2022-09-30 0000310158 mrk:A2.40NotesDue2022Member 2022-09-30 0000310158 mrk:A2.40NotesDue2022Member 2022-09-30 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2022-09-30 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2022-09-30 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-09-30 0000310158 mrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2022-09-30 0000310158 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:NondesignatedMember 2022-09-30 0000310158 us-gaap:NondesignatedMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-07-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-07-01 2021-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2021-01-01 2021-09-30 0000310158 us-gaap:InterestRateSwapMember 2022-07-01 2022-09-30 0000310158 us-gaap:InterestRateSwapMember 2021-07-01 2021-09-30 0000310158 us-gaap:InterestRateSwapMember 2022-01-01 2022-09-30 0000310158 us-gaap:InterestRateSwapMember 2021-01-01 2021-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-07-01 2022-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-07-01 2021-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2022-01-01 2022-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2021-01-01 2021-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2022-07-01 2022-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2021-07-01 2021-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2021-01-01 2021-09-30 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:CommercialPaperMember 2022-09-30 0000310158 us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:EquityFundsMember 2022-07-01 2022-09-30 0000310158 us-gaap:EquityFundsMember 2021-07-01 2021-09-30 0000310158 us-gaap:EquityFundsMember 2022-01-01 2022-09-30 0000310158 us-gaap:EquityFundsMember 2021-01-01 2021-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2022-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2022-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0000310158 us-gaap:FairValueInputsLevel2Member 2022-09-30 0000310158 us-gaap:FairValueInputsLevel2Member 2021-12-31 0000310158 mrk:SanofiPasteurMember 2022-09-30 0000310158 2021-01-01 2021-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2022-09-30 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2021-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2022-09-30 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2021-12-31 0000310158 us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-07-01 2022-09-30 0000310158 mrk:NemtabrutinibMember us-gaap:InProcessResearchAndDevelopmentMember 2022-09-30 0000310158 mrk:FosamaxMember 2022-09-30 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2014-03-01 2014-03-31 0000310158 mrk:JanuviaMember mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember 2022-09-30 0000310158 mrk:GardasilGardasil9Member country:US 2022-09-30 0000310158 mrk:GardasilGardasil9Member us-gaap:NonUsMember 2022-09-30 0000310158 mrk:GardasilGardasil9Member country:CO 2022-09-30 0000310158 mrk:ZetiaantitrustlitigationMember 2020-08-31 0000310158 mrk:ZetiaantitrustlitigationMember us-gaap:PendingLitigationMember 2022-06-30 2022-06-30 0000310158 us-gaap:PatentsMember mrk:BridionMember srt:ScenarioForecastMember us-gaap:PendingLitigationMember 2022-12-19 2022-12-19 0000310158 us-gaap:PatentsMember mrk:BridionMember 2022-01-01 2022-09-30 0000310158 us-gaap:PatentsMember mrk:BridionMember us-gaap:PendingLitigationMember 2022-09-30 0000310158 us-gaap:PatentsMember mrk:JanuviaAndJanumetMember 2022-01-01 2022-09-30 0000310158 mrk:PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember srt:ScenarioForecastMember us-gaap:PendingLitigationMember 2023-01-09 2023-01-09 0000310158 mrk:LegalDefenseCostsMember 2022-09-30 0000310158 mrk:LegalDefenseCostsMember 2021-12-31 0000310158 us-gaap:CommonStockMember 2021-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000310158 us-gaap:RetainedEarningsMember 2021-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000310158 us-gaap:TreasuryStockCommonMember 2021-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2021-06-30 0000310158 2021-06-30 0000310158 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2021-07-01 2021-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000310158 us-gaap:CommonStockMember 2021-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000310158 us-gaap:RetainedEarningsMember 2021-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2021-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2021-09-30 0000310158 us-gaap:CommonStockMember 2022-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000310158 us-gaap:RetainedEarningsMember 2022-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000310158 us-gaap:TreasuryStockCommonMember 2022-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2022-06-30 0000310158 2022-06-30 0000310158 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2022-07-01 2022-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0000310158 us-gaap:CommonStockMember 2022-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000310158 us-gaap:RetainedEarningsMember 2022-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2022-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2022-09-30 0000310158 us-gaap:CommonStockMember 2020-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000310158 us-gaap:RetainedEarningsMember 2020-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2020-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2020-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-01-01 2021-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2021-01-01 2021-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-09-30 0000310158 us-gaap:CommonStockMember 2021-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2021-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000310158 us-gaap:TreasuryStockCommonMember 2021-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2021-12-31 0000310158 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0000310158 us-gaap:TreasuryStockCommonMember 2022-01-01 2022-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-01-01 2022-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2022-07-01 2022-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-01-01 2021-09-30 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-09-30 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-01-01 2021-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentContinuingOperationsMember 2021-01-01 2021-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-03-31 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2021-01-01 2021-09-30 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:SegmentDiscontinuedOperationsMember 2021-01-01 2021-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-07-01 2021-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-07-01 2022-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-01-01 2021-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2021-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-01-01 2022-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueReblozylMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:DificidMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasVerquvoMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LagevrioMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember 2022-07-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember 2021-07-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember 2022-01-01 2022-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2021-01-01 2021-09-30 0000310158 us-gaap:OperatingSegmentsMember 2021-01-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2022-07-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2022-07-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2022-07-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2021-07-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2021-07-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2022-01-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2022-01-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2021-01-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2021-01-01 2021-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2021-01-01 2021-09-30 0000310158 country:US 2022-07-01 2022-09-30 0000310158 mrk:InternationalMember 2022-07-01 2022-09-30 0000310158 country:US 2021-07-01 2021-09-30 0000310158 mrk:InternationalMember 2021-07-01 2021-09-30 0000310158 country:US 2022-01-01 2022-09-30 0000310158 mrk:InternationalMember 2022-01-01 2022-09-30 0000310158 country:US 2021-01-01 2021-09-30 0000310158 mrk:InternationalMember 2021-01-01 2021-09-30 0000310158 us-gaap:EMEAMember 2022-07-01 2022-09-30 0000310158 us-gaap:EMEAMember 2021-07-01 2021-09-30 0000310158 us-gaap:EMEAMember 2022-01-01 2022-09-30 0000310158 us-gaap:EMEAMember 2021-01-01 2021-09-30 0000310158 country:CN 2022-07-01 2022-09-30 0000310158 country:CN 2021-07-01 2021-09-30 0000310158 country:CN 2022-01-01 2022-09-30 0000310158 country:CN 2021-01-01 2021-09-30 0000310158 country:JP 2022-07-01 2022-09-30 0000310158 country:JP 2021-07-01 2021-09-30 0000310158 country:JP 2022-01-01 2022-09-30 0000310158 country:JP 2021-01-01 2021-09-30 0000310158 srt:AsiaPacificMember 2022-07-01 2022-09-30 0000310158 srt:AsiaPacificMember 2021-07-01 2021-09-30 0000310158 srt:AsiaPacificMember 2022-01-01 2022-09-30 0000310158 srt:AsiaPacificMember 2021-01-01 2021-09-30 0000310158 srt:LatinAmericaMember 2022-07-01 2022-09-30 0000310158 srt:LatinAmericaMember 2021-07-01 2021-09-30 0000310158 srt:LatinAmericaMember 2022-01-01 2022-09-30 0000310158 srt:LatinAmericaMember 2021-01-01 2021-09-30 0000310158 mrk:OtherCountriesMember 2022-07-01 2022-09-30 0000310158 mrk:OtherCountriesMember 2021-07-01 2021-09-30 0000310158 mrk:OtherCountriesMember 2022-01-01 2022-09-30 0000310158 mrk:OtherCountriesMember 2021-01-01 2021-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2022-07-01 2022-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2021-07-01 2021-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2022-01-01 2022-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2021-01-01 2021-09-30 shares iso4217:USD iso4217:USD shares pure mrk:research_program mrk:collaboration_target mrk:market mrk:course mrk:interest_rate_swap mrk:case mrk:claim mrk:segment false 2022 Q3 0000310158 --12-31 0.1 0 0 0 0 http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense P1D 10-Q true 2022-09-30 false 1-6571 Merck & Co., Inc. NJ 22-1918501 126 East Lincoln Avenue Rahway NJ 07065 (908) 740-4000 Common Stock ($0.50 par value) MRK NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE Yes Yes Large Accelerated Filer false false false 2535395974 14959000000 13154000000 45453000000 35183000000 3934000000 3450000000 13530000000 9752000000 2520000000 2336000000 7355000000 6804000000 4399000000 2445000000 9773000000 9177000000 94000000 107000000 288000000 487000000 -429000000 450000000 -1576000000 1007000000 11376000000 7888000000 32522000000 25213000000 3583000000 5266000000 12931000000 9970000000 330000000 695000000 1423000000 1436000000 3253000000 4571000000 11508000000 8534000000 5000000 4000000 6000000 9000000 3248000000 4567000000 11502000000 8525000000 0 0 0 766000000 3248000000 4567000000 11502000000 9291000000 1.28 1.81 4.55 3.37 0 0 0 0.30 1.28 1.81 4.55 3.67 1.28 1.80 4.53 3.36 0 0 0 0.30 1.28 1.80 4.53 3.66 3248000000 4567000000 11502000000 9291000000 338000000 84000000 584000000 324000000 186000000 -38000000 -92000000 -1522000000 -568000000 -84000000 -990000000 -251000000 -416000000 38000000 -314000000 1595000000 2832000000 4605000000 11188000000 10886000000 11145000000 8096000000 103000000 0 77000000 62000000 9482000000 9230000000 2641000000 2194000000 5614000000 5953000000 7217000000 6987000000 33561000000 30266000000 984000000 370000000 17921000000 18192000000 20424000000 19279000000 21160000000 21264000000 21368000000 22933000000 9584000000 11582000000 107081000000 105694000000 1936000000 2412000000 3371000000 4609000000 14222000000 13859000000 1698000000 1224000000 1771000000 1768000000 22998000000 23872000000 28482000000 30690000000 2417000000 3441000000 8660000000 9434000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 44243000000 44238000000 59928000000 53696000000 -4743000000 -4429000000 101216000000 95293000000 1043697097 1049499023 56758000000 57109000000 44458000000 38184000000 66000000 73000000 44524000000 38257000000 107081000000 105694000000 11508000000 8534000000 1623000000 1231000000 1394000000 1148000000 910000000 0 -1361000000 1535000000 0 1556000000 -1261000000 28000000 396000000 360000000 -1169000000 -499000000 2435000000 3794000000 14665000000 8027000000 3239000000 3240000000 710000000 1000000 709000000 497000000 0 1554000000 121000000 89000000 -149000000 -15000000 -3212000000 -4372000000 0 -3983000000 2250000000 1153000000 0 9000000000 0 822000000 5262000000 4967000000 119000000 68000000 -172000000 -253000000 -7565000000 -2110000000 0 1051000000 0 -134000000 0 -504000000 0 413000000 -776000000 -65000000 3112000000 1893000000 71000000 103000000 8167000000 8153000000 134000000 30000000 11279000000 10046000000 Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements. Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022. The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</span></div>In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements. Spin-Off of Organon &amp; Co. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100 million and $293 million and related cost of sales of $104 million and $312 million for the three and nine months ended September 30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September 30, 2022 and September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $567 million and $964 million at September 30, 2022 and December 31, 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $333 million and $400 million at September 30, 2022 and December 31, 2021, respectively, and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off, as well as interest expense related to the debt issuance in 2021, have been reflected as discontinued operations in the Company’s condensed consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $556 million for the nine months ended September 30, 2021 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div> 9500000000 9000000000 P25M P31M P4Y P10Y 100000000 293000000 104000000 312000000 567000000 964000000 333000000 400000000 556000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.642%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,755 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">769 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Reflects amounts through the June 2, 2021 spin-off date.</span></div> 2512000000 789000000 877000000 103000000 1000000 15000000 1755000000 757000000 -12000000 769000000 3000000 766000000 Acquisitions, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Merck and Royalty Pharma plc (Royalty Pharma) entered into a funding arrangement under which Royalty Pharma paid Merck $50 million to co-fund Merck’s development costs for a Phase 2b trial of MK-8189, an investigational oral Phosphodiesterase 10A (PDE10A) inhibitor, which is being evaluated for the treatment of schizophrenia. Under the agreement, Royalty Pharma has no rights to MK-8189 and has no decision-making authority over the program. If Merck elects to advance MK-8189 into a Phase 3 study, Royalty Pharma has the option to provide additional funding of 50% of the development costs up to $375 million for the Phase 3 trial. If such additional funding is provided, Royalty Pharma becomes eligible to receive future regulatory milestone payments contingent upon certain marketing approvals, as well as royalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, Merck exercised its option to jointly develop and commercialize personalized cancer vaccine mRNA-4157/V940 pursuant to the terms of an existing collaboration and license agreement with Moderna, Inc. (Moderna), which resulted in a $250 million charge in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. The payment to Moderna was made in the fourth quarter of 2022. mRNA-4157/V940 is currently being evaluated in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with high-risk melanoma in a Phase 2 clinical trial being conducted by Moderna. Under the 2016 agreement, as amended in 2018, Merck and Moderna will collaborate on development and commercialization and will share costs and any profits equally under this worldwide collaboration. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Merck and Orna Therapeutics (Orna), a biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, entered into a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Under the terms of the agreement, Merck made an upfront payment to Orna of $150 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. In addition, Orna is eligible to receive future contingent development-related payments aggregating up to $440 million, $675 million in regulatory milestones, and $2.4 billion in sales milestones associated with the progress of the multiple vaccine and therapeutic programs, as well as royalties </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ranging from a high-single-digit rate to a low-double-digit rate on any approved products derived from the collaboration. Merck also invested $100 million in Orna’s Series B preferred shares in the fourth quarter of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Merck and Orion Corporation (Orion) announced a global co-development and co-commercialization agreement for Orion’s investigational candidate ODM-208 (MK-5684) and other drugs targeting cytochrome P450 11A1 (CYP11A1), an enzyme important in steroid production. ODM-208 is an oral, non-steroidal inhibitor of CYP11A1 currently being evaluated in a Phase 2 clinical trial for the treatment of patients with metastatic castration-resistant prostate cancer. Merck made an upfront payment to Orion of $290 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Orion is responsible for the manufacture of clinical and commercial supply of ODM-208. In addition, the contract provides both parties with an option to convert the initial co-development and co-commercialization agreement into a global exclusive license to Merck. If the option is exercised, Merck would assume full responsibility for all past development and commercialization expenses associated with the program since inception of the agreement, as well as all future development and commercialization expenses. In addition, Orion would be eligible to receive milestone payments associated with progress in the development and commercialization of ODM-208 as well as tiered double-digit royalties on sales if the product is approved. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in July 2022, Merck and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) closed a license and collaboration agreement in which Merck gained exclusive worldwide rights for the development, manufacture and commercialization of an investigational antibody drug conjugate (ADC) (MK-1200) for the treatment of solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on the early clinical development of the investigational ADC. Merck made an upfront payment of $35 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2022. Kelun-Biotech is also eligible to receive future contingent milestone payments aggregating up to $82 million in developmental milestones, $334 million in regulatory milestones, and $485 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, in connection with an existing arrangement, Merck exercised its option to obtain an exclusive license outside of China for the development, manufacture and commercialization of Kelun-Biotech’s trophoblast antigen 2 (TROP2)-targeting ADC programs, including its lead compound, SKB-264 (MK-2870). SKB-264 is currently being evaluated in Phase 2 trials for non-small-cell lung cancer and advanced solid tumors. Under the terms of the agreement, Merck and Kelun-Biotech will collaborate on certain early clinical development plans, including evaluating the potential of SKB-264 as a monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for advanced solid tumors. Upon option exercise, Merck made a payment of $30 million, which was recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2022, and agreed to make additional payments of $30 million upon completion of specified project activities and $25 million upon technology transfer. Merck also agreed to make quarterly payments in 2022 and 2023 aggregating up to $101 million to fund Kelun-Biotech’s ongoing research and development activities. In addition, Kelun-Biotech is eligible to receive future contingent milestone payments (which includes all program compounds) aggregating up to $90 million in developmental milestones, $290 million in first commercial sale milestones, and $780 million in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from a mid-single-digit rate to a low-double-digit rate on future net sales.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Transactions</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck acquired Pandion Therapeutics, Inc. (Pandion), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion is advancing a pipeline of precision immune modulators targeting critical immune control nodes. Total consideration paid of $1.9 billion included $147 million of costs primarily comprised of share-based compensation payments to settle equity awards. The transaction was accounted for as an acquisition of an asset. Merck recorded net assets of $156 million (primarily cash) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $1.7 billion in the first nine months of 2021 related to the transaction. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $30 million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $15 million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to $217.5 million in developmental milestones, $570 million in regulatory milestones, and $1.05 billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from 7% to 14% on future sales.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Merck’s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $207 million in the first nine months of 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span> 50000000 0.50 375000000 250000000 250000000 150000000 440000000 675000000 2400000000 100000000 290000000 35000000 82000000 334000000 485000000 30000000 30000000 25000000 101000000 90000000 290000000 780000000 1900000000 147000000 156000000 1700000000 3 30000000 15000000 3 217500000 570000000 1050000000.00 0.07 0.14 207000000 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $600 million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $600 million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $250 million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In the first nine months of 2022, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $400 million. As of September 30, 2022, sales-based milestone payments accrued but not yet paid totaled $600 million. Potential future sales-based milestone payments of $2.1 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lynparza received regulatory approvals triggering capitalized milestone payments of $250 million from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.2 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.5 billion at September 30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $125 million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first nine months of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $600 million. Potential future sales-based milestone payments of $2.6 billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first nine months of 2022, Lenvima received regulatory approvals triggering capitalized milestone payments of $50 million from Merck to Eisai. There are no regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $867 million at September 30, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $400 million sales-based milestone payment under this collaboration to Bayer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $597 million and $53 million, respectively, at September 30, 2022 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit sharing calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than 40 markets. As of September 30, 2022, the Company has 0.8 million remaining courses to be supplied under these agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron Pharma Inc. that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a 20% sales royalty from BMS which could increase to a maximum of 24% based on sales levels. This royalty will be reduced by 50% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $80 million. Merck recorded alliance revenue of $39 million (consisting of royalties) within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the third quarter of 2022 related to this collaboration. Merck recorded alliance revenue of $124 million in the first nine months of 2022, which includes royalties of $104 million, as well as the receipt of a regulatory approval milestone payment of $20 million.</span></div> 600000000 600000000 250000000 400000000 600000000 2100000000 250000000 1200000000 1500000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:63.364%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.535%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first nine months of 2022 includes $250 million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount as of December 31, 2021 includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first nine months of 2021 includes $153 million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div> 284000000 246000000 825000000 721000000 10000000 6000000 43000000 20000000 294000000 252000000 868000000 741000000 64000000 42000000 425000000 125000000 45000000 44000000 135000000 127000000 28000000 27000000 79000000 87000000 290000000 271000000 12000000 415000000 600000000 0 250000000 125000000 600000000 2600000000 50000000 867000000 202000000 188000000 660000000 498000000 53000000 49000000 159000000 143000000 42000000 34000000 115000000 88000000 24000000 43000000 128000000 165000000 202000000 200000000 1000000 625000000 400000000 597000000 53000000 88000000 100000000 258000000 248000000 57000000 59000000 181000000 188000000 6000000 2000000 15000000 3000000 151000000 161000000 454000000 439000000 55000000 53000000 158000000 328000000 42000000 31000000 107000000 84000000 18000000 16000000 52000000 36000000 144000000 114000000 75000000 472000000 153000000 40 800000 436000000 0 4859000000 0 234000000 4000000 2580000000 56000000 41000000 6000000 105000000 13000000 8000000 58000000 29000000 167000000 193000000 283000000 0.20 0.24 0.50 80000000 39000000 124000000 104000000 20000000 Restructuring<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. The Company estimates that approximately 70% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 30% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $175 million and $168 million in the third quarter of 2022 and 2021, respectively, and $559 million and $630 million for the first nine months of 2022 and 2021, respectively, related to </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">restructuring program activities. Since inception of the Restructuring Program through September 30, 2022, Merck has recorded total pretax accumulated costs of approximately $3.2 billion. For the full year of 2022, the Company expects to record charges of approximately $600 million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the program. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 11) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023. 3500000000 0.70 0.30 175000000 168000000 559000000 630000000 3200000000 600000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">630 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 16000000 38000000 54000000 0 51000000 116000000 167000000 0 5000000 21000000 26000000 0 17000000 57000000 74000000 0 0 1000000 1000000 0 29000000 1000000 30000000 65000000 0 29000000 94000000 197000000 0 91000000 288000000 65000000 21000000 89000000 175000000 197000000 97000000 265000000 559000000 0 11000000 37000000 48000000 0 32000000 81000000 113000000 0 4000000 1000000 5000000 0 8000000 1000000 9000000 0 7000000 1000000 8000000 0 20000000 1000000 21000000 17000000 0 90000000 107000000 310000000 0 177000000 487000000 17000000 22000000 129000000 168000000 310000000 60000000 260000000 630000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">596 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(761)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023. 596000000 0 41000000 637000000 197000000 97000000 265000000 559000000 303000000 0 458000000 761000000 0 -97000000 183000000 86000000 490000000 0 31000000 521000000 Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, five interest rate swap contracts with a total notional amount of $1.25 billion matured. These swaps effectively converted the Company’s $1.25 billion, 2.35% fixed-rate notes due 2022 to variable rate debt. In September 2022, four interest rate swap contracts with a total notional amount of $1.0 billion matured. These swaps effectively converted the Company’s $1.0 billion, 2.40% fixed rate notes due 2022 to variable rate debt. The interest rate swap contracts were designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate were recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company is not currently a party to any interest rate swaps.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">Other current assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,523 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,026 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,958 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.362%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022, the Company estimates $864 million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $221 million and $415 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022. Unrealized net (gains) losses of $(90) million and $109 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2021, respectively, on equity securities still held at September 30, 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and September 30, 2021, the Company also had $705 million and $578 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $21 million and unrealized net losses of $12 million related to certain of these equity investments still held at September 30, 2022. During the first nine months</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $104 million and unrealized losses of $1 million related to certain of these investments still held at September 30, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at September 30, 2022 were $255 million and $19 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2022 and September 30, 2021, the Company also had $655 million and $1.2 billion, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $141 million and $(391) million for the third quarter of 2022 and 2021, respectively, and were $952 million and $(893) million for the first nine months of 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $10.0 billion and $6.8 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">At September 30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments of contingent consideration in 2022 relate to the Sanofi Pasteur MSD liabilities described above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2022, was $25.9 billion compared with a carrying value of $30.4 billion and at December 31, 2021, was $35.7 billion compared with a carrying value of $33.1 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals and government agencies. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.3 billion and $2.8 billion of accounts receivable as of September 30, 2022 and December 31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of September 30, 2022 and December 31, 2021, the Company had collected $55 million and $62 million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in October 2022 and January 2022, respectively. The net cash flows related to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $794 million and $164 million at September 30, 2022 and December 31, 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span>. P2Y P1Y <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.366%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(431)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div> 1000000 -1000000 47000000 27000000 0 4000000 2000000 12000000 250000000 77000000 431000000 199000000 0 0 0 0 5 1250000000 1250000000 0.0235 4 1000000000 1000000000 0.0240 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded in the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.040%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,263 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 2263000000 0 13000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.241%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4beacbd1-84ea-489f-8ac6-b09392c17877"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNC0xLTEtMS0xMDUwNTY_4c50954f-2f04-4bb2-9e7e-854b1813a13f">Other current assets</span></span></span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_2a5d2377-4bbd-47ad-9925-404ca9a51736"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNS0xLTEtMS05NDQxNA_c6df00f3-bff8-4562-abe7-498764d34146">Other current assets</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_6baf831a-4ac8-4464-8eb1-254345d36853"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNi0xLTEtMS05NDQxNA_95f68aac-d3b4-4319-9f3d-70e85b1424c4">Other Assets</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,408 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_6a9babb4-e747-4df0-a56c-3595290d8927"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfNy0xLTEtMS05NDQxNA_ae73e90d-8b40-4bfe-b1e5-b0c0132d4407">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_3d168174-838c-4aa7-834d-0305c0dea6db"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfOC0xLTEtMS05NDQxNA_8a78e2f6-5d79-40d5-8cfd-da850ad40e02">Other Noncurrent Liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">328 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_0942da13-4366-4941-8d73-f86fd1003d65"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTEtMS0xLTEtMTA1MTE3_ed1a83b6-f315-4484-ba3e-ac3634db5ded">Other current assets</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,523 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,073 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_35d04908-60bc-47a5-b559-4d800d70da91"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOjdhNWE4ZDUwODVkZjQyZjQ4ZGJjZGNhNDBjYTA3NWFhL3RhYmxlcmFuZ2U6N2E1YThkNTA4NWRmNDJmNDhkYmNkY2E0MGNhMDc1YWFfMTItMS0xLTEtMTA1MTE5_f4049782-8c11-4ab1-9f60-0268bac9cd63">Accrued and other current liabilities</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,715 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17,238 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,713 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,026 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,958 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 0 14000000 2250000000 826000000 7250000000 271000000 6778000000 85000000 1408000000 43000000 1551000000 1000000 37000000 24000000 1623000000 1000000 93000000 1000000 43000000 911000000 2000000 8788000000 328000000 25000000 12245000000 597000000 9523000000 221000000 10073000000 240000000 7715000000 96000000 10640000000 597000000 240000000 17238000000 221000000 96000000 20713000000 1508000000 242000000 26026000000 549000000 121000000 32958000000 The following table provides information on the Company’s derivative positions subject to these master <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">497 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1508000000 242000000 549000000 121000000 217000000 217000000 110000000 110000000 794000000 0 164000000 0 497000000 25000000 275000000 11000000 <div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.636%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.907%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">491 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(491)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_415ec0c9-4bba-4fb9-aa01-b4c7b84244a9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_a2ea2169-dd57-478e-b872-7cc7be5bf76a"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_c6f59e51-c8a0-4c45-930c-4ef2ed96eb20"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF80OS9mcmFnOmRiNzAzMDQwOThhNDQ0OTc5N2E5MjBhMzY2Nzg3ZjkxL3RhYmxlOmNlYTUyMGEzMTIwYjQ2NWU4OTA2NWE3NDQ2ODg1M2Q5L3RhYmxlcmFuZ2U6Y2VhNTIwYTMxMjBiNDY1ZTg5MDY1YTc0NDY4ODUzZDlfMTMtMC0xLTEtOTQ0MTQ_ff915512-cf0d-456d-a25d-7aab715fc26c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></span></span></span></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 14959000000 13154000000 -429000000 450000000 -416000000 38000000 45453000000 35183000000 -1576000000 1007000000 -314000000 1595000000 -1000000 9000000 13000000 29000000 0 1000000 -4000000 1000000 682000000 72000000 1233000000 193000000 253000000 -36000000 -253000000 36000000 491000000 -219000000 -491000000 219000000 -1000000 0 -2000000 -2000000 -1000000 0 -2000000 -2000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.362%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. Amount in the first nine months of 2021 includes a loss on forward exchange contracts entered into in conjunction with the spin-off of Organon.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div> 41000000 -18000000 77000000 -234000000 4000000 4000000 42000000 -6000000 864000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.063%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.502%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,647 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,410 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,733 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $221 million and $415 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2022, respectively, on equity securities still held at September 30, 2022. Unrealized net (gains) losses of $(90) million and $109 million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> in the third quarter and first nine months of 2021, respectively, on equity securities still held at September 30, 2021.</span></div> 67000000 0 0 67000000 80000000 0 0 80000000 4000000 0 0 4000000 0 0 0 0 3000000 0 0 3000000 4000000 0 0 4000000 2000000 0 0 2000000 2000000 0 0 2000000 76000000 0 0 76000000 86000000 0 0 86000000 1334000000 1647000000 1410000000 1733000000 -221000000 -415000000 90000000 -109000000 705000000 578000000 21000000 12000000 104000000 1000000 255000000 19000000 655000000 1200000000 -141000000 391000000 -952000000 893000000 <div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,081 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,087 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">370 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,508 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,514 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,918 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,731 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,282 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">741 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 4000000 0 4000000 0 0 0 0 0 2000000 0 2000000 0 2000000 0 2000000 1081000000 0 0 1081000000 368000000 0 0 368000000 1081000000 6000000 0 1087000000 368000000 2000000 0 370000000 67000000 0 0 67000000 80000000 0 0 80000000 3000000 0 0 3000000 4000000 0 0 4000000 253000000 0 0 253000000 1279000000 0 0 1279000000 323000000 0 0 323000000 1363000000 0 0 1363000000 0 945000000 0 945000000 0 351000000 0 351000000 0 563000000 0 563000000 0 184000000 0 184000000 0 0 0 0 0 14000000 0 14000000 0 1508000000 0 1508000000 0 549000000 0 549000000 1404000000 1514000000 0 2918000000 1731000000 551000000 0 2282000000 0 0 499000000 499000000 0 0 777000000 777000000 0 242000000 0 242000000 0 120000000 0 120000000 0 0 0 0 0 1000000 0 1000000 0 242000000 0 242000000 0 121000000 0 121000000 0 242000000 499000000 741000000 0 121000000 777000000 898000000 10000000000 6800000000 <div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">902 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">At September 30, 2022, $358 million of the liabilities relate to the 2016 termination of the Sanofi Pasteur MSD joint venture. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate to present value the cash flows. Balance at September 30, 2022 includes $139 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div> 777000000 841000000 -156000000 73000000 119000000 0 3000000 12000000 499000000 902000000 358000000 0.115 139000000 25900000000 30400000000 35700000000 33100000000 2300000000 2800000000 55000000 62000000 794000000 164000000 Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September 30, 2022 and December 31, 2021, these amounts included $2.2 billion and $1.9 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $417 million and $256 million at September 30, 2022 and December 31, 2021, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,220 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,442 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,163 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,614 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,953 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,641 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1683000000 1747000000 6532000000 6220000000 227000000 196000000 8442000000 8163000000 187000000 16000000 8255000000 8147000000 5614000000 5953000000 2641000000 2194000000 2200000000 1900000000 417000000 256000000 Other Intangibles<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2022, the Company recorded $887 million of impairment charges within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses related to intangible assets obtained in connection with the 2020 acquisition of ArQule, Inc. Of this amount, $807 million represents an in-process research and development (IPR&amp;D) impairment charge related to nemtabrutinib (MK-1026), a novel, oral BTK inhibitor currently being evaluated for the treatment of B-cell malignancies. Following discussions with regulatory authorities in the third quarter, the development period for nemtabrutinib was extended, which constituted a triggering event that required the evaluation of the nemtabrutinib intangible asset for impairment. The Company estimated the current fair value of nemtabrutinib utilizing an income approach which calculates the present value of projected future cash flows. The market participant assumptions used to derive the forecasted cash flows were updated to reflect a delay in the anticipated launch date for nemtabrutinib, which resulted in lower cumulative revenue forecasts and a reduction in the estimated fair value. The revised estimated fair value of nemtabrutinib when compared with its related carrying value resulted in the IPR&amp;D impairment charge noted above. The remaining IPR&amp;D intangible asset related to nemtabrutinib is $1.2 billion. If the assumptions used to estimate the fair value of nemtabrutinib prove to be incorrect and the development of nemtabrutinib does not progress as anticipated thereby adversely affecting projected future cash flows, the Company may record an additional impairment charge in the future and such charge could be material.</span> 887000000 807000000 1200000000 Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of September 30, 2022, approximately 3,450 cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck’s motion and ruled that plaintiffs’ failure to warn claims are preempted as a matter of law to the extent they </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Plaintiffs have indicated that they do not intend to move forward with any other claims at this point and intend to appeal the District Court’s preemption ruling to the Third Circuit.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims were filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). In March 2021, the MDL court issued an omnibus order granting defendants’ summary judgment motions based on preemption and failure to establish general causation, as well as granting defendants’ motions to exclude plaintiffs’ expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and in October 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants. The MDL court’s judgment is now final and no longer appealable with respect to remaining claims.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims were filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants’ summary judgment motions and also granting defendants’ motions to exclude plaintiffs’ expert witnesses. On May 31, 2022, the court entered judgment in favor of Merck as to all of the claims pending against Merck in that jurisdiction.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil 9</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 (Human Papillomavirus 9-valent Vaccine, Recombinant). As of September 30, 2022, approximately 65 cases were filed and pending against Merck in either federal or state court. In these actions, plaintiffs allege, among other things, that they suffered various personal injuries after vaccination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, with postural orthostatic tachycardia syndrome as a predominate alleged injury. In August 2022, the Judicial Panel on Multidistrict Litigation ordered that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil/Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9 product liability cases pending in federal courts nationwide be transferred to Judge Robert J. Conrad in the Western District of North Carolina for coordinated pre-trial proceedings. There are fewer than 15 product liability cases pending outside the U.S., including one purported class action in Colombia.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in a number of lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases were consolidated in a federal multidistrict litigation (the Zetia MDL) before Judge Rebecca Beach Smith in the Eastern District of Virginia.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of 35 direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court denied the direct purchaser plaintiffs’ renewed motion for class certification. In August 2021, the district court granted certification of a class of indirect purchasers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020 and 2021, United Healthcare Services, Inc., Humana Inc., Centene Corporation and others, and Kaiser Foundation Health Plan, Inc. (collectively, the Insurer Plaintiffs), each filed a lawsuit in a jurisdiction outside of the Eastern District of Virginia against the Merck Defendants and others, making similar allegations as those made in the Zetia MDL, as well as additional allegations about Vytorin. These cases have been transferred to the Eastern District of Virginia to proceed with the Zetia MDL.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 9, 2022, the Insurer Plaintiffs filed amended complaints. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the Insurer Plaintiffs’ complaints, including any claims for Vytorin damages. That motion to dismiss the Vytorin-related claims is still pending.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the direct purchaser plaintiffs moved for an order setting a deadline for direct purchasers of Zetia not currently parties to the case to file cases against defendants in order for those cases to be coordinated for trial with the existing direct purchaser plaintiffs and other MDL plaintiff groups. The court granted that motion, setting a deadline of June 30, 2022 for unnamed direct purchasers to file claims. On June 30, 2022, 23 new entities, many related, brought new complaints against defendants or otherwise sought to intervene. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 2, 2022, the Magistrate Judge issued a Report and Recommendation denying the Merck Defendants’ and Glenmark Defendants’ motions for summary judgment. Defendants have objected to the Report and Recommendation, and are awaiting a final decision from Judge Smith. The court has scheduled trial for all plaintiffs other than the Insurer Plaintiffs for April 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">340B Program Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has filed a complaint in the U.S. District Court for the District of Columbia to challenge the letter Merck received from the Health Resources and Services Administration (HRSA) in May 2022 regarding Merck’s 340B Program integrity initiative. HRSA’s letter to Merck asserts that Merck is in violation of the 340B statute. HRSA further claims that continued failure to provide the 340B price to covered entities using contract pharmacies may result in civil monetary penalties for each instance of alleged overcharging, in addition to repayment for any instance of overcharging. The letter is very similar to letters HRSA has sent to other manufacturers, which letters have been held to be unlawful by multiple federal courts. Merck disagrees with HRSA’s assertion. Merck remains committed to the 340B Program and to providing 340B discounts to eligible covered entities. Merck’s 340B Program integrity initiative is consistent with the requirements of the 340B statute and is intended to ensure the integrity and sustainability of the 340B statute by reducing prohibited duplicate discounts and diversion and putting patients back at the center of the program. Merck continues to offer all of the Company’s covered outpatient drugs to all 340B covered entities for purchase at or below the 340B ceiling price. On September 13, 2022, the court stayed the case pending the D.C. Circuit’s ruling in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis Pharmaceuticals Corp. v. Johnson and United Therapeutics Corp. v. Johnson</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection. In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. All actions in the District of New Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any, whichever may occur earlier. The West Virginia case was jointly dismissed with prejudice on August 8, 2022 in favor of proceeding in New Jersey. The remaining defendants in the New Jersey action have stipulated to infringement of the asserted claims and have stated they are withdrawing all remaining claims and defenses other than a defense seeking to shorten the patent term extension of the sugammadex patent to December 2022. In light of this, the U.S. District Court for the District of New Jersey cancelled the scheduled trial and scheduled a <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjZiNGU0MjgwYWQyMzQ0YTViYzdmZGNhYTc3ZTQxN2YwL3NlYzo2YjRlNDI4MGFkMjM0NGE1YmM3ZmRjYWE3N2U0MTdmMF81NS9mcmFnOjNiNDE0ZjBmNjBmMDQwMzliNDRkNjY1ODhlODBiYTcyL3RleHRyZWdpb246M2I0MTRmMGY2MGYwNDAzOWI0NGQ2NjU4OGU4MGJhNzJfMTY0OTI2NzQ4NjEyNg_dc252ca0-1f84-47f5-aa4a-e30b0bbfb328">one</span>-day trial on December 19, 2022 on this remaining patent term extension calculation defense.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with five generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin that expires in May 2027, including pediatric exclusivity (2027 salt/polymorph patent). In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. On September 21, 2022, the District Court for the Northern District of West Virginia issued a decision in the Company’s favor, upholding all asserted patent claims. Mylan (now Viatris) has appealed to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with 22 generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit, and a hearing was held on August 2, 2022. On September 29, 2022, the Court of Appeals for the Federal Circuit ruled in the Company’s favor, upholding the USPTO’s decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s application seeking approval of its sitagliptin tablets. While the U.S. District Court for the District of Delaware originally set a three-day bench trial in this matter beginning on October 31, 2022, the trial date has been moved to January 9, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in a number of European countries. In February 2022, a Finnish court referred certain questions to the Court of Justice of the European Union that could determine the validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPCs in Europe. In June 2021, a German court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. The validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPC was upheld in the Czech Republic in March 2022 in a first instance decision, which has been appealed. In June 2022, a Romanian court decided </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was invalid in a first instance decision. In August 2022, the validity of the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was upheld in Sweden in a first instance decision, which decision has been appealed. MSD has filed injunction actions against generic companies in Belgium, Finland, France, Greece, Ireland and Portugal. In September 2022, the following decisions were issued: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex-parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were granted in Finland; a preliminary injunction was granted in France, and the validity of the SPC and the associated patent were held to be </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">prima facie</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> valid in these proceedings; and a temporary restraining order was granted in Greece. In October 2022, requests for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> preliminary injunctions were refused in Portugal.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2022 and December 31, 2021 of approximately $230 million represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. 3450 650 515 50 65 15 1 35 23 5 2 22 P3D 230000000 230000000 Equity<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,115 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,437 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,770)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,318 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.95 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($2.07 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,039 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48,777 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,682)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,388 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,115 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,437 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,770)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43,318 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.69 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.747%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.775%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,588 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,787)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,404 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.95 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,962)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(822)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spin-off of Organon &amp; Co.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,643 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,091 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,149 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,691 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,244)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35,863 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,238 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53,696 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,049 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(57,109)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,257 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($2.07 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">351 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,243 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,928 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,044 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,758)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44,524 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3577000000 1788000000 44039000000 48777000000 -4628000000 1044000000 -56682000000 94000000 33388000000 4567000000 4567000000 38000000 38000000 0.65 1653000000 1653000000 8000000 583000000 583000000 -110000000 -21000000 -131000000 4000000 4000000 29000000 29000000 3577000000 1788000000 44149000000 51691000000 -4590000000 1052000000 -57244000000 69000000 35863000000 3577000000 1788000000 44115000000 58437000000 -4327000000 1044000000 -56770000000 75000000 43318000000 3248000000 3248000000 -416000000 -416000000 0.69 1757000000 1757000000 -128000000 -12000000 -140000000 5000000 5000000 14000000 14000000 3577000000 1788000000 44243000000 59928000000 -4743000000 1044000000 -56758000000 66000000 44524000000 3577000000 1788000000 39588000000 47362000000 -6634000000 1047000000 -56787000000 87000000 25404000000 9291000000 9291000000 1595000000 1595000000 1.95 4962000000 4962000000 11000000 822000000 822000000 4643000000 449000000 -1000000 5091000000 82000000 6000000 -365000000 -283000000 12000000 12000000 29000000 29000000 3577000000 1788000000 44149000000 51691000000 -4590000000 1052000000 -57244000000 69000000 35863000000 3577000000 1788000000 44238000000 53696000000 -4429000000 1049000000 -57109000000 73000000 38257000000 11502000000 11502000000 -314000000 -314000000 2.07 5270000000 5270000000 -5000000 5000000 -351000000 -356000000 6000000 6000000 13000000 13000000 3577000000 1788000000 44243000000 59928000000 -4743000000 1044000000 -56758000000 66000000 44524000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit cost (credit) for pension and other postretirement benefit plans in the first nine months of 2021 includes expenses for curtailments, settlements and termination benefits provided to certain employees in connection with the spin-off of Organon.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. In addition, lump sum payments to U.S. pension plan participants triggered partial settlement charges in the third quarter and first nine months of 2022 and 2021. These partial settlements triggered remeasurements of some of the Company’s U.S. pension plans. The third quarter 2022 remeasurement, which was calculated using discount rates and asset values as of September 30, 2022, resulted in a net increase of $296 million to net pension liabilities and also resulted in a related adjustment to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Remeasurements during the first nine months of 2022 have resulted in a net increase of $131 million to net pension liabilities with related adjustments to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 12), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions or in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if related to the spin-off of Organon (each as noted above).</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first nine months of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.096%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(93)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(576)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(292)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 91000000 66000000 104000000 75000000 289000000 213000000 302000000 254000000 123000000 35000000 102000000 33000000 330000000 110000000 305000000 92000000 182000000 93000000 188000000 105000000 576000000 292000000 568000000 313000000 -8000000 -3000000 -9000000 -3000000 -24000000 -10000000 -29000000 -12000000 -10000000 -24000000 -75000000 -32000000 -122000000 -73000000 -218000000 -110000000 1000000 0 2000000 0 2000000 1000000 54000000 3000000 -3000000 0 1000000 0 -11000000 0 -15000000 27000000 -79000000 0 -139000000 0 -180000000 0 -139000000 -2000000 117000000 29000000 224000000 32000000 334000000 95000000 436000000 109000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.947%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 11000000 11000000 36000000 37000000 11000000 12000000 34000000 34000000 21000000 20000000 64000000 59000000 -14000000 -16000000 -42000000 -48000000 11000000 12000000 32000000 30000000 0 0 0 37000000 0 1000000 1000000 29000000 -24000000 -26000000 -69000000 -58000000 -296000000 -131000000 Other (Income) Expense, Net<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September 30, 2022 and 2021 was $660 million and $570 million, respectively.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.847%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,535)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,576 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. 40000000 7000000 62000000 27000000 244000000 196000000 727000000 597000000 -96000000 -46000000 -220000000 -202000000 -371000000 683000000 -1361000000 1535000000 -60000000 40000000 -208000000 -159000000 182000000 42000000 462000000 85000000 -429000000 450000000 -1576000000 1007000000 660000000 570000000 Taxes on Income<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 9.2% and 13.2% for the third quarter of 2022 and 2021, respectively, and 11.0% and 14.4% for the first nine months of 2022 and 2021, respectively. The effective income tax rates from continuing operations reflect the beneficial impact of foreign earnings. The effective income tax rates from continuing operations in the third quarter and first nine months of 2022 also include the favorable impact of net unrealized losses from investments in equity securities and intangible asset impairment charges, which were taxed at the U.S. tax rate. The effective income tax rate from continuing operations in the first nine months of 2021 reflects the unfavorable effect of a charge for the acquisition of Pandion for which no tax benefit was recognized, as well as a net tax benefit of $207 million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190 million (of which $172 million related to continuing operations and $18 million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $236 million net tax benefit in the first nine months of 2021 (of which $207 million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div> 0.092 0.132 0.110 0.144 0 0 207000000 190000000 172000000 18000000 236000000 207000000 29000000 Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div>For the third quarter of 2022 and 2021, 2 million and 8 million, respectively, and for the first nine months of 2022 and 2021, 5 million and 10 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.677%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,248 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,567 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,502 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,291 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,533 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,531 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,542 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,540 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.55 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.67 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.28 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.80 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.53 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.66 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div> 3248000000 4567000000 11502000000 8525000000 0 0 0 766000000 3248000000 3248000000 4567000000 4567000000 11502000000 11502000000 9291000000 9291000000 2533000000 2530000000 2531000000 2531000000 9000000 6000000 9000000 8000000 2542000000 2536000000 2540000000 2539000000 1.28 1.81 4.55 3.37 0 0 0 0.30 1.28 1.81 4.55 3.67 1.28 1.80 4.53 3.36 0 0 0 0.30 1.28 1.80 4.53 3.66 2000000 8000000 5000000 10000000 Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note 2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,574)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,465)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,252)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,327)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">682 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(618)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(254)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(201)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(416)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.531%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.870%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,540)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,828)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,634)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,739 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,765 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(385)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(510)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,354 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,255 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,595 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spin-off of Organon (see Note 2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2021, net of taxes</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,658)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,590)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,743)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,830)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,429)</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(125)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,001)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">974 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(493)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(198)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(990)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(314)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2022, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,651)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,820)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,743)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 11).</span></div> -26000000 -3028000000 -1574000000 -4628000000 72000000 -24000000 -96000000 -48000000 16000000 -16000000 -12000000 -12000000 56000000 -8000000 -84000000 -36000000 -36000000 -68000000 0 -104000000 -8000000 -22000000 0 -30000000 -28000000 -46000000 0 -74000000 84000000 38000000 -84000000 38000000 58000000 -2990000000 -1658000000 -4590000000 390000000 -2465000000 -2252000000 -4327000000 682000000 -294000000 -618000000 -230000000 143000000 -62000000 -50000000 31000000 539000000 -232000000 -568000000 -261000000 254000000 -77000000 0 177000000 53000000 -31000000 0 22000000 201000000 -46000000 0 155000000 338000000 -186000000 -568000000 -416000000 728000000 -2651000000 -2820000000 -4743000000 -266000000 -4540000000 -1828000000 -6634000000 193000000 1739000000 -167000000 1765000000 41000000 385000000 84000000 510000000 152000000 1354000000 -251000000 1255000000 -218000000 -210000000 0 -428000000 -46000000 -42000000 0 -88000000 -172000000 -168000000 0 -340000000 324000000 1522000000 -251000000 1595000000 0 28000000 421000000 449000000 58000000 -2990000000 -1658000000 -4590000000 144000000 -2743000000 -1830000000 -4429000000 1233000000 -125000000 -1001000000 107000000 259000000 -25000000 -11000000 223000000 974000000 -100000000 -990000000 -116000000 493000000 -266000000 0 227000000 103000000 -74000000 0 29000000 390000000 -192000000 0 198000000 584000000 92000000 -990000000 -314000000 728000000 -2651000000 -2820000000 -4743000000 Segment Reporting<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include two operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,095 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,777 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,974 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,047 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,021 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,322 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,637 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,276 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,878 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,927 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,526 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,166 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,017 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2022 and 2021 also includes $156 million and $191 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.3 billion and $3.1 billion for the three months ended September 30, 2022 and 2021, respectively, and $9.1 billion for both the nine months ended September 30, 2022 and 2021. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,935 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing arrangements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div> 2 <div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,331 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,095 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,954 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,108 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,501 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">117 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">397 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">825 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">721 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">426 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">235 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">660 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">287 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">211 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">498 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">124 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">957 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">839 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,993 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,803 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,605 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">537 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">661 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,716 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,255 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,626 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">154 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">135 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">427 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">218 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">644 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">457 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">369 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">545 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">551 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,096 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">174 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">310 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">108 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">185 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">64 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue-Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">248 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">436 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">466 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">238 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">619 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">233 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">332 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">385 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">717 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">852 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">958 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,294 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,252 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">997 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,448 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,445 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">90 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">401 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">258 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,089 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">321 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">616 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,565 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">637 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">950 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,589 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,620 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,343 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,963 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,670 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,496 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,119 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,707 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39,826 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,611 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,103 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30,714 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">643 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">190 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">521 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,965 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,486 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">508 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,996 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">542 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">277 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">553 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">904 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">855 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">475 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">896 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,371 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">467 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">951 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,417 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,425 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,894 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,363 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,944 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,095 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,334 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,137 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,777 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,544 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23,601 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,974 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,047 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,021 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,322 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,637 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,276 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,878 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,927 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24,526 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16,166 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,017 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Reblozyl represents royalties and, for the year-to-date period, a payment received related to the achievement of a regulatory milestone (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenue, including revenue hedging activities, as well as revenue from third-party manufacturing arrangements (including sales to Organon). Other for the nine months ended September 30, 2022 and 2021 also includes $156 million and $191 million, respectively, related to upfront and milestone payments received by Merck for out-licensing arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">.</span></div> 3331000000 2095000000 5426000000 2580000000 1954000000 4534000000 9307000000 6180000000 15487000000 7108000000 5501000000 12609000000 144000000 140000000 284000000 129000000 117000000 246000000 427000000 397000000 825000000 371000000 350000000 721000000 142000000 60000000 202000000 114000000 74000000 188000000 426000000 235000000 660000000 287000000 211000000 498000000 32000000 7000000 39000000 0 0 0 87000000 37000000 124000000 0 0 0 957000000 1337000000 2294000000 839000000 1154000000 1993000000 1803000000 3624000000 5428000000 1605000000 2539000000 4144000000 532000000 136000000 668000000 537000000 125000000 661000000 1337000000 379000000 1716000000 1255000000 371000000 1626000000 154000000 102000000 256000000 135000000 92000000 227000000 427000000 218000000 644000000 364000000 229000000 593000000 68000000 63000000 131000000 181000000 97000000 277000000 280000000 177000000 457000000 354000000 247000000 600000000 27000000 36000000 64000000 32000000 16000000 48000000 72000000 62000000 134000000 80000000 58000000 138000000 233000000 190000000 423000000 181000000 188000000 369000000 665000000 579000000 1244000000 545000000 551000000 1096000000 49000000 64000000 114000000 39000000 57000000 96000000 136000000 174000000 310000000 111000000 159000000 270000000 72000000 6000000 77000000 52000000 2000000 54000000 184000000 12000000 196000000 108000000 7000000 115000000 0 63000000 63000000 0 69000000 70000000 1000000 185000000 185000000 0 194000000 194000000 13000000 49000000 62000000 19000000 45000000 64000000 39000000 141000000 180000000 48000000 149000000 197000000 2000000 48000000 50000000 -2000000 55000000 53000000 4000000 144000000 148000000 -2000000 159000000 157000000 1000000 42000000 43000000 1000000 56000000 56000000 5000000 133000000 138000000 4000000 164000000 168000000 24000000 19000000 43000000 -1000000 -1000000 -2000000 64000000 55000000 120000000 -5000000 -6000000 -11000000 85000000 3000000 88000000 73000000 27000000 100000000 244000000 14000000 258000000 222000000 26000000 248000000 0 57000000 57000000 0 59000000 59000000 0 181000000 181000000 0 188000000 188000000 0 436000000 436000000 0 0 0 1523000000 3336000000 4859000000 0 0 0 68000000 93000000 161000000 77000000 112000000 189000000 196000000 270000000 466000000 222000000 368000000 590000000 20000000 42000000 62000000 23000000 58000000 81000000 60000000 139000000 199000000 56000000 183000000 238000000 0 173000000 173000000 0 203000000 203000000 0 540000000 540000000 0 619000000 619000000 0 49000000 49000000 0 73000000 73000000 0 163000000 163000000 0 233000000 233000000 332000000 385000000 717000000 365000000 487000000 852000000 958000000 1294000000 2252000000 997000000 1448000000 2445000000 90000000 327000000 417000000 86000000 401000000 487000000 258000000 1089000000 1347000000 244000000 1205000000 1449000000 244000000 321000000 564000000 210000000 306000000 518000000 616000000 949000000 1565000000 637000000 950000000 1589000000 6620000000 6343000000 12963000000 5670000000 5826000000 11496000000 19119000000 20707000000 39826000000 14611000000 16103000000 30714000000 186000000 643000000 829000000 190000000 675000000 864000000 521000000 1965000000 2486000000 508000000 1996000000 2503000000 289000000 253000000 542000000 277000000 276000000 553000000 904000000 929000000 1834000000 855000000 948000000 1804000000 475000000 896000000 1371000000 467000000 951000000 1417000000 1425000000 2894000000 4320000000 1363000000 2944000000 4307000000 7095000000 7239000000 14334000000 6137000000 6777000000 12913000000 20544000000 23601000000 44146000000 15974000000 19047000000 35021000000 227000000 398000000 625000000 139000000 101000000 241000000 383000000 925000000 1307000000 192000000 -30000000 162000000 7322000000 7637000000 14959000000 6276000000 6878000000 13154000000 20927000000 24526000000 45453000000 16166000000 19017000000 35183000000 156000000 191000000 3300000000 3100000000 9100000000 9100000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,276 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,927 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,342 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,912 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,307 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,957 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">638 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,776 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,929 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,631 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,959 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,154 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,453 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,183 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7322000000 6276000000 20927000000 16166000000 3286000000 3342000000 11228000000 9912000000 1442000000 1307000000 3957000000 3004000000 673000000 638000000 2776000000 1929000000 854000000 613000000 2792000000 1782000000 684000000 599000000 1933000000 1631000000 698000000 379000000 1840000000 759000000 14959000000 13154000000 45453000000 35183000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.531%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,590 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,606 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,263 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,672 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,629 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,105 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,111 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,935 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,079 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(727)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,623)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(358)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,031)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,312)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,775)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(487)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,628)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,044)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,583 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,931 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,970 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 9590000000 8606000000 28263000000 22450000000 515000000 505000000 1672000000 1629000000 10105000000 9111000000 29935000000 24079000000 377000000 141000000 831000000 29000000 40000000 7000000 62000000 27000000 244000000 196000000 727000000 597000000 460000000 360000000 1623000000 1231000000 448000000 358000000 1257000000 1031000000 4277000000 2312000000 9374000000 8775000000 94000000 107000000 288000000 487000000 1416000000 660000000 4628000000 2044000000 3583000000 5266000000 12931000000 9970000000 EXCEL 82 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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ƒ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end XML 83 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 84 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 85 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 968 344 1 false 155 0 false 12 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME CONDENSED CONSOLIDATED STATEMENT OF INCOME Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET CONDENSED CONSOLIDATED BALANCE SHEET Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation Sheet http://www.merck.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 0000009 - Disclosure - Spin-Off of Organon & Co. Sheet http://www.merck.com/role/SpinOffofOrganonCo Spin-Off of Organon & Co. Notes 9 false false R10.htm 0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements Acquisitions, Research Collaborations and License Agreements Notes 10 false false R11.htm 0000011 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 12 false false R13.htm 0000013 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 13 false false R14.htm 0000014 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 14 false false R15.htm 0000015 - Disclosure - Other Intangibles Sheet http://www.merck.com/role/OtherIntangibles Other Intangibles Notes 15 false false R16.htm 0000016 - Disclosure - Contingencies Sheet http://www.merck.com/role/Contingencies Contingencies Notes 16 false false R17.htm 0000017 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 17 false false R18.htm 0000018 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 18 false false R19.htm 0000019 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 19 false false R20.htm 0000020 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesonIncome Taxes on Income Notes 20 false false R21.htm 0000021 - Disclosure - Earnings Per Share Sheet http://www.merck.com/role/EarningsPerShare Earnings Per Share Notes 21 false false R22.htm 0000022 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 22 false false R23.htm 0000023 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 23 false false R24.htm 0000024 - Disclosure - Basis of Presentation (Policies) Sheet http://www.merck.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 24 false false R25.htm 0000025 - Disclosure - Spin-Off of Organon & Co. (Tables) Sheet http://www.merck.com/role/SpinOffofOrganonCoTables Spin-Off of Organon & Co. (Tables) Tables http://www.merck.com/role/SpinOffofOrganonCo 25 false false R26.htm 0000026 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 26 false false R27.htm 0000027 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 27 false false R28.htm 0000028 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 28 false false R29.htm 0000029 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 29 false false R30.htm 0000030 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 30 false false R31.htm 0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 31 false false R32.htm 0000032 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIntangibles 32 false false R33.htm 0000033 - Disclosure - Earnings Per Share (Tables) Sheet http://www.merck.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.merck.com/role/EarningsPerShare 33 false false R34.htm 0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 34 false false R35.htm 0000035 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 35 false false R36.htm 0000036 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details) Sheet http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails Spin-Off of Organon & Co. - Narrative (Details) Details 36 false false R37.htm 0000037 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) Sheet http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details) Details 37 false false R38.htm 0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails Acquisitions, Research Collaborations and License Agreements (Details) Details http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements 38 false false R39.htm 0000039 - Disclosure - Collaborative Arrangements - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements - Narrative (Details) Details 39 false false R40.htm 0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails Collaborative Arrangements - Financial Information (Details) Details 40 false false R41.htm 0000041 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 41 false false R42.htm 0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 42 false false R43.htm 0000043 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 43 false false R44.htm 0000044 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 44 false false R45.htm 0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 45 false false R46.htm 0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails Financial Instruments - Fair Value Hedges (Details) Details 46 false false R47.htm 0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 47 false false R48.htm 0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 48 false false R49.htm 0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Details 49 false false R50.htm 0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 50 false false R51.htm 0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails Financial Instruments - Information on Available-for-sale Investments (Details) Details 51 false false R52.htm 0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 52 false false R53.htm 0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 53 false false R54.htm 0000054 - Disclosure - Inventories - Schedule of Inventories (Details) Sheet http://www.merck.com/role/InventoriesScheduleofInventoriesDetails Inventories - Schedule of Inventories (Details) Details 54 false false R55.htm 0000055 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 55 false false R56.htm 0000056 - Disclosure - Other Intangibles (Details) Sheet http://www.merck.com/role/OtherIntangiblesDetails Other Intangibles (Details) Details http://www.merck.com/role/OtherIntangibles 56 false false R57.htm 0000057 - Disclosure - Contingencies (Details) Sheet http://www.merck.com/role/ContingenciesDetails Contingencies (Details) Details http://www.merck.com/role/Contingencies 57 false false R58.htm 0000058 - Disclosure - Equity - Rollforward Reconciliations (Details) Sheet http://www.merck.com/role/EquityRollforwardReconciliationsDetails Equity - Rollforward Reconciliations (Details) Details 58 false false R59.htm 0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details) Details 59 false false R60.htm 0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans - Narrative (Details) Details 60 false false R61.htm 0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 61 false false R62.htm 0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 62 false false R63.htm 0000063 - Disclosure - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesonIncomeDetails Taxes on Income (Details) Details http://www.merck.com/role/TaxesonIncome 63 false false R64.htm 0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails Earnings Per Share - Calculations of Earnings Per Share (Details) Details 64 false false R65.htm 0000065 - Disclosure - Earnings Per Share - Narrative (Details) Sheet http://www.merck.com/role/EarningsPerShareNarrativeDetails Earnings Per Share - Narrative (Details) Details 65 false false R66.htm 0000066 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 66 false false R67.htm 0000067 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 67 false false R68.htm 0000068 - Disclosure - Segment Reporting - Sales from Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesfromProductsDetails Segment Reporting - Sales from Products (Details) Details 68 false false R69.htm 0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails Segment Reporting - Consolidated Sales by Geographic Area (Details) Details 69 false false R70.htm 0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details) Details 70 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 6 fact(s) appearing in ix:hidden were eligible for transformation: mrk:LossContingencyTrialPeriod, us-gaap:RelatedPartiesAmountInCostOfSales, us-gaap:RevenueFromRelatedParties, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 - mrk-20220930.htm 4 mrk-20220930.htm exhibit311-rule13ax14a15dx.htm exhibit312-rule13ax14a15dx.htm exhibit321-section1350cert.htm exhibit322-section1350cert.htm mrk-20220930.xsd mrk-20220930_cal.xml mrk-20220930_def.xml mrk-20220930_lab.xml mrk-20220930_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 88 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrk-20220930.htm": { "axisCustom": 0, "axisStandard": 39, "contextCount": 968, "dts": { "calculationLink": { "local": [ "mrk-20220930_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20220930_def.xml" ] }, "inline": { "local": [ "mrk-20220930.htm" ] }, "labelLink": { "local": [ "mrk-20220930_lab.xml" ] }, "presentationLink": { "local": [ "mrk-20220930_pre.xml" ] }, "schema": { "local": [ "mrk-20220930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 657, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 23, "http://www.merck.com/20220930": 1, "http://xbrl.sec.gov/dei/2022": 5, "total": 29 }, "keyCustom": 44, "keyStandard": 300, "memberCustom": 77, "memberStandard": 71, "nsprefix": "mrk", "nsuri": "http://www.merck.com/20220930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "role": "http://www.merck.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Acquisitions, Research Collaborations and License Agreements", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements", "shortName": "Acquisitions, Research Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Collaborative Arrangements", "role": "http://www.merck.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Restructuring", "role": "http://www.merck.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Financial Instruments", "role": "http://www.merck.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Inventories", "role": "http://www.merck.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Other Intangibles", "role": "http://www.merck.com/role/OtherIntangibles", "shortName": "Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Contingencies", "role": "http://www.merck.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Equity", "role": "http://www.merck.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Pension and Other Postretirement Benefit Plans", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Other (Income) Expense, Net", "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "shortName": "Other (Income) Expense, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "mrk:CostsExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Taxes on Income", "role": "http://www.merck.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Earnings Per Share", "role": "http://www.merck.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Other Comprehensive Income (Loss)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Segment Reporting", "role": "http://www.merck.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.merck.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Spin-Off of Organon & Co. (Tables)", "role": "http://www.merck.com/role/SpinOffofOrganonCoTables", "shortName": "Spin-Off of Organon & Co. (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Collaborative Arrangements (Tables)", "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Restructuring (Tables)", "role": "http://www.merck.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Financial Instruments (Tables)", "role": "http://www.merck.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Inventories (Tables)", "role": "http://www.merck.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Equity (Tables)", "role": "http://www.merck.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i320809a777744dfdb73841889368aa2c_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i320809a777744dfdb73841889368aa2c_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Other (Income) Expense, Net (Tables)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "shortName": "Other (Income) Expense, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.merck.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Segment Reporting (Tables)", "role": "http://www.merck.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ic7ff920b80fa44a2bb7838de95556452_I20210602", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Spin-Off of Organon & Co. - Narrative (Details)", "role": "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails", "shortName": "Spin-Off of Organon & Co. - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ic7ff920b80fa44a2bb7838de95556452_I20210602", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i4068211e109d4d7da65c6be7b495d094_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)", "role": "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails", "shortName": "Spin-Off of Organon & Co. - Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i4068211e109d4d7da65c6be7b495d094_D20210101-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Details)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AdjustmentForAmortization", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Collaborative Arrangements - Narrative (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "shortName": "Collaborative Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-1", "lang": "en-US", "name": "mrk:SupplyCommitmentMinimumNumberOfMarkets", "reportCount": 1, "unique": true, "unitRef": "market", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Collaborative Arrangements - Financial Information (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "shortName": "Collaborative Arrangements - Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "id55d4ae3b325406e91eef2de4b2e7b99_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Restructuring - Narrative (Details)", "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "2", "lang": "en-US", "name": "mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000042 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ic03376b1c2a3499d90e8c3ebcf2e8843_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Restructuring - Activities by Program (Details)", "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "shortName": "Restructuring - Activities by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeNotionalAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Financial Instruments - Narrative (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ie27e3a1d731a4e8aab46753956e07c5d_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ibdb46049abd240818d8639edc52d2396_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Financial Instruments - Fair Value Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "shortName": "Financial Instruments - Fair Value Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ibdb46049abd240818d8639edc52d2396_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "iaf409d1f24c84ee6b661d53c0d63d271_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i1a250ba5d2eb4f398ca0d688c55ce97b_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8487d36b908947f3b19f1402064fea62_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8487d36b908947f3b19f1402064fea62_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i03d038eb8e67488896fcaf65d65f5a4c_I20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:TradingSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Inventories - Schedule of Inventories (Details)", "role": "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails", "shortName": "Inventories - Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Inventories - Narrative (Details)", "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i5a678e64e2774577a007e2d6f57ae9e6_I20220930", "decimals": "-8", "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000056 - Disclosure - Other Intangibles (Details)", "role": "http://www.merck.com/role/OtherIntangiblesDetails", "shortName": "Other Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i0b998b01dd7b4aedbe8d12d9cd13b5db_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i5e7203ee8afa4167bcbca2845a05174c_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Contingencies (Details)", "role": "http://www.merck.com/role/ContingenciesDetails", "shortName": "Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i5e7203ee8afa4167bcbca2845a05174c_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ib9490e02538244c88fb94e67f0f84467_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Equity - Rollforward Reconciliations (Details)", "role": "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "shortName": "Equity - Rollforward Reconciliations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Net Benefit Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ie3dcb6bbb4364846bb3cb11e71d7614c_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Pension and Other Postretirement Benefit Plans - Narrative (Details)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails", "shortName": "Pension and Other Postretirement Benefit Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "shortName": "Other (Income) Expense, Net - Schedule of Other (Income) Expense, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Other (Income) Expense, Net - Narrative (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails", "shortName": "Other (Income) Expense, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000063 - Disclosure - Taxes on Income (Details)", "role": "http://www.merck.com/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperations", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Earnings Per Share - Calculations of Earnings Per Share (Details)", "role": "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "shortName": "Earnings Per Share - Calculations of Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000065 - Disclosure - Earnings Per Share - Narrative (Details)", "role": "http://www.merck.com/role/EarningsPerShareNarrativeDetails", "shortName": "Earnings Per Share - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i0d5f781c87ab40f58ea21a9500d8154a_I20220630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Other Comprehensive Income (Loss) (Details)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Segment Reporting - Narrative (Details)", "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Segment Reporting - Sales from Products (Details)", "role": "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails", "shortName": "Segment Reporting - Sales from Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Segment Reporting - Consolidated Sales by Geographic Area (Details)", "role": "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "shortName": "Segment Reporting - Consolidated Sales by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ide9fd53158404da68f8ed38707c6e730_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i8a7d4a67ce7b463ca92f0dbb2b24f332_I20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i32519da4a0d740c5a2c6637b4502c8c5_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "role": "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "shortName": "Segment Reporting - Reconciliation of Segment Profits to Income before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "ie736eb61ba964832abed00a756bb99fe_D20220701-20220930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Basis of Presentation", "role": "http://www.merck.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Spin-Off of Organon & Co.", "role": "http://www.merck.com/role/SpinOffofOrganonCo", "shortName": "Spin-Off of Organon & Co.", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20220930.htm", "contextRef": "i22cf75a29d3e4069a2f26f93abb01112_D20220101-20220930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 155, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_CO": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COLOMBIA", "terseLabel": "COLOMBIA" } } }, "localname": "CO", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r780" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r781" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r789" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r778" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r777" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r779" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mrk_A0.500Notesdue2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "0.500% Notes due 2024 [Member]", "label": "0.500% Notes due 2024 [Member]", "terseLabel": "0.500% Notes due 2024" } } }, "localname": "A0.500Notesdue2024Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.375Notesdue2036Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.375% Notes due 2036 [Member]", "label": "1.375% Notes due 2036 [Member]", "terseLabel": "1.375% Notes due 2036" } } }, "localname": "A1.375Notesdue2036Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.875Notesdue2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "1.875% Notes due 2026 [Member]", "label": "1.875% Notes due 2026 [Member]", "terseLabel": "1.875% Notes due 2026" } } }, "localname": "A1.875Notesdue2026Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A2.35NotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.35% Notes Due 2022 [Member]", "label": "2.35% Notes Due 2022 [Member]", "terseLabel": "2.35% Notes Due 2022" } } }, "localname": "A2.35NotesDue2022Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.40NotesDue2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.40% Notes Due 2022 [Member]", "label": "2.40% Notes Due 2022 [Member]", "terseLabel": "2.40% Notes Due 2022" } } }, "localname": "A2.40NotesDue2022Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.500Notesdue2034Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2.500% Notes due 2034 [Member]", "label": "2.500% Notes due 2034 [Member]", "terseLabel": "2.500% Notes due 2034" } } }, "localname": "A2.500Notesdue2034Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_AcceleratedDepreciationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accelerated Depreciation [Member]", "label": "Accelerated Depreciation [Member]", "terseLabel": "Accelerated Depreciation" } } }, "localname": "AcceleratedDepreciationMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "terseLabel": "Acquisitions, Research Collaborations and License Agreements" } } }, "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "mrk_AdempasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adempas", "label": "Adempas [Member]", "terseLabel": "Adempas" } } }, "localname": "AdempasMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueAdempasVerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Adempas/Verquvo", "label": "Alliance revenue - Adempas/Verquvo [Member]", "terseLabel": "Alliance revenue - Adempas/Verquvo" } } }, "localname": "AllianceRevenueAdempasVerquvoMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueKoselugoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "terseLabel": "Alliance revenue - Koselugo" } } }, "localname": "AllianceRevenueKoselugoMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueReblozylMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance Revenue - Reblozyl", "label": "Alliance Revenue - Reblozyl [Member]", "terseLabel": "Alliance Revenue - Reblozyl" } } }, "localname": "AllianceRevenueReblozylMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AlliancerevenueLynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alliance revenue - Lynparza [Member]", "label": "Alliance revenue - Lynparza [Member]", "terseLabel": "Alliance revenue - Lynparza" } } }, "localname": "AlliancerevenueLynparzaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AnimalHealthsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Animal Health segment [Member]", "label": "Animal Health segment [Member]", "terseLabel": "Animal Health", "verboseLabel": "Animal Health segment" } } }, "localname": "AnimalHealthsegmentMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ArtivaBiotherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Artiva Biotherapeutics, Inc.", "label": "Artiva Biotherapeutics, Inc. [Member]", "terseLabel": "Artiva Biotherapeutics, Inc." } } }, "localname": "ArtivaBiotherapeuticsIncMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Other Assets and Liabilities Recognized, Net", "label": "Asset Acquisition, Other Assets and Liabilities Recognized, Net", "terseLabel": "Net assets" } } }, "localname": "AssetAcquisitionOtherAssetsAndLiabilitiesRecognizedNet", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AstraZenecaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BayerAGMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bayer AG [Member]", "label": "Bayer AG [Member]", "terseLabel": "Bayer AG" } } }, "localname": "BayerAGMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_BelsomraMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Belsomra [Member]", "label": "Belsomra [Member]", "terseLabel": "Belsomra" } } }, "localname": "BelsomraMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BridionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bridion [Member].", "label": "Bridion [Member]", "terseLabel": "Bridion" } } }, "localname": "BridionMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol Myers Squibb", "label": "Bristol Myers Squibb [Member]", "terseLabel": "Bristol Myers Squibb" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_COVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19", "label": "COVID-19 [Member]", "terseLabel": "COVID-19" } } }, "localname": "COVID19Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_CancidasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cancidas [Member].", "label": "Cancidas [Member]", "terseLabel": "Cancidas" } } }, "localname": "CancidasMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]", "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]", "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations" } } }, "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_ChargesRelatedToProgramDiscontinuation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Charges related to program discontinuation", "label": "Charges related to program discontinuation", "terseLabel": "Charges related to program discontinuation" } } }, "localname": "ChargesRelatedToProgramDiscontinuation", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementNumberOfCollaborationTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Number Of Collaboration Targets", "label": "Collaborative Arrangement, Number Of Collaboration Targets", "terseLabel": "Number of collaboration targets" } } }, "localname": "CollaborativeArrangementNumberOfCollaborationTargets", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "integerItemType" }, "mrk_CollaborativeArrangementNumberOfResearchPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Number Of Research Programs", "label": "Collaborative Arrangement, Number Of Research Programs", "terseLabel": "Number of research programs" } } }, "localname": "CollaborativeArrangementNumberOfResearchPrograms", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "integerItemType" }, "mrk_CollaborativeArrangementProfitSharing": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Profit Sharing", "label": "Collaborative Arrangement, Profit Sharing", "terseLabel": "Alliance revenue - profit sharing" } } }, "localname": "CollaborativeArrangementProfitSharing", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementSalesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Sales, Net", "label": "Collaborative Arrangement, Sales, Net", "terseLabel": "Net sales by Merck" } } }, "localname": "CollaborativeArrangementSalesNet", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "terseLabel": "Collaborative Arrangements [Abstract]" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.merck.com/20220930", "xbrltype": "stringItemType" }, "mrk_CompanionAnimalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Companion Animals [Member]", "label": "Companion Animals [Member]", "terseLabel": "Companion Animals" } } }, "localname": "CompanionAnimalsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Line Items]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Table]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "mrk_ContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.", "label": "Contingent Payments Collaborative Arrangement", "terseLabel": "Contingent milestone payments collaborative arrangement" } } }, "localname": "ContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CostsExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.", "label": "Costs Expenses And Other", "totalLabel": "Total Costs, Expenses and Other" } } }, "localname": "CostsExpensesAndOther", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities and Equity Securities, FV-NI", "label": "Debt Securities and Equity Securities, FV-NI", "totalLabel": "Total debt and publicly traded equity securities, fair value" } } }, "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DeferredIncomeTaxesAndOtherAssetsCurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes and Other Assets, Current", "label": "Deferred Income Taxes and Other Assets, Current [Member]", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrentMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mrk_DeferredIncomeTaxesAndOtherAssetsNoncurrentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income Taxes And Other Assets, Noncurrent", "label": "Deferred Income Taxes And Other Assets, Noncurrent [Member]", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrentMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "mrk_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Development Milestones [Member]", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_DificidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dificid", "label": "Dificid [Member]", "terseLabel": "Dificid" } } }, "localname": "DificidMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_DisposalGroupInclDiscontinuedOperationsDistributionReceived": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group Incl. Discontinued Operations Distribution Received", "label": "Disposal Group Incl. Discontinued Operations Distribution Received", "terseLabel": "Distribution from Organon & Co." } } }, "localname": "DisposalGroupInclDiscontinuedOperationsDistributionReceived", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 4.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net", "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense), Net", "negatedTerseLabel": "Other (income) expense, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Research and Development Expenses", "label": "Disposal Group, Including Discontinued Operations, Research and Development Expenses", "terseLabel": "Research and development" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts": { "auth_ref": [], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 3.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operations, Restructuring Costs", "label": "Disposal Group, Including Discontinued Operations, Restructuring Costs", "terseLabel": "Restructuring costs" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_EisaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eisai [Member]", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will be noncash.", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "terseLabel": "Estimate of cumulative pre tax costs that will be noncash" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).", "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays", "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EurodominatedNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Euro-dominated Notes [Member]", "label": "Euro-dominated Notes [Member]", "terseLabel": "Euro-denominated notes" } } }, "localname": "EurodominatedNotesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Other", "negatedTerseLabel": "Other" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "mrk_FederalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Federal.", "label": "Federal [Member]", "terseLabel": "Federal" } } }, "localname": "FederalMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_FemurFractureLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Femur Fracture litigation.", "label": "Femur Fracture Litigation [Member]", "terseLabel": "Femur Fracture Litigation" } } }, "localname": "FemurFractureLitigationMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_FirstCommercialSaleMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Commercial Sale Milestones", "label": "First Commercial Sale Milestones [Member]", "terseLabel": "First Commercial Sale Milestones" } } }, "localname": "FirstCommercialSaleMilestonesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_FosamaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fosamax [Member].", "label": "Fosamax [Member]", "terseLabel": "Fosamax" } } }, "localname": "FosamaxMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_GardasilGardasil9Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gardasil/Gardasil 9 [Member].", "label": "Gardasil/Gardasil 9 [Member]", "terseLabel": "Gardasil/Gardasil 9" } } }, "localname": "GardasilGardasil9Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "Int\u2019l" } } }, "localname": "InternationalMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InvanzMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Invanz [Member].", "label": "Invanz [Member]", "terseLabel": "Invanz" } } }, "localname": "InvanzMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventories Produced in Preparation for Product Launches [Member]", "label": "Inventories Produced in Preparation for Product Launches [Member]", "terseLabel": "Inventories Produced in Preparation for Product Launches" } } }, "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryNetAndInventoryNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total of current and noncurrent inventories.", "label": "Inventory Net And Inventory Noncurrent", "totalLabel": "Total current and noncurrent inventories" } } }, "localname": "InventoryNetAndInventoryNoncurrent", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Not Expected to be Sold Within One Year [Member]", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "terseLabel": "Inventories Not Expected to be Sold Within One Year" } } }, "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Table]", "label": "Inventory [Table]", "terseLabel": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_IsentressIsentressHDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Isentress/Isentress HD [Member].", "label": "Isentress/Isentress HD [Member]", "terseLabel": "Isentress/Isentress HD" } } }, "localname": "IsentressIsentressHDMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanumetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Janumet [Member].", "label": "Janumet [Member]", "terseLabel": "Janumet" } } }, "localname": "JanumetMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaAndJanumetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Januvia and Janumet", "label": "Januvia and Janumet [Member]", "terseLabel": "Januvia and Janumet" } } }, "localname": "JanuviaAndJanumetMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Januvia [Member] .", "label": "Januvia [Member]", "terseLabel": "Januvia" } } }, "localname": "JanuviaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_KeytrudaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Keytruda [Member]", "label": "Keytruda [Member]", "terseLabel": "Keytruda" } } }, "localname": "KeytrudaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LagevrioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lagevrio", "label": "Lagevrio [Member]", "terseLabel": "Lagevrio" } } }, "localname": "LagevrioMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LegalDefenseCostsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Legal Defense Costs [Member]", "label": "Legal Defense Costs [Member]", "terseLabel": "Legal Defense Costs" } } }, "localname": "LegalDefenseCostsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_LenvimaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lenvima [Member]", "label": "Lenvima [Member]", "terseLabel": "Alliance revenue - Lenvima", "verboseLabel": "Lenvima" } } }, "localname": "LenvimaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Licenseoptionpaymentrelatedtocollaborativearrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License option payment related to collaborative arrangement", "label": "License option payment related to collaborative arrangement", "terseLabel": "License option payment related to collaborative arrangement" } } }, "localname": "Licenseoptionpaymentrelatedtocollaborativearrangement", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LivestockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Livestock [Member]", "label": "Livestock [Member]", "terseLabel": "Livestock" } } }, "localname": "LivestockMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long Term Debt, Current Maturities [Member]", "label": "Long Term Debt, Current Maturities [Member]", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LossContingencyClaimsonAppealNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Claims on Appeal, Number", "label": "Loss Contingency, Claims on Appeal, Number", "terseLabel": "Loss contingency, claims on appeal" } } }, "localname": "LossContingencyClaimsonAppealNumber", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "mrk_LossContingencyRecoveryFromThirdPartyBenchTrialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Recovery From Third Party, Bench Trial Period", "label": "Loss Contingency, Recovery From Third Party, Bench Trial Period", "terseLabel": "Loss contingency, recovery from third party, bench trial period" } } }, "localname": "LossContingencyRecoveryFromThirdPartyBenchTrialPeriod", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "durationItemType" }, "mrk_LossContingencyTrialPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Trial Period", "label": "Loss Contingency, Trial Period", "terseLabel": "Loss contingency, trial period" } } }, "localname": "LossContingencyTrialPeriod", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "durationItemType" }, "mrk_LynparzaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lynparza [Member]", "label": "Lynparza [Member]", "terseLabel": "Lynparza" } } }, "localname": "LynparzaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ManufacturingAndSupplyAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing and supply agreements", "label": "Manufacturing and supply agreements [Member]", "terseLabel": "Manufacturing and supply agreements" } } }, "localname": "ManufacturingAndSupplyAgreementsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_MilestonePaymentToBeMadeToACollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payment to be Made to a Collaborative Partner", "label": "Milestone Payment to be Made to a Collaborative Partner", "terseLabel": "Milestone payment to be made to a collaborative partner" } } }, "localname": "MilestonePaymentToBeMadeToACollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsAccruedSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Accrued Sales Based", "label": "Milestone Payments Accrued Sales Based", "terseLabel": "Milestone payments accrued but not yet paid" } } }, "localname": "MilestonePaymentsAccruedSalesBased", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsMadetoCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Made to Collaborative Partner", "label": "Milestone Payments Made to Collaborative Partner", "terseLabel": "Capitalized milestone payment" } } }, "localname": "MilestonePaymentsMadetoCollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments Sales-Based", "label": "Milestone Payments Sales-Based", "terseLabel": "Sales-based milestone payments" } } }, "localname": "MilestonePaymentsSalesBased", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_MilestonePaymentsToBeMadeToACollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Milestone Payments to be Made to a Collaborative Partner", "label": "Milestone Payments to be Made to a Collaborative Partner", "terseLabel": "Milestone payments to be made to a collaborative partner" } } }, "localname": "MilestonePaymentsToBeMadeToACollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_NemtabrutinibMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "nemtabrutinib", "label": "nemtabrutinib [Member]", "terseLabel": "nemtabrutinib" } } }, "localname": "NemtabrutinibMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "mrk_NoxafilMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noxafil [Member].", "label": "Noxafil [Member]", "terseLabel": "Noxafil" } } }, "localname": "NoxafilMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.", "label": "Offsetting Assets And Liabilities [Table Text Block]", "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis" } } }, "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "mrk_OrganonCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organon & Co.", "label": "Organon & Co. [Member]", "terseLabel": "Organon & Co." } } }, "localname": "OrganonCoMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_OrionCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orion Corporation", "label": "Orion Corporation [Member]", "terseLabel": "Orion Corporation" } } }, "localname": "OrionCorporationMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_OrnaTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Orna Therapeutics", "label": "Orna Therapeutics [Member]", "terseLabel": "Orna Therapeutics" } } }, "localname": "OrnaTherapeuticsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherNonoperatingIncomeExpenseOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other nonoperating income and expense items not separately disclosed.", "label": "Other Nonoperating Income Expense, Other", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpenseOther", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherPharmaceuticalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other pharmaceutical.", "label": "Other Pharmaceutical [Member]", "terseLabel": "Other pharmaceutical" } } }, "localname": "OtherPharmaceuticalMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PandionTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pandion Therapeutics", "label": "Pandion Therapeutics [Member]", "terseLabel": "Pandion Therapeutics" } } }, "localname": "PandionTherapeuticsMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd.", "label": "Patent Infringement Lawsuit Against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. And Cadila Healthcare Ltd. [Member]", "terseLabel": "Patent Infringement Lawsuit Against Zydus" } } }, "localname": "PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "mrk_PharmaceuticalsegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pharmaceutical segment.", "label": "Pharmaceutical segment [Member]", "terseLabel": "Pharmaceutical", "verboseLabel": "Pharmaceutical segment" } } }, "localname": "PharmaceuticalsegmentMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Pneumovax23Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pneumovax 23[Member].", "label": "Pneumovax 23 [Member]", "terseLabel": "Pneumovax 23" } } }, "localname": "Pneumovax23Member", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PotentialFutureMilestonePaymentsRegulatory": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Regulatory", "label": "Potential Future Milestone Payments Regulatory", "terseLabel": "Potential future regulatory milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsRegulatory", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PotentialFutureMilestonePaymentsSalesBased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Potential Future Milestone Payments Sales-Based", "label": "Potential Future Milestone Payments Sales-Based", "terseLabel": "Potential future sales-based milestone payments" } } }, "localname": "PotentialFutureMilestonePaymentsSalesBased", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_PrevymisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Prevymis [Member]", "label": "Prevymis [Member]", "terseLabel": "Prevymis" } } }, "localname": "PrevymisMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrimaxinMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primaxin [Member].", "label": "Primaxin [Member]", "terseLabel": "Primaxin" } } }, "localname": "PrimaxinMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProQuadMMRIIVarivaxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ProQuad/M-M-R II/Varivax [Member].", "label": "ProQuad MMR II Varivax [Member]", "terseLabel": "ProQuad/M-M-R II/Varivax" } } }, "localname": "ProQuadMMRIIVarivaxMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProbableContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Probable Contingent Payments Collaborative Arrangement", "label": "Probable Contingent Payments Collaborative Arrangement", "terseLabel": "Probable contingent payments" } } }, "localname": "ProbableContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RecognizedAsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Recognized as.", "label": "Recognized As [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "RecognizedAsAbstract", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "stringItemType" }, "mrk_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regulatory Milestones [Member]", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RemicadeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Remicade [Member].", "label": "Remicade [Member]", "terseLabel": "Remicade" } } }, "localname": "RemicadeMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding", "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Development Costs Subject To Funding", "terseLabel": "Additional funding by others, development costs subject to funding" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersDevelopmentCostsSubjectToFunding", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs", "label": "Research And Development Arrangement, Contract To Perform For Others, Additional Funding By Others, Percentage Of Development Costs", "terseLabel": "Additional funding by others, percentage of development costs" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersAdditionalFundingByOthersPercentageOfDevelopmentCosts", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "percentItemType" }, "mrk_ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and Development Payments to be Made to a Collaborative Partner", "label": "Research and Development Payments to be Made to a Collaborative Partner", "terseLabel": "Research and development payments to be made to a collaborative partner (up to)" } } }, "localname": "ResearchAndDevelopmentPaymentsToBeMadeToACollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RestructuringReserveIncreaseDecreaseNoncashActivity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.", "label": "Restructuring Reserve, Increase (Decrease) Noncash Activity", "terseLabel": "Non-cash activity" } } }, "localname": "RestructuringReserveIncreaseDecreaseNoncashActivity", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RidgebackBiotherapeuticsLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ridgeback Biotherapeutics LP", "label": "Ridgeback Biotherapeutics LP [Member]", "terseLabel": "Ridgeback Biotherapeutics LP" } } }, "localname": "RidgebackBiotherapeuticsLPMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "mrk_RotateqMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RotaTeq [Member]", "label": "Rotateq [Member]", "terseLabel": "RotaTeq" } } }, "localname": "RotateqMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RoyaltyRateDeductionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Deduction, Percentage", "label": "Royalty Rate, Deduction, Percentage", "terseLabel": "Royalty rate, deduction" } } }, "localname": "RoyaltyRateDeductionPercentage", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "pureItemType" }, "mrk_RoyaltyRatePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty Rate, Percentage", "label": "Royalty Rate, Percentage", "terseLabel": "Royalty rate" } } }, "localname": "RoyaltyRatePercentage", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sales-Based Milestones [Member]", "label": "Sales-Based Milestones [Member]", "terseLabel": "Sales-Based Milestones" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sales Discounts", "label": "Sales Discounts", "terseLabel": "Sales discounts" } } }, "localname": "SalesDiscounts", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SanofiPasteurMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sanofi Pasteur [Member]", "label": "Sanofi Pasteur [Member]", "terseLabel": "Sanofi Pasteur" } } }, "localname": "SanofiPasteurMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other net expenses not allocated to segments.", "label": "Segment Reporting Unallocated Other Expenses Net", "negatedLabel": "Other unallocated, net" } } }, "localname": "SegmentReportingUnallocatedOtherExpensesNet", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SichuanKelunBiotechBiopharmaceuticalCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.", "label": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. [Member]", "terseLabel": "Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd." } } }, "localname": "SichuanKelunBiotechBiopharmaceuticalCoLtdMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "mrk_SimponiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Simponi [Member].", "label": "Simponi [Member]", "terseLabel": "Simponi" } } }, "localname": "SimponiMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Line Items] for Stockholders Equity [Table]", "label": "Stockholders Equity [Line Items]", "terseLabel": "Stockholders Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_SupplyCommitmentMinimumNumberOfMarkets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply Commitment, Minimum, Number of Markets", "label": "Supply Commitment, Minimum, Number of Markets", "terseLabel": "Number of markets (more than)" } } }, "localname": "SupplyCommitmentMinimumNumberOfMarkets", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_SupplyCommitmentRemainingMinimumCoursesCommitted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supply Commitment, Remaining Minimum Courses Committed", "label": "Supply Commitment, Remaining Minimum Courses Committed", "terseLabel": "Remaining minimum courses committed (in courses)" } } }, "localname": "SupplyCommitmentRemainingMinimumCoursesCommitted", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition services agreement", "label": "Transition services agreement [Member]", "terseLabel": "Transition services agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.", "label": "Upfront And Milestone Payments Made To Collaborative Partner", "terseLabel": "Upfront and milestone payments" } } }, "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront and Milestone Payments to be Made to Collaborative Partner", "label": "Upfront and Milestone Payments to be Made to Collaborative Partner", "terseLabel": "Upfront and milestone payments to be made" } } }, "localname": "UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_VaqtaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vaqta [Member]", "label": "Vaqta [Member]", "terseLabel": "Vaqta" } } }, "localname": "VaqtaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VerquvoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Verquvo", "label": "Verquvo [Member]", "terseLabel": "Verquvo" } } }, "localname": "VerquvoMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_ZerbaxaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zerbaxa [Member]", "label": "Zerbaxa [Member]", "terseLabel": "Zerbaxa" } } }, "localname": "ZerbaxaMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaantitrustlitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Zetia antitrust litigation [Member]", "label": "Zetia antitrust litigation [Member]", "terseLabel": "Zetia antitrust litigation" } } }, "localname": "ZetiaantitrustlitigationMember", "nsuri": "http://www.merck.com/20220930", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (other than China and Japan)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r162", "r215", "r228", "r229", "r230", "r231", "r233", "r235", "r239", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r162", "r215", "r228", "r229", "r230", "r231", "r233", "r235", "r239", "r346", "r347", "r348", "r349", "r350", "r351", "r353", "r354", "r356", "r358", "r359" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r88", "r91", "r160", "r161", "r365", "r386" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r335", "r337", "r338", "r339", "r364", "r385", "r495", "r501", "r661", "r662", "r663", "r664", "r665", "r666", "r685", "r735", "r738", "r774", "r775" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r335", "r337", "r338", "r339", "r364", "r385", "r495", "r501", "r661", "r662", "r663", "r664", "r665", "r666", "r685", "r735", "r738", "r774", "r775" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r242", "r337", "r338", "r406", "r407", "r687", "r734", "r736" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIntangiblesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r242", "r337", "r338", "r406", "r407", "r687", "r734", "r736" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIntangiblesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r310", "r335", "r337", "r338", "r339", "r364", "r385", "r436", "r495", "r501", "r503", "r504", "r505", "r661", "r662", "r663", "r664", "r665", "r666", "r685", "r735", "r738", "r774", "r775" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r310", "r335", "r337", "r338", "r339", "r364", "r385", "r436", "r495", "r501", "r503", "r504", "r505", "r661", "r662", "r663", "r664", "r665", "r666", "r685", "r735", "r738", "r774", "r775" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r90", "r91", "r160", "r161", "r365", "r386" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r177", "r496" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r177", "r182", "r333", "r496" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r243", "r244", "r406", "r408", "r737", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r243", "r244", "r406", "r408", "r737", "r763", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r177", "r182", "r333", "r496", "r654" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r78" ], "lang": { "en-us": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r69", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r248", "r249" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $77 in 2022 and $62 in 2021)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r268" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Factored accounts receivable" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r46", "r694", "r717" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r94", "r100", "r109", "r110", "r111", "r568" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r40", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r100", "r109", "r110", "r111", "r567" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r100", "r109", "r110", "r111", "r112", "r567" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r56", "r97", "r99", "r100", "r719", "r743", "r744" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r109", "r110", "r633", "r634", "r635", "r636", "r637", "r639" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r96", "r100", "r109", "r110", "r111", "r169", "r170", "r171", "r568", "r646", "r739", "r740" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r92", "r100", "r109", "r110", "r111", "r568", "r634", "r635", "r636", "r637", "r639" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r54" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Other paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r169", "r170", "r171", "r507", "r508", "r509", "r613" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Other Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r146", "r297" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "negatedLabel": "Amortization", "terseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r60", "r250", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r146", "r292", "r297" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r199" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetAcquisitionAxis": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by asset acquisition.", "label": "Asset Acquisition [Axis]", "terseLabel": "Asset Acquisition [Axis]" } } }, "localname": "AssetAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "auth_ref": [ "r551", "r552", "r553", "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.", "label": "Asset Acquisition, Consideration Transferred", "terseLabel": "Consideration transferred, asset acquisition" } } }, "localname": "AssetAcquisitionConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "auth_ref": [ "r551", "r552", "r553", "r554" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Transaction Cost", "terseLabel": "Asset acquisition costs" } } }, "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetAcquisitionDomain": { "auth_ref": [ "r550" ], "lang": { "en-us": { "role": { "documentation": "Asset acquisition.", "label": "Asset Acquisition [Domain]", "terseLabel": "Asset Acquisition [Domain]" } } }, "localname": "AssetAcquisitionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r43", "r154", "r223", "r230", "r237", "r265", "r346", "r347", "r348", "r350", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r564", "r569", "r627", "r650", "r652", "r692", "r716" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r33", "r68", "r154", "r265", "r346", "r347", "r348", "r350", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r564", "r569", "r627", "r650", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r616" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r256" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r257" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r254", "r274" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r252", "r255", "r274", "r700" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Debt securities, fair value", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r581", "r586" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r145", "r549" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r544", "r545", "r547" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r544", "r546" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r619" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input, discount rate" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r29", "r39", "r148" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r142", "r148", "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134 and $30 at September\u00a030, 2022 and 2021, respectively, included in Other current assets)", "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r142", "r632" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Increase in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash used in financing activities" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r22", "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash used in investing activities" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r22", "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash provided by operating activities" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r608" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r50", "r51", "r52", "r151", "r154", "r187", "r188", "r193", "r196", "r198", "r206", "r207", "r208", "r265", "r346", "r351", "r352", "r353", "r359", "r360", "r383", "r384", "r388", "r392", "r399", "r627", "r782" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r555", "r556", "r558" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.", "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r329", "r330", "r331", "r341", "r764" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common stock (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r169", "r170", "r613" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock ($0.50\u00a0par value)", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Common stock, ending balance (in shares)", "periodStartLabel": "Common stock, beginning balance (in shares)", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r52", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2022 and 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r105", "r107", "r108", "r120", "r707", "r729" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r119", "r130", "r706", "r728" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r437", "r485", "r745" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r228", "r229", "r230", "r231", "r233", "r239", "r241" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment", "verboseLabel": "Corporate, Non-Segment" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r125", "r687" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Currency Swap" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of debt and lease obligation, classified as current.", "label": "Debt, Current", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r44", "r46", "r48", "r153", "r162", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r380", "r381", "r382", "r644", "r693", "r695", "r713" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r361", "r379", "r380", "r642", "r644", "r645" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r370", "r379", "r380", "r626" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of loans payable and long-term debt, including current portion" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r73", "r362" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r74", "r153", "r162", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r380", "r381", "r382", "r644" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-Term and Short-Term, Combined Amount", "terseLabel": "Debt, carrying amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r146", "r155", "r524", "r529", "r530", "r531" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r514", "r515" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r413", "r452", "r479", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net loss amortization" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r413", "r453", "r480", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of unrecognized prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement": { "auth_ref": [ "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from remeasurement due to settlement. Excludes decrease to benefit obligation for settlement payment.", "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Remeasurement due to Settlement", "negatedTerseLabel": "Increase to pension liabilities due to remeasurement" } } }, "localname": "DefinedBenefitPlanBenefitObligationIncreaseDecreaseForRemeasurementDueToSettlement", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "auth_ref": [ "r466" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "terseLabel": "Termination benefits" } } }, "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r413", "r451", "r478", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r413", "r418", "r450", "r477", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r448", "r475", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r414", "r455", "r482" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 8.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r414", "r455", "r482" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r416", "r449", "r476", "r485", "r486" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r146", "r302" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedLabel": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r85", "r87" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, asset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r82", "r83", "r87" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative asset.", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r81", "r86", "r91", "r626" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "terseLabel": "Derivative assets", "verboseLabel": "Fair Value of Derivative, Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Maximum average period of maturities of contracts in years (less than)" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r84", "r87", "r89", "r604" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset", "negatedLabel": "Cash collateral received, asset", "terseLabel": "Cash collateral received from counterparties" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r84", "r87", "r89", "r604" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "negatedLabel": "Cash collateral received, liability" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r583" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": { "auth_ref": [ "r583" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.", "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]", "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]" } } }, "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r91", "r582", "r585", "r591", "r599" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r579", "r582", "r591", "r599", "r600", "r606", "r609" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r610" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Pretax net unrealized gains on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r590", "r592" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r81", "r86", "r91", "r626" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Fair Value of Derivative, Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r85", "r87" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, liability" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r82", "r83", "r87" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability.", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": { "auth_ref": [ "r581" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes derivative liability.", "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r576", "r578" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Total swap notional amount", "verboseLabel": "U.S Dollar Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r575", "r577", "r578", "r579", "r580", "r587", "r591", "r603", "r605", "r609", "r611" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax": { "auth_ref": [ "r7", "r8", "r20" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until its disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, before Income Tax", "totalLabel": "Income from discontinued operations before taxes" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Income from Discontinued Operations (in dollars per share)" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Period of continuing involvement after disposal" } } }, "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": { "auth_ref": [ "r8", "r24", "r534" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.", "label": "Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period", "terseLabel": "Income tax benefit" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]", "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Consideration received" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r21", "r27" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 5.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r21" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r21" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": { "auth_ref": [ "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Expense", "terseLabel": "Disposal group, other expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r21", "r27" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r28", "r309" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Spin-Off of Organon & Co." } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCo" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r71" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r490", "r494", "r500" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DueFromRelatedPartiesCurrent": { "auth_ref": [ "r31", "r53", "r158", "r349", "r351", "r352", "r358", "r359", "r360", "r648" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).", "label": "Due from Related Parties, Current", "terseLabel": "Due from related parties, current" } } }, "localname": "DueFromRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r69", "r158", "r349", "r351", "r352", "r358", "r359", "r360", "r648" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Due to related parties, current" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r121", "r174", "r175", "r176", "r177", "r178", "r184", "r187", "r196", "r197", "r198", "r202", "r203", "r614", "r615", "r708", "r730" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net Income (in dollars per share)", "totalLabel": "Net Income (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic [Abstract]", "terseLabel": "Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r121", "r174", "r175", "r176", "r177", "r178", "r187", "r196", "r197", "r198", "r202", "r203", "r614", "r615", "r708", "r730" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net Income (in dollars per share)", "totalLabel": "Net Income (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted [Abstract]", "terseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:", "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:" } } }, "localname": "EarningsPerShareDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r199", "r200", "r201", "r204" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r632" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r517" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r109", "r110", "r111", "r169", "r170", "r171", "r173", "r179", "r181", "r205", "r266", "r399", "r400", "r507", "r508", "r509", "r525", "r526", "r613", "r633", "r634", "r635", "r636", "r637", "r639", "r646", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityFundsMember": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "An investment that pools funds from many investors to invest in a combination of underlying investments, primarily equity investments.", "label": "Equity Funds [Member]", "terseLabel": "Equity Funds" } } }, "localname": "EquityFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "auth_ref": [ "r625" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent.", "label": "Equity Securities, FV-NI, Noncurrent", "terseLabel": "Equity securities, noncurrent" } } }, "localname": "EquitySecuritiesFVNINoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r32", "r45", "r625" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.", "label": "Equity Securities, FV-NI, Current", "terseLabel": "Publicly traded equity securities, fair value", "verboseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r264" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Loss (income) from investments in equity securities, net", "negatedTerseLabel": "Loss (income) from investments in equity securities, net" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r264", "r731" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized net (gains) losses" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r260", "r714", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r262" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized losses on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized gains on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r616", "r617", "r623" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r370", "r379", "r380", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r485", "r617", "r658", "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r616", "r617", "r618", "r619", "r624" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r370", "r437", "r439", "r444", "r485", "r617", "r658" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r370", "r379", "r380", "r437", "r439", "r444", "r485", "r617", "r659" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r370", "r379", "r380", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r485", "r617", "r660" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r620", "r623" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r621" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r370", "r379", "r380", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r485", "r658", "r659", "r660" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r622", "r624" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r581", "r587", "r606" ], "lang": { "en-us": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r258", "r259", "r261", "r262", "r263", "r269", "r270", "r271", "r272", "r273", "r275", "r276", "r277", "r278", "r378", "r397", "r611", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r296", "r688" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r628", "r629", "r630", "r631" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r91", "r437", "r597" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeFutureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).", "label": "Foreign Exchange Future [Member]", "terseLabel": "Foreign Exchange Future" } } }, "localname": "ForeignExchangeFutureMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Currency options" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r437", "r745" ], "lang": { "en-us": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign government bonds" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r490", "r494", "r500" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r41", "r280", "r281", "r288", "r290", "r652", "r691" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r601" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Carrying Amount of Hedged Liabilities" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r602" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r579", "r600" ], "lang": { "en-us": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r146", "r299" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r146", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)", "terseLabel": "Impairment charge" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In Process Research and Development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r124", "r147", "r174", "r175", "r176", "r177", "r194", "r198", "r561" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "terseLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc.", "totalLabel": "Net Income from Continuing Operations Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r559", "r562" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Net Income Attributable to Noncontrolling Interests" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r116", "r223", "r229", "r233", "r236", "r239", "r689", "r703", "r710", "r732" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Profits", "totalLabel": "Income from Continuing Operations Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r154", "r172", "r223", "r229", "r233", "r236", "r239", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r562", "r615", "r627" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income from continuing operations", "totalLabel": "Net Income from Continuing Operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r113", "r121", "r172", "r174", "r175", "r176", "r177", "r187", "r196", "r197", "r615", "r702", "r704", "r708", "r725" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Income from Continuing Operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r113", "r121", "r172", "r174", "r175", "r176", "r177", "r187", "r196", "r197", "r198", "r615", "r708", "r725", "r728", "r730" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Income from Continuing Operations (in dollars per share)" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r24", "r27", "r535", "r726" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income from discontinued operations, net of taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r20", "r24", "r559", "r562" ], "calculation": { "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Income of discontinued operations attributable to noncontrolling interests" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r7", "r8", "r9", "r10", "r11", "r20", "r24", "r562" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0 }, "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent", "terseLabel": "Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests", "totalLabel": "Income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails", "http://www.merck.com/role/SpinOffofOrganonCoIncomefromDiscontinuedOperationsNetofTaxesandAmountsAttributabletoNoncontrollingInterestsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": { "auth_ref": [ "r188", "r196", "r197", "r573" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share", "terseLabel": "Income from Discontinued Operations (in dollars per share)" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r2", "r13", "r14", "r15", "r16", "r18", "r19", "r23", "r25", "r26", "r27", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r305", "r315" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r156", "r518", "r522", "r523", "r527", "r532", "r536", "r537", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r157", "r180", "r181", "r221", "r516", "r528", "r533", "r733" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on Income from Continuing Operations" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r143", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r145" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r293", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r293", "r298" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Other Intangibles" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r291", "r295" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangibles, Net", "verboseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r114", "r217", "r641", "r643", "r709" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r91", "r437", "r596" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r596" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap contracts", "verboseLabel": "Interest rate swaps" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r61" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r66" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates current cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r65" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r30", "r66", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021 classified in Other assets - see Note\u00a07)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails_1": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventories classified in Other assets", "verboseLabel": "Other assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/InventoriesNarrativeDetails", "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r66" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Raw materials and work in process" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r127", "r216" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r70", "r154", "r231", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r565", "r569", "r570", "r627", "r650", "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r59", "r154", "r265", "r627", "r652", "r697", "r722" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r34", "r72", "r154", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r565", "r569", "r570", "r627", "r650", "r651", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Payables included in Accrued and other liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r616" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r36", "r37", "r38", "r48", "r49", "r154", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r565", "r569", "r570", "r627", "r650", "r651" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Payables included in Other Noncurrent Liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r542" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "Licensing Agreements" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r76", "r332" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Legal defense costs reserve" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r74", "r345" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [ "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Loss contingency, claims dismissed" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [ "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss contingency, claims settled" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r332", "r334", "r335", "r336", "r337", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Loss contingency, new claims filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r334", "r336" ], "lang": { "en-us": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss contingency, pending claims" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Segment Reconciling Items" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r80", "r154", "r265", "r346", "r351", "r352", "r353", "r359", "r360", "r627", "r696", "r721" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions attributable to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "auth_ref": [ "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.", "label": "Net Cash Provided by (Used in) Discontinued Operations", "totalLabel": "Net Cash Flows Provided by Discontinued Operations" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]", "terseLabel": "Cash Flows from Discontinued Operations" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net Cash Used in Financing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r142" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net Cash Used in Investing Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r142", "r144", "r147" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net Cash Provided by Operating Activities of Continuing Operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r27", "r103", "r106", "r111", "r118", "r147", "r154", "r172", "r174", "r175", "r176", "r177", "r180", "r181", "r194", "r223", "r229", "r233", "r236", "r239", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r615", "r627", "r705", "r727" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Attributable to Merck\u00a0& Co., Inc.", "totalLabel": "Net Income Attributable to Merck & Co., Inc.", "verboseLabel": "Net income attributable to Merck\u00a0& Co., Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r103", "r106", "r111", "r180", "r181", "r566", "r572" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "verboseLabel": "Net income attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r174", "r175", "r176", "r177", "r184", "r185", "r195", "r198", "r223", "r229", "r233", "r236", "r239" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to Merck & Co., Inc., basic" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r186", "r189", "r190", "r191", "r192", "r195", "r198" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income attributable to Merck & Co., Inc., diluted" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r413" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards and Recently Issued Accounting Standards Not Yet Adopted" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "Non-US" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r169", "r170", "r171", "r400", "r559" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r576", "r578" ], "lang": { "en-us": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r211" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r100" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r100", "r112" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r313", "r314", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Separation Costs" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r228", "r229", "r230", "r231", "r233", "r239" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "verboseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r168", "r183", "r209", "r574" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r95", "r97", "r562", "r567" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Benefit plan net (loss) gain and prior service (cost) credit, net of amortization" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r562", "r563", "r567" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r98", "r109" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r97" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "verboseLabel": "Net unrealized gain on derivatives, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r93", "r97", "r584", "r589", "r607" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of gain (loss) recognized in OCI on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r97", "r101" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Increase (decrease) in Sales as a result of AOCL reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r593" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r594" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r104", "r107", "r109", "r110", "r112", "r119", "r399", "r633", "r638", "r639", "r706", "r728" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive (Loss) Income Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r104", "r107", "r562", "r563", "r567" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r581", "r606" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r409", "r510" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventorySupplies": { "auth_ref": [ "r62" ], "calculation": { "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.", "label": "Other Inventory, Supplies, Gross", "terseLabel": "Supplies" } } }, "localname": "OtherInventorySupplies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesScheduleofInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r71", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r75" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r147" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r129" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 5.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r411", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r463", "r466", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefit Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [ "r313", "r314", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r132", "r135" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r138" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r141", "r314" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "(Payments) receipts, net" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r138" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r135" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Pandion Therapeutics, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r133" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Other acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r135" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Amount paid for investment" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r253" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of securities and other investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r134", "r551", "r552", "r553" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PendingLitigationMember": { "auth_ref": [ "r332" ], "lang": { "en-us": { "role": { "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.", "label": "Pending Litigation [Member]", "terseLabel": "Pending Litigation" } } }, "localname": "PendingLitigationMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r436", "r438", "r444", "r462", "r464", "r465", "r466", "r467", "r468", "r485", "r487", "r488", "r489", "r502" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r410", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r463", "r466", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r497", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r137", "r140" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-Term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r132" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales of securities and other investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfIntangibleAssets": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Proceeds from Sale of Intangible Assets", "terseLabel": "Revenue related to the sale of the marketing rights" } } }, "localname": "ProceedsFromSaleOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r136", "r506" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r304", "r652", "r712", "r724" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921 in 2022 and $18,192 in 2021" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r652", "r723", "r746" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "verboseLabel": "Receivables included in Other current assets" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r100" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Reclassification adjustments, pretax" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r100", "r112" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTotalLabel": "Reclassification adjustments, net of taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r98", "r102", "r109" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r229", "r233" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of Segment Profits to Income before Taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartiesAmountInCostOfSales": { "auth_ref": [ "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount included in cost of sales related to transactions with related parties incurred and recorded in the statement of operations for the period.", "label": "Related Parties Amount in Cost of Sales", "terseLabel": "Related party amount in cost of sales" } } }, "localname": "RelatedPartiesAmountInCostOfSales", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r463", "r647", "r648", "r649" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r463" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r139" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-Term Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": { "auth_ref": [ "r512", "r513" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned", "terseLabel": "Compensation earned" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "auth_ref": [ "r294" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.", "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off", "terseLabel": "Charge for the acquisition of Pandion Therapeutics, Inc." } } }, "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r511", "r686", "r776" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 3.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r39", "r148", "r150", "r690", "r718" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r39", "r150" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r312", "r314", "r317", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r313", "r316", "r323", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative costs since program inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r313", "r316", "r323", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected restructuring and related cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r313", "r316", "r323", "r326" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Total pretax restructuring costs", "verboseLabel": "Expense" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r146", "r311", "r320", "r323" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 4.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r320", "r325" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [ "r313", "r314", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r314", "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r55", "r400", "r652", "r720", "r742", "r744" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r169", "r170", "r171", "r173", "r179", "r181", "r266", "r507", "r508", "r509", "r525", "r526", "r613", "r739", "r741" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r490", "r494", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r463", "r466", "r471", "r472", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r490", "r494", "r500" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r410", "r411", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r463", "r466", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r410", "r411", "r412", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r460", "r461", "r463", "r466", "r470", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r489", "r490", "r491", "r492", "r493", "r494", "r497", "r498", "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r122", "r349", "r351", "r352", "r358", "r359", "r360", "r747" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue from Related Parties", "terseLabel": "Revenue from related party" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r115", "r154", "r214", "r215", "r228", "r234", "r235", "r242", "r243", "r246", "r265", "r346", "r347", "r348", "r351", "r352", "r353", "r355", "r357", "r359", "r360", "r627", "r710" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales", "totalLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyIncomeNonoperating": { "auth_ref": [ "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.", "label": "Royalty Income, Nonoperating", "terseLabel": "Royalties" } } }, "localname": "RoyaltyIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r598" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r100", "r638", "r639" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in AOCI by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "terseLabel": "Information on Investments in Debt and Equity Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r548" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Collaboration Arrangements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r469", "r470", "r473", "r474", "r485" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansNetBenefitCostsDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r582", "r591", "r600" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Location and Amount of Pretax Gains and Losses of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r587" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r2", "r13", "r14", "r15", "r16", "r18", "r19", "r23", "r25", "r26", "r27", "r307", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Disposal Groups, Including Discontinued Operations" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculations of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Sales from Products" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r588" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r35", "r63", "r64", "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r448" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Net Benefit Costs" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r595" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r590", "r592" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r313", "r314", "r315", "r316", "r323", "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r318", "r319", "r322" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r314", "r324" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r123", "r243" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Consolidated Sales by Geographic Area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r115", "r245" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingConsolidatedSalesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r223", "r226", "r232", "r289" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r399" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentContinuingOperationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component of an entity expected to operate in the foreseeable future.", "label": "Continuing Operations [Member]", "terseLabel": "Continuing Operations" } } }, "localname": "SegmentContinuingOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDiscontinuedOperationsMember": { "auth_ref": [ "r3", "r4", "r5", "r6" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations [Member]", "terseLabel": "Discontinued Operations" } } }, "localname": "SegmentDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r239", "r246", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r316", "r326", "r734" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentOperatingActivitiesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operations of an entity including continuing and discontinued operations.", "label": "Operating Activities [Domain]", "terseLabel": "Operating Activities [Domain]" } } }, "localname": "SegmentOperatingActivitiesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r210", "r212", "r213", "r223", "r227", "r233", "r237", "r238", "r239", "r240", "r242", "r245", "r246", "r247" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r126" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r145" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermInvestments": { "auth_ref": [ "r67", "r698", "r699", "r715" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.", "label": "Short-Term Investments", "terseLabel": "Short-term investments" } } }, "localname": "ShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r12", "r210", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r228", "r229", "r230", "r231", "r233", "r234", "r235", "r236", "r237", "r239", "r246", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r306", "r316", "r326", "r734" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingReconciliationofSegmentProfitstoIncomebeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesfromProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r50", "r51", "r52", "r151", "r154", "r187", "r188", "r193", "r196", "r198", "r206", "r207", "r208", "r265", "r346", "r351", "r352", "r353", "r359", "r360", "r383", "r384", "r388", "r392", "r399", "r627", "r782" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r77", "r109", "r110", "r111", "r169", "r170", "r171", "r173", "r179", "r181", "r205", "r266", "r399", "r400", "r507", "r508", "r509", "r525", "r526", "r613", "r633", "r634", "r635", "r636", "r637", "r639", "r646", "r739", "r740", "r741" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOperatingActivitiesSegmentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by continuing and discontinuing operations.", "label": "Operating Activities [Axis]", "terseLabel": "Operating Activities [Axis]" } } }, "localname": "StatementOperatingActivitiesSegmentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r52", "r57", "r58", "r154", "r251", "r265", "r627", "r652" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "Stockholders' Equity before Treasury Stock", "totalLabel": "Stockholders' equity before deduction for treasury stock" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r110", "r154", "r169", "r170", "r171", "r173", "r179", "r265", "r266", "r400", "r507", "r508", "r509", "r525", "r526", "r559", "r560", "r571", "r613", "r627", "r633", "r634", "r639", "r646", "r740", "r741" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r152", "r384", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r400", "r405", "r612" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityNoteSpinoffTransaction": { "auth_ref": [ "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The change in equity as a result of a spin-off transaction (a regular or reverse spin-off) which is based on the recorded amounts.", "label": "Stockholders' Equity Note, Spinoff Transaction", "terseLabel": "Spin-off of Organon & Co." } } }, "localname": "StockholdersEquityNoteSpinoffTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.", "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Stock conversion ratio" } } }, "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/SpinOffofOrganonCoNarrativeDetails" ], "xbrltype": "pureItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Share-based compensation plans and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "negatedLabel": "Share-based compensation plans and other (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r640", "r653" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r640", "r653" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r640", "r653" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/OtherIncomeExpenseNetScheduleofOtherIncomeExpenseNetDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r32", "r45", "r701" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "totalLabel": "Investments" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r258", "r259", "r261", "r262", "r263", "r378", "r397", "r611", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r782", "r783", "r784", "r785", "r786", "r787", "r788" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonMember": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockCommonMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Shares", "periodEndLabel": "Treasury stock, ending balance (in shares)", "periodStartLabel": "Treasury stock, beginning balance (in shares)", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockCommonValue": { "auth_ref": [ "r79", "r402", "r403" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury Stock, Common, Value", "terseLabel": "Less treasury stock, at cost: 1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021" } } }, "localname": "TreasuryStockCommonValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r52", "r399", "r400" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock shares purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r399", "r400", "r402" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury stock shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsDetails", "http://www.merck.com/role/CollaborativeArrangementsFinancialInformationDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [ "r313", "r314", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r159", "r437", "r711" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "terseLabel": "Tax benefit recognized related to settlement" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.", "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition", "terseLabel": "Tax benefit resulting from acquisition" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r163", "r164", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/ContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r198" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Common shares issuable (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r186", "r198" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common shares outstanding assuming dilution (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r184", "r198" ], "calculation": { "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.merck.com/role/EarningsPerShareCalculationsofEarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 12 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(2))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "https://asc.fasb.org/topic&trid=2134417" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r209": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r247": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r260": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117546-209714" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r279": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org/topic&trid=2126998" }, "r28": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721491-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/subtopic&trid=2144471" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r309": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(e))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "https://asc.fasb.org/topic&trid=2175745" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r331": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r341": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "60", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=6406278&loc=d3e26268-112671" }, "r405": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org/topic&trid=49130413" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(21))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721501-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r502": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org/topic&trid=2122503" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(2))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r538": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "15", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6829253&loc=SL6831962-166255" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r558": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "https://asc.fasb.org/topic&trid=5833765" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.E)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120398118&loc=d3e355146-122828" }, "r574": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(4))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r777": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r778": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r779": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r780": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r781": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r782": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r783": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r784": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r785": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r786": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r787": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r788": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r789": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(ii)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" } }, "version": "2.1" } ZIP 89 0000310158-22-000034-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000310158-22-000034-xbrl.zip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«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